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Abstract
1. ABSTRACT
Over one-third of the population in developing countries lack access to
essential medicines. According to WHO report, over 80% of the world
population relies on traditional medicine largely plant based for their primary
healthcare needs, especially in the under developed and developing
countries, because of better cultural acceptability, better compatibility with the
human body and lesser side effects. The provision of safe and effective herbal
therapies could become a critical tool to increase access to health care.
However, in the last few years there has been a major increase in their use in
the developed world. In Germany and France, many herbs and herbal
extracts are used as prescription drugs. About 25% of modern medicines are
descended from plants first used traditionally. The Indian systems of medicine
have identified 1500 medicinal plants, of which 500 species are mostly used
therapeutically. The Ayurved drug market alone is to the order of Rs. 3500
crores. Besides this, there is also a growing demand for natural products
including items of medicinal value/pharmaceuticals, food supplements and
cosmetics in both domestic and international markets. Presently, India’ s
export from medicinal and herbal plants is Rs.3000 crores. India, with its
diversified biodiversity has a tremendous potential and advantage in this
emerging area. India is sitting on a gold mine of well-recorded and well-
practiced knowledge of traditional herbal medicine. But, unlike China, India
has not been able to capitalize on this herbal wealth by promoting its use in
the developed world despite their renewed interest in herbal medicines. This
can be achieved by judicious product identification based on diseases found
in the developed world for which no medicine or only palliative therapy is
available; such herbal medicines will find speedy access into those countries.
Backward integration from market demands will pay rich dividends.
Strategically, India should enter through those plant-based medicines, which
are already well accepted in Europe, USA and Japan. Simultaneously, it
should identify those herbs (medicinal plants), which are time-tested and
dispensed all over in India.
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Wheat, (Triticum species) a cereal grass of the Gramineae (Poaceae) family,
is the world's largest edible grain cereal-grass crop. Wheat has been a food
crop for mankind since the beginning of agriculture. For over fifty years,
researchers have known that the cereal plant, at this young green stage, is
many times richer in the levels of vitamins, minerals and proteins as
compared to seed kernel, or grain products of the mature cereal plant. The
young germinated plant is a factory of enzyme and growth activity. In the early
stages of growth they store large amounts of vitamins and proteins in the
young blades. After jointing stage, the nutritional level in the leaves drops
rapidly while the fiber content increases rapidly. Agriculturally, important
species of Triticum include - Triticum aestivum, Triticum durum and Triticum
dicoccum. Wheatgrass has been traditionally used, since ancient times, to
treat various diseases and disorders. Presently, there are number of
wheatgrass suppliers, in almost all cities of India, supply fresh wheatgrass, on
daily basis to their regular customers by home-delivery system for various
ailments and as a health tonic. Dr. Ann Wigmore, U. S. A. founder director of
the Hippocrates Health Institute, Boston, U.S.A. was one of the proponents of
the ‘‘ Wheatgrass Therapy'. Dr. Wigmore claimed that wheatgrass is a safe
and effective treatment for ailments such as high blood pressure, some
cancers, obesity, diabetes, gastritis, ulcers, anemia, asthma and eczema.
Scientific reports on nutritional analysis of wheatgrass have been published
frequently in various journals. These reports and the chemical analyses
undertaken reveal that wheatgrass is rich in chlorophyll, minerals like
magnesium, selenium, zinc, chromium, antioxidants like beta-carotene (pro-
vitamin A), vitamin E, vitamin C, antianemic factors like vitamin B12, iron, folic
acid, pyridoxine and many other minerals, amino acids and enzymes, which
have significant nutritious and medicinal value.
Anemia is a hematological condition in which there is quantitative deficiency
of circulating hemoglobin, often accompanied by a reduced number of red
blood cells. Further, causes of anemia are blood loss, impaired erythropoiesis
and abnormal erythrocyte destruction. Nutritional deficiencies (iron, vitamin
B12 and folic acid) are the most common cause of anemia through out the
world (Brown 1991).
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Thalassemia is one of the most common groups of genetic blood disorder.
Countries like Italy, Greece and Cyprus have the highest frequency of
Thalassemia cases in the world. There exists a Thalassemic "belt" that
includes countries like Turkey, Iran, Afghanistan onto Pakistan and India.
There are an estimated 240 million carriers of thalassemia in the world. India
has the largest pool of numbering around 30 million (every 8th carrier of
thalassemia is an Indian). The highest frequency of ß-thalassemia trait is
reported in Gujarat (10-15%), followed by Sindh (10%), Tamil Nadu (8.4%),
Maharashtra (7.04%), Punjab (6.5%) and South India (4.3%). Very high rates
have been found in certain communities such as Sindhis 12.4% and in
Lohana Gujratis 13.6 % (Ambekar et al., 2001).
The thalassemias (µ and b) are characterized by impaired production of one
or more polypeptide chains of globin. Any of the four polypeptides (?, ?, ?,  )
that occur in normal hemoglobin may be involved. The fact that there are only
two genes for the beta chain of hemoglobin makes ß-thalassemia simpler to
understand. The ?-globin gene is present, but produces little ?-globin protein.
The degree of suppression varies. As per the clinical manifestations, ß-
thalassemia is classified in to three categories, (i) Thalassemia minor, or
thalassemia trait (ii) Thalassemia intermedia (iii) Thalassemia major. The
synthesis and accumulation of excess normal ?-globin chain within the red
cell, lead to the formation of unstable aggregates, which upon oxidation, due
to oxidative stress generated by iron overload, may precipitate and cause cell
membrane damage. These deformed cells undergo premature destruction
either in the bone marrow (extravascular hemolysis) or the peripheral
circulation (intravascular hemolysis). Management of ß-thalassemia major
(Cooley's Anemia) requires patients to have life-long regimen of regular blood
transfusions coupled with iron chelation therapy. Blood transfusion produces
on long term, serious and unavoidable side-effects because with each unit of
blood transfused 200 to 250 mg of iron gets deposited in the heart, liver,
pancreas and other glands in the body. This may lead to heart failure,
cirrhosis of liver, diabetes mellitus and malfunctioning of other glands.
______________________________________________________________
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Generally, regular blood transfusions and iron chelation treatment with
desferrioxamine are initiated early in life; therefore, the patients and their
families have to sustain regular treatment throughout their childhood,
adolescent, and adult years. The release of hemoglobin, during hemolysis,
and the subsequent therapeutic transfusion lead to systemic iron overloading
that further potentiates the generation of Reactive Oxygen Species (ROS) and
consequent oxidative stress, in thalassemia. The iron-induced liver damage in
thalassemia may play a major role in the depletion of lipid-soluble
antioxidants. Data indicate that dietary magnesium supplementation improves
some of the characteristic cellular function abnormalities of b-thalassemia
intermedia.
Thus, in thalassemia, there is a vicious cycle of iron overload leading to
oxidative stress with consequent increase in hemolysis and increase in blood
transfusion requirement causing further iron overload and its toxicities on
other organs. Replenishing magnesium and antioxidants by administration of
wheatgrass can break this vicious cycle.
Some research workers have studied chlorophyll, one of the major ingredients
present in wheatgrass. The chemical similarity between hemoglobin and
chlorophyll was first suggested by Verdel (1855). Owing to the close
molecular resemblance between chlorophyll and hemoglobin, it was
hypothesized that chlorophyll is nature's blood-building element for all
herbivorous animals and humans. Some studies have indicated that feeding
chlorophyll-rich foods to rats stimulates the regeneration of red blood cells.
The deficiency of magnesium in serum or erythrocytes has also been reported
in human ?-thalassemia. These deficiencies may play a significant role in
various cellular abnormalities characteristic of this disorder. The iron-induced
liver damage in thalassemia may play a major role in the depletion of lipid-
soluble antioxidants like vitamin A and vitamin E. Considering the above facts,
we hypothesized that major ingredients of wheatgrass like chlorophyll, beta-
carotene, vitamin A, vitamin E, vitamin C, selenium, zinc, magnesium, iron,
folic acid and vitamin B12 may be useful in treatment of anemia and ß-
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thalassemia. Hence, we have undertaken clinical studies to evaluate the
effects of wheatgrass in patients with anemia and thalassemia.
Traditionally, wheatgrass has been used as an adjunct in treatment of cancer.
It has also been suspected that wheatgrass is useful as anticancer
preparation by virtue of its several components like chlorophyll, P4D1
compound, abscisic acid and laetrile (vitamin B17). Chlorophyllin, which is
obtained by hydrolysis of chlorophyll to remove phytyl alcohol, is an efficient
antimutagenic agent and has been used as a dietary supplement or to
diminish the intensity of the discomforting side effects of chemopreventive
therapy. More recently, the cancer chemopreventive properties of chlorophylls
have come to be recognized. Chlorophyll has been reported to exhibit anti-
mutagenic activity in short-term genotoxicity assays.
Apart from the use of wheatgrass in cancer, it has been recommended that
the topical application of wheatgrass juice is useful for treatment of skin
infections. It has also been claimed that wheatgrass juice may have
antibacterial activity and that chlorophyll limits the growth of many types of
germs not by directly killing them, but by providing an environment, which
interferes with their growth especially against anaerobic bacteria, those that
do not require oxygen.
As mentioned above, fresh wheatgrass has been proposed to be used as a
juice, which is prepared in a mixer/blender with addition of little water followed
by filtration through a cloth. In a chronic disease like thalassemia, the drug
treatment is of long duration, may even be for years. In such a circumstances
the factor of patient compliance becomes very important. Outcome of the
therapy will largely depend upon regular supply (round the year and in all
seasons) and acceptability of the drug by patient. As a pharmaceutical
scientist, preparation of a suitable dosage form is prime area of research in
the development of new drug formulations. Preparation of wheatgrass tablets
was a challenge for us. We attempted to use different drying techniques such
as freeze drying, spray drying and shade drying to prepare dried wheatgrass
powder. It is well known that the stability of components present in
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wheatgrass, like chlorophyll, beta-carotene, vitamin A, vitamin E, vitamin C
etc, are adversely affected upon exposure to changes in air, light, humidity
and temperature. Since, all of the above mentioned drying processes involve
exposure of wheatgrass to some of these variables, potency of wheatgrass
powder obtained at the end of each drying process might be different,
consequently affecting the therapeutic effectiveness and out come of the
clinical trial. Hence, we also evaluated the potency of dried wheatgrass
powder, using UV spectra and HPTLC methods. It is well known that the
contents of an herbal drug can be affected by changes in species variety and
choice of soil or fertilizer used. In order to ascertain the most therapeutically
potent verity of Wheat and best type of fertilizer to grow wheatgrass, we
carried out UV spectral and HPTLC analysis of different verities of wheat
grown in similar soil/fertilizer and same variety of wheat grown in different
soils/fertilizers.
In nutshell the objectives of the present project were -
1. To carry out pharmacognostic study and phytochemical standardization
of different verities of Triticum grass (wheatgrass) and crude extract
using HPTLC fingerprinting.
2. To evaluate clinical effects of wheatgrass in the treatment of anemia, b
- thalassemia (major), cancer and bacterial diseases.
3. To prepare tablets of wheatgrass and to evaluate the most suitable
method of drying the wheatgrass for the same.
4. To standardize various formulations of wheatgrass by HPTLC.
5. To evaluate effect of wheat variety and fertilizer on potentially
therapeutic contents in wheatgrass.
In our investigation, certified samples of three major species of wheat viz.
Triticum aestivum, Triticum durum and Triticum dicoccum were acquired form
the Wheat Research Center, Gujarat Krushi University, Junagadh, Gujarat.
Adequate quantity of unpolished wheat grain of these varieties were soaked
overnight in water and were grown in plastic trays filled with soil, on the next
day. Trays were watered adequately everyday, for 8 days. On 9th day the
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wheatgrass was harvested. To characterize and differentiate among the three
varieties of wheatgrass, all three varieties of the grass were subjected to
microscopic study, which included transverse sections, surface preparations
and powder study. These wheat varieties were grown in plastic trays as per
the standard procedure. Microscopic studies of transverse sections, surface
preparations and powder studies of the three species of wheatgrass were
conducted using high-resolution microscope.
In conformation with the description in literature; the leaves were mainly near
glabrous, auriculate, with blades narrowly to broadly linear; broad to narrow;
2–20 mm wide; flat; without cross venation (Percival 1974). The leaf blade
was linear and parallel –veined with mid rib projecting on the back continuing
someway along the sheath. In T. Dicoccum the hairs on the swollen base of
leaf were longer than those of other species. The longest leaves were
possessed by T. durum. Observations in microscopic studies of different
species also confirmed characteristics reported in literature (Percival 1974). In
transverse section, the wheatgrass leaf showed 1. elaborate epidermis with
characteristic stomata and trichomes 2. green assimilating parenchyma, 3.
conducting vascular bundles and 4. longitudinal strands of fibrous stereome or
supporting tissue. The upper surface of the leaf showed a series of
longitudinal ridges or ribs, the lower surface being almost flat. At the summit
of each ridge was a single row of elongated thick-walled and pitted cells
alternating with hairs. The trichomes or hairs were always unicellular, and
vary much in length and stoutness. On the leaves of T. aestivum, ample
numbers of hair were present, while in T. dicoccum and T. durum they were
sparsely distributed on the surface of the leaf. Stomata were observed at the
base of the ridge arranged in single or double lines. Each stoma on the leaf
consisted of four cells; the two guard cells being narrow, with specially
thickened walls round the stomatal pore and thin-walled widely dilated ends.
Pores of the stomata were seen to be in communication with large
intracellular cavities in the mesophyll, called lacune. The ratio of the number
of stomata on the upper and lower epidermis respectively was about 10:7, the
number on the upper surface examined being 7000 per square centimeter. In
the furrow between two ridges was a band of three to seven rows of motor
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cells. vascular bundles were collateral, with the xylem towards the upper
surface of the leaf and the phloem bellow. In surface preparation, trichomes or
hairs of various lengths were found scattered along the rows at more or less
at regular intervals except in T. durum. The pharmacognostic characteristics
observed in our study were in confirmation with that reported in the literature.
Phytochemical analyses of dried wheatgrass powder revealed that
wheatgrass contains protein (25.2 %), carbohydrates (52.4 %), chlorophyll
(5.12 %), iron (43.5 mg/100 gm), magnesium (1455 mg/100 gm), zinc (97.8
mg/100 gm), beta-carotene (10.9075 I. U./100 gm), insoluble dietary fiber
(64.54 %) and fat (1.75 %). Our quantitative analyses revealed that
wheatgrass is a rich source of chlorophyll, various minerals like iron,
magnesium, calcium, phosphorus, antioxidants like beta carotene and
insoluble dietary fibers while being low in fat content.
Three different techniques were adapted to prepare dried wheatgrass powder
including spray drying, freeze drying and shade drying. In freeze-drying
technique, fresh wheatgrass was frozen to sub-zero temperature and
subsequently subjected to low-temperature heating (10o C -15o C) in vacuum
to evaporate crystallized water content. Dried wheatgrass was then milled to
obtain powder. In spray drying technique, fresh wheatgrass was pressed in a
hydraulic press to obtain juice. The juice was then sprayed in aerosol form
through a nebulizing nozzle in a conical vessel from top. A hot air counter
current (55o C) was passed from bottom of the vessel. The nebulized juice
settled on the bottom of the vessel in the form of powder. In shade drying
technique, fresh wheatgrass was dried at room temperature in a well-
ventilated dark room. The dried wheatgrass after 3-4 days of drying period
was powdered in a mill.
Samples of different methanolic extracts of wheatgrass and methanolic
solutions of reference standard beta-carotene were used for TLC. Suitably
diluted sample solutions were spotted on pre-coated silica gel 60 F254 TLC
plates (E. Merck) using CAMAG Linomat IV Automatic Sample Spotter. The
plates were developed in the solvent system consisting of Hexane: Acetone
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(65:35). The plates were dried at room temperature and scanned using
CAMAG TLC scanner 3 at UV 254 and 354 nm and Rf values, absorption
spectra of resolved bands were recorded. In all, 13 spots were observed at
different Rf values viz. (1) 0.07(Light green), (2) 0.21(Yellow), (3) 0.27(Grey),
(4) 0.35(Yellow), (5) 0.40(Yellow), (6) 0.47(Light green), (7) 0.54(Yellow), (8)
0.57(Green), (9) 0.61(Blue green), (10) 0.64(Light gray), (11) 0.69(Light gray),
(12) 0.74(Grey), (13) 0.92(Orange). By comparing standard Rf values and
colors reported in literature, out of 13 spots representing 13 different
components of wheatgrass, seven components at spot number 4, 7, 8, 9, 11,
12 and 13 were identified as xanthophyll c, xanthophyll a, chlorophyll b,
chlorophyll a, pheophytin b, pheophytin a and beta-carotene respectively. In
comparative TLC study, chlorophyll a was found to be present in significant
quantity in fresh wheatgrass and was absent in rest of the formulations.
Intense grey-colored spots of pheophytin compensated the absence of
chlorophyll in these formulations, as pheophytin is the degradation product of
chlorophyll. Except chlorophyll a, 12 components were found present in
shade-dried powder. Spot no. 4, 5, 6, 9 and 10 were absent in freeze-dried
and spray-dried powders. Beta-carotene was present in all formulations. Thus
shade drying, the natural method of drying, was found to preserve all
components of wheatgrass and hence, the most suitable one.
In qualitative HPTLC chromatograms of methanolic extracts of Standard b
Carotene, fresh wheatgrass, shade-dried wheatgrass powder, freeze-dried
wheatgrass powder and spray dried wheatgrass powders were subjected to
HPTLC study. The chromatograms were scanned in combined as well as
individual modes at 254 nm and 354 nm wavelengths. Findings of qualitative
HPTLC confirmed the patterns obtained in TLC study. Shade drying, the
natural method of drying, was found to preserve all components of
wheatgrass. Individual spots (components), in chromatogram of shade-dried
powder, were scanned at 254 nm wavelength to obtain their spectra for the
purpose of identification of these components of wheatgrass in further
investigations.
______________________________________________________________
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While, qualitative HPTLC was carried out on extracts of wheatgrass
formulations at maximum concentration (for detecting presence of various
constituents), for quantitative evaluation the methanolic extracts of equivalent
amounts of these formulations were subjected to quantitative HPTLC
analyses along with those of different species of wheatgrass. Chromatograms
of the formulations or species were recorded. Area under curve (AUC) of
different components were measured in chromatogram of each formulation or
species and analyzed for comparison with that of fresh wheatgrass. Since all
the constituents of wheatgrass could not be identified or were not present in
all chromatograms, the AUCs of only chlorophyll, pheophytin and beta-
carotene were used for the purpose of comparison of contents among
formulations of wheatgrass.
The quantitative HPTLC analyses of wheatgrass grown from three major
wheat species revealed that Triticum aestivum had lowest contents (76.8%)
as compared to the contents of Triticum durum (86.92%) and Triticum
dicoccum (100 %). Thus, it seems that wheatgrass grown from tetraploid
species of wheat, especially Triticum dicoccum  (local variety called as DDK)
and T. durum, is more suitable for medicinal use as compared to the
hexaploid species i.e. T. aestivum or the common wheat.
To determine the effect of fertilizer on quality of wheatgrass, same species of
wheat i.e. T. durum was grown separately in plain soil, in compost fertilizer
and in organic fertilizer. When subjected to quantitative HPTLC analyses,
contents of wheatgrass grown in organic fertilizer (91.36%) and that of
wheatgrass grown in compost fertilizer (92.05%) were nearly similar while the
contents of wheatgrass grown in plain soil (100%) were highest among the
three. Thus, presence of a fertilizer does not seem to hamper or interfere
much with the sensitive phytochemical processes being carried out in the
young growing grass in early stages of growth.
It is well known that the stability of components present in wheatgrass, like
chlorophyll, beta-carotene, vitamin A, vitamin E, vitamin C etc, are likely to be
adversely affected upon exposure to changes in air, light, humidity and
______________________________________________________________
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temperature. This fact was confirmed by the results of our analyses. When
subjected to quantitative HPTLC analyses, wheatgrass tablets of spray-dried
powder was found to have lowest contents (21.66%) as compared to the
contents of tablets of freeze-dried powder (46.68%) and shade-dried powder
(87.75%) considering the contents of methanolic extract of fresh wheatgrass
as 100%. Hence, it may be concluded that the most suitable method of
preparing dry wheatgrass powder, among the above three techniques, is
shade drying technique.
Traditionally, wheatgrass juice is prepared by grinding fresh wheatgrass in
mixer/grinder adding little water that is subsequently filtered through a cloth.
When subjected to quantitative HPTLC analyses the fresh wheatgrass juice,
prepared by traditional method, was found to have 96.7% contents
considering the contents of methanolic extract of fresh wheatgrass as 100%.
Thus, the traditional method i.e. fresh wheatgrass juice seems to be the best
method for wheatgrass therapy compared to any formulations of wheatgrass
that were made in our study.
The in-vitro antibacterial activity profiles of undiluted wheatgrass juice as well
as acetone and methanolic extracts of wheatgrass were studied by agar–well
diffusion method. Acetone and methanolic extracts did not show any kind of
antibacterial activity while, fresh and undiluted wheatgrass juice exhibited mild
antibacterial activity against Staphylococcus aureus, Bacillus cereus,
Salmonella typhimurium and Kleibsella pneumoneae at 2.7 gm/ml
concentration. In terms of zone of inhibition, the diameter of the zone was
found to be 12.1, 12.4, 13.2 and 12.2 % respectively. It is known that
availability of iron increases host susceptibility to K. pneumoniae infection and
that thalassemic patients are chronic sufferers of iron overload. Thus, the
antibacterial activity of wheatgrass could be beneficial for thalassemic
patients, in addition to its clinical effects on blood picture. Investigation in to
antibacterial profile of wheatgrass revealed two important features. The
antibacterial activity was exibited only by undiluted extract of wheatgrass.
Further, this antibacterial activity was lost within 2 hours of preparing the
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extract. This leads us to conclude that topical application of only fresh and
undiluted wheatgrass extract could be beficial in treatment of skin infections.
The antiproliferative activity of wheatgrass was studied by comparing seed
germination rate of green grams, groundnuts and wheat in presence of
distilled water (control) and wheatgrass juice. Presence of wheatgrass juice
reduced rate of wheat germination by 50% while those of green gram and
groundnut were reduced by 70% and 90% respectively. The strong
antiproliferative activity exibited by wheatgrass could be a clue to its potential
anticancer activity. Chlorophyll, abscisic acid and laetrile present in
wheatgrass may contribute to this activity.
To assess clinical effects of wheatgrass on anemia an open clinical trial of
wheatgrass on patients with anemia was carried out at Ayurved Hospital,
working under Civil Hospital, Rajkot. Necessary permission for conducting the
clinical trial was obtained from the concerned ethical committee. Twenty
anemic patients (age 20 to 50 years) were enrolled for the trial after taking
informed consent. The patients were given wheatgrass tablets with dosage
regimen of 2 tablets (shade-dried wheatgrass powder 250 mg.) 3 times in a
day for 1 month. Blood samples were collected before and at the end of
period of clinical trial (i.e. 1-month period). To assess effect of wheatgrass on
haemopoietic activity, hemoglobin gm%, RBC count, WBC count were
recorded while, to assess effect of wheatgrass on defense mechanism
neutrophil count, lymphocyte count and total lymphocyte count were recorded.
After 1-month treatment with wheatgrass, hemoglobin content (Hb gm%) was
found to be significantly (P<0.05) increased (before treatment: 11.75 ± 0.245,
after treatment: 12.63 ± 0.307). RBC count was significantly (P<0.05)
decreased (before treatment: 4.72 ± 0.132, after treatment: 4.37 ± 0.087). The
decrease in RBC count indicated that wheatgrass might have suppressed
haemopoietic process. Rise in hemoglobin content indicated stimulation of
hemoglobin synthesis in individual RBC, probably by replenishment of
deficient nutritional factors like iron. It is known that the major cause of
anemia, in absence of any primary disease, is malnutrition. WBC count
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(before treatment: 8615 ± 593, after treatment: 7725 ± 440), neutrophil count
(before treatment: 62.2 ± 1.51, after treatment: 60.8 ± 1.7), lymphocyte count
(before treatment: 32.25 ± 1.62, after treatment: 33.7 ± 1.86) and total
lymphocyte count (before treatment: 2661.5 ± 83, after treatment: 2483 ± 120)
were not affected significantly (P<0.05). This showed that either wheatgrass
had no effect on body’ s defense mechanism or the duration of treatment i.e.1
month, was insufficient for such an effect.
To assess clinical effects of wheatgrass on b-thalassemia (major) a
randomized clinical trial of wheatgrass on b-thalassemia was carried out at K.
T. Children Hospital working under Civil Hospital, Rajkot. Necessary
permission for conducting the clinical trial was obtained from the concerned
ethical committee. Thalassemic patients, visiting K. T. Children Hospital
regularly for blood transfusion and registered at the hospital were enrolled for
the trial, after taking informed consent. The patients were given wheatgrass
tablets with dosage regimen of 2 tablets (wheatgrass powder 250 mg.) 3
times in a day for 9 months. Blood samples were collected at the start, after 6
months and at the end of period of clinical trial. The parameters recorded
were Hemoglobin content, Total RBC count, PCV, MCV, MCH, MCHC, Total
WBC count, Neutrophil count, Eosinophil count, Basophil count, Lymphocyte
count, Serum iron, Serum ferritin, Serum magnesium and TBARS.
After 9 months treatment with wheatgrass, Hemoglobin gm% in normal-range
subgroup (i.e. Male-13.5-18 gm%, F–12-16 gm%) was significantly decreased
(before treatment: 12.87 ± 0.10, after treatment: 10.77 ± 0.36). RBC count in
normal-range subgroup (Male-4.5-6.5/cmm, Female-4.2-5.4/cmm) was also
significantly decreased (before treatment: 4.55 ± 0.13, after treatment: 3.74 ±
0.20). This may be an indication of haemopoietic suppression effect of
wheatgrass.
Reticulocyte count in abnormal-range subgroup was significantly decreased
(before treatment: 10.8 ± 2.55, after treatment: 2.8 ± 1.21). The chronic
hypoxic condition in thalassemia, which may occur due to persistent low
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hemoglobin content of blood, stimulates secretion of erythropoietin and is
reported to increase the ineffective erythropoiesis and reticulocyte count.
Decrease in reticulocyte count observed in our study, after wheatgrass
treatment, indicates an increase in the tissue oxygenation and decrease in
ineffective erythropoiesis.
Mean corpuscular volume (MCV) in normal-range subgroup was significantly
increased (before treatment: 86.26 ± 1.06, after treatment: 77.02 ± 2.58) and
that in abnormal-range subgroup was also significantly increased (before
treatment: 77.63 ± 0.94, after treatment: 82.99 ± 1.74). Mean corpuscular
hemoglobin concentration (MCHC) in abnormal-range subgroup was
significantly increased (before treatment: 28.85 ± 1.06, after treatment: 32.63
± 1.06). Positive changes in both these parameters reflect correction of both
hypochromia and microcytosis, thus exhibiting reversal of abnormal condition
in thalassemia. In our investigation, the increase in MCHC i.e. increase in
hemoglobin content of individual RBC was possibly offset by haemopoietic
suppression effect of wheatgrass i.e. decrease in number of RBC. Hence, the
reduction in overall transfusion requirement was not observed after 9 months
treatment with wheatgrass. This further supports a positive effect of
wheatgrass in thalassemia.
After 9 months treatment with wheatgrass, various parameters in abnormal-
range subgroup, including platelet count (before treatment: 199000 ±
126572.1, after treatment: 258000 ± 154149.3), WBC count (before treatment:
13875.0 ± 2902.8, after treatment: 16057.1 ± 2033.11), neutrophil % (before
treatment: 51.69 ± 2.04, after treatment: 54.23 ± 3.39), lymphocyte % (before
treatment: 40.00 ± 1.83, after treatment: 40.53 ± 2.00) and total lymphocyte
count (before treatment: 5274.00 ± 916.94, after treatment: 6968.29 ±
1364.91) were not affected to any significant level, while eosinophil count
(Eosin %) was significantly decreased (before treatment: 3.22 ± 1.14, after
treatment: 0.33 ± 0.22). Eosinophilia is seen in allergic disorders. Thalassemic
patients on regular blood transfusion therapy are subject to various allergens
hence, eosinophilia is commonly found in thalassemic patients. Thus, reversal
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of eosinophilia may be an indicator of much acclaimed detoxifying or
antiallergic property of wheatgrass.
Treatment with wheatgrass did not produce any effect on serum iron, serum
magnesium and TBARS. These parameters were included to investigate
probable mechanism of action of wheatgrass. Thus, our data indicate that
although wheatgrass treatment exhibits beneficial therapeutic effects in
thalassemia, the mechanism of action is neither iron or magnesium
supplementation nor replenishment of antioxidants.
As wheatgrass contains substantial quantity of iron that is contraindicated for
thalassemic patients, the major apprehension expressed by patients and
doctors, at the outset of this study, was the possibility of increase in iron load
after wheatgrass treatment. Since, the plasma or serum ferritin is the most
commonly used indirect estimate of body iron stores, we measured serum
ferritin levels in thalassemic patients. In our investigation serum ferritin level,
against all predictions, was significantly decreased at the end of 9 months
treatment with wheatgrass. In absence of substantial rise in hemoglobin
content, the only possible explanation for decreased iron load is increased
excretion of iron. Thus, the most notable outcome of our investigation, apart
from ascertaining the ability of wheatgrass to increase hemoglobin content, is
the detection of its probable ability to decrease iron load in thalassemia.
Wheatgrass may well be the long sought-after safe, oral and economical iron-
chelating agent for thalassemic patients.
Comparison of effects of wheatgrass treatment in different groups of patients
reveals that patients above 12 years age had more beneficial effects of
wheatgrass treatment as compared to the patients below 12 years age. This
was probably due to the lower dose of wheatgrass (two tablets twice in a day)
administered to patients bellow 12 years age as compared to higher dose
(two tablets three time in a day) to patients above 12 years age. Significant
difference in the clinical effectiveness between these two dosage regimen
indicate that the minimum dose of wheatgrass should be two tablets (250 mg
tablets) three times in a day, for thalassemic patients of all age group.
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Reversal of ineffective erythropoiesis and consequent reversal of
splenomegaly with subsequent release of trapped lymphocytes may be the
cause of significantly increased total lymphocyte count (before treatment:
1768.5 ± 151.04, after treatment: 2351.8 ± 157.97) in patients of above 12
years age grouping our investigation. Reversal of splenomegaly after
wheatgrass treatment is further supported by the fact that lymphocyte count
was significantly increased (before treatment: 26.5 ± 2.47, after treatment:
41.5 ± 1.06) in patients with spleen, while it remained unaffected in
spleenectomized group.
In nutshell, our studies support, scientifically, some of the therapeutic claims
for wheatgrass. The potential benefit of wheatgrass in thalassemia appears to
be convincing and opens new vista of investigation.
12. INTRODUCTION
Herbal medicine is still the mainstay of about 75% of the world population,
especially in the under developed and developing countries, for primary health
care because of better cultural acceptability, better compatibility with the
human body and lesser side effects. However, in the last few years there has
been a major increase in their use in the developed world. In Germany and
France, many herbs and herbal extracts are used as prescription drugs. Their
sales in the countries of European Union were around $ 6 billion in 1991 and
may be over $ 20 billion now. About 25% of modern medicines are descended
from plants first used traditionally.
According to The National Medicinal Plants Board, Ministry of Health and
Family Welfare, Govt. of India ‘ India has 15 agro climatic zones, with 47000
different plant species and 15000 medicinal plants The Indian Systems of
Medicine have identified 1500 medicinal plants, of which 500 species are
mostly used therapeutically. The medicinal plants contribute to cater 80% of
the raw materials used in the preparation of drugs. The effectiveness of these
drugs mainly depends upon the proper use and sustained availability of
genuine raw materials. The domestic market of Indian Systems of Medicine
and Homoeopathy is about Rs. 4000 crores (2000), which is expanding day
by day. The Ayurved drug market alone is to the order of Rs. 3500 crores.
Besides this, there is also a growing demand for natural products including
items of medicinal value/pharmaceuticals, food supplements and cosmetics in
both domestic and international markets. Presently, India’ s export, from
medicinal and herbal plants, is Rs. 3000 crores. India, with its diversified
biodiversity has a tremendous potential and advantage in this emerging area.
According to WHO report, over 80% of the world population relies on
traditional medicine largely plant based for their primary healthcare needs.
The EXIM bank of India, in its report (1997) has reported the value of
medicinal plants related trade in India of the order of 5.5 billion US dollars and
is growing rapidly. According to WHO, the International market of herbal
products is estimated to be US $ 62 billion which is poised to grow to US $ 5
2trillion by the year 2050. India’ s share in the global export market of medicinal
plants related trade is just 0.5%. In India, the herbal drug market is about $
one billion and the export of plant-based crude drugs is around $ 80 million
(Esau 1974). Herbal medicines also find market as nutraceuticals (health
foods) whose current market is estimated at about $ 80–250 billion in USA
(Cutter 1978). India is sitting on a gold mine of well-recorded and well-
practiced knowledge of traditional herbal medicine. But, unlike China, India
has not been able to capitalize on this herbal wealth by promoting its use in
the developed world despite their renewed interest in herbal medicines. This
can be achieved by judicious product identification based on diseases found
in the developed world for which no medicine or only palliative therapy is
available; such herbal medicines will find speedy access into those countries.
Backward integration from market demands will pay rich dividends.
Strategically, India should enter through those plant-based medicines, which
are already well accepted in Europe, USA and Japan. Simultaneously, it
should identify those herbs (medicinal plants), which are time-tested and
dispensed all over in India.
Wheat, (Triticum species) a cereal grass of the Gramineae (Poaceae) family,
is the world's largest edible grain cereal-grass crop. Wheat has been a food
crop for mankind since the beginning of agriculture. The wheat plant is an
annual grass. In early growth stages the wheat plant consists of a much-
compressed stem or crown and numerous narrowly linear or linear-lanceolate
leaves. For over fifty years, researchers have known that the cereal plant, at
this young green stage, is many times richer in the levels of vitamins, minerals
and proteins as compared to seed kernel, or grain products of the mature
cereal plant (Schnabel 1940).
The young germinated plant is a factory of enzyme and growth activity. In the
early stages of growth they store large amounts of vitamins and proteins in
the young blades. After jointing stage, the nutritional level in the leaves drops
rapidly while the fiber content increases rapidly. The jointing stage is that point
at which the internodal tissue in the grass leaf begins to elongate, forming a
3stem. This stage represents the peak of the cereal plant's vegetative
development (Kohler 1944).
Although over 30,000 varieties of wheat exist, they are of two major types:
bread wheat and durum wheat. In U. S. Dept. of Agriculture- Technical
Bulletin 1287 has classified wheat into 10 species of Triticum. Six of these are
cultivated and four are non-cultivated, or rarely so. Agriculturally, Important
species of Triticum include – (I) Triticum aestivum (Common wheat, bread
wheat, local varieties - Lok1, GW273) - Triticum aestivum comprises nearly 95
percent of the wheat grown. Its principal use is for flour. It is the most
important variety for agriculture. (II) Triticum durum (Durum wheat, local
variety Raj 1555) - Triticum durum is used mainly for the manufacture of
semolina, which is made into macaroni, spaghetti and related products. It is
next in importance to Triticum aestivum. (III) Triticum dicoccum (Emmer
wheat, local variety DDK) - Triticum dicoccum is one of the most ancient of
cultivated cereals. Emmer was formerly grown in the United States for feed on
a limited acreage but now has substantially disappeared from cultivation.
Wheatgrass has been traditionally used, since ancient times, to treat various
diseases and disorders. Presently, there are a number of wheatgrass
suppliers, in almost all cities of India, supply fresh wheatgrass, on daily basis
to their regular customers by home-delivery system for various ailments and
as health tonic.
Dr. Ann Wigmore, U. S. A. founder director of the Hippocrates Health Institute,
Boston, U.S.A. was one of the proponents of the ‘ Wheatgrass Therapy'. Dr.
Wigmore utilized the chlorophyll present in wheatgrass as body cleanser,
rebuilder and neutralizer of toxins. She claimed that wheatgrass is a safe and
effective treatment for ailments such as high blood pressure, some cancers,
obesity, diabetes, gastritis, ulcers, anemia, asthma and eczema (Wigmore
1985).
Scientific reports on nutritional analysis of wheatgrass have been published
frequently in various journals (Kohler 1953, Hamilton et al., 1988, Laboratory
4Analyses 1989). These reports and the chemical analyses undertaken reveal
that wheatgrass is rich in chlorophyll, minerals like magnesium, selenium,
zinc, chromium, antioxidants like beta-carotene (pro-vitamin A), vitamin E,
vitamin C, antianemic factors like vitamin B12, iron, folic acid, pyridoxine and
many other minerals, amino acids and enzymes, which have significant
nutritious and medicinal value.
Anemia is a hematological condition in which there is quantitative deficiency
of circulating hemoglobin, often accompanied by a reduced number of red
blood cells. Further, causes of anemia are blood loss, impaired erythropoiesis
and abnormal erythrocyte destruction. Nutritional deficiencies (iron, vitamin
B12 and folic acid) are the most common cause of anemia through out the
world (Brown 1991).
Thalassemia is one of the most common groups of genetic blood disorder.
The word thalassemia was derived from two Greek words - Thalassa meaning
the sea and haima meaning blood. Thomas Benton Cooley (1871-1945) was
the first American physician to describe the clinical presentation and features
of unexplained severe anemia and hence it was coined Cooley's anemia.
Countries like Italy, Greece and Cyprus have the highest frequency of
Thalassemia cases in the world. There exists a Thalassemic "belt" that
includes the Mediterranean passing through West and Central Asian countries
like Turkey, Iran, Afghanistan onto Pakistan and India and passes on to the
South East Asian countries like Indonesia, Burma and Thailand. There are an
estimated 240 million carriers of thalassemia in the world.
India has the largest pool of numbering around 30 million (every 8th carrier of
thalassemia is an Indian). The distribution of ß-thalassemia gene is not
uniform in the Indian subcontinent. The highest frequency of ß-thalassemia
trait is reported in Gujarat (10-15%), followed by Sindh (10%), Tamil Nadu
(8.4%), Maharashtra (7.04%), Punjab (6.5%) and South India (4.3%)
(Varawalla et al., 1991, Balgir 1996, Sukumaran and Master 1974 ). The
condition is uncommon south of Vindhyas. Very high rates have been found in
certain communities such as Sindhis 12.4% and in Lohana Gujratis 13.6 %.
5The reason is attributed to intra-caste and intra-community marriages. It is
estimated that every year about 10,000 children are born in India with the
disorders. In terms of cost of ideal maintenance of these children a staggering
Rs. 150 crores is required to be spent every year (Varawalla et al., 1991).
The thalassemias are characterized by impaired production of one or more
polypeptide chains of globin. Any of the four polypeptides (?, ?,?,  ) that
occur in normal hemoglobin may be involved. However, the most prevalent
thalassemia syndromes are those that involve diminished or absent synthesis
of  the ? or  ?-globin chains of HbA1 (Weatherall 1997, Jandl 1987, Steinberg
1988). ?-thalassemia occurs when one or more of the four ? chain genes fails
to function. With ?-thalassemia, the "failed" genes are almost invariably lost
from the cell due to a genetic accident. ?-thalassemia has four manifestations,
which correlate with the number of defective genes. (i) Silent carrier state (ii)
Mild alpha-thalassemia (iii) Hemoglobin H disease (iv) Hydrops fetalis.
The fact that there are only two genes for the beta chain of hemoglobin makes
ß-thalassemia simpler to understand than ?-thalassemia (Rund and
Rachmilewitz 1995). Unlike ?-thalassemia, ß-thalassemia rarely arises from
the complete loss of a ?-globin gene. The ?-globin gene is present, but
produces little ?-globin protein. The degree of suppression varies. As per the
clinical manifestations, ß-thalassemia is classified in to three categories, (i)
Thalassemia minor, or thalassemia trait (ii) Thalassemia intermedia (iii)
Thalassemia major. The synthesis and accumulation of excess normal ?-
globin chain within the red cell, lead to the formation of unstable aggregates,
which upon oxidation, due to oxidative stress generated by iron overload, may
precipitate and cause cell membrane damage. These deformed cells undergo
premature destruction either in the bone marrow (extravascular hemolysis) or
the peripheral circulation (intravascular hemolysis) (Weatherall 1997, Festa
1985).
Management of ß-thalassemia major (Cooley's Anemia) requires patients to
have life-long regimen of regular blood transfusions coupled with iron
chelation therapy (Modell 1994, Cao et al., 1997). The frequency of blood
6transfusion requirement increases with growing age. On an average
transfusion is required every fortnight. Blood transfusion produces on long
term, serious and unavoidable side-effects because with each unit of blood
transfused 200 to 250 mg of iron gets deposited in the heart, liver, pancreas
and other glands in the body. This may lead to heart failure, cirrhosis of liver,
diabetes mellitus and malfunctioning of other glands. Generally, regular blood
transfusions and iron chelation treatment with desferrioxamine are initiated
early in life; therefore, the patients and their families have to sustain regular
treatment throughout their childhood, adolescent, and adult years (Olivieri et
al., 1994, Zurlo et al., 1989).
The release of hemoglobin, during hemolysis, and the subsequent therapeutic
transfusion lead to systemic iron overloading that further potentiates the
generation of Reactive Oxygen Species (ROS) in thalassemia. A number of
major cellular defense mechanisms exist to neutralize and combat the
damaging effects of these reactive substances. The enzymic system functions
by direct or sequential removal of ROS (superoxide dismutase, catalase, and
glutathione peroxidase), thereby terminating their activities. Nonenzymic
defense consists of scavenging molecules that are endogenously produced
(GSH, ubiquinols, uric acid) or those derived from the diet (vitamins C and E,
lipoic acid, selenium, riboflavin, zinc, and the carotenoids or vitamin A) (Chan
et al., 1999). The iron-induced liver damage in thalassemia may play a major
role in the depletion of lipid-soluble antioxidants (Livrea et al., 1996). Data
indicate that dietary magnesium supplementation improves some of the
characteristic cellular function abnormalities of b-thalassemia intermedia (De
Franceschi et al., 1998).
Patients receiving regular blood transfusions, if given less than two-thirds of
the recommended desferrioxamine dose, are known to have increased risk of
developing complications later in life as a result of accumulation of iron
(Brittenham et al., 1994, Gabutti and Piga 1996). Desferioxamine is required
to be given at least five times a week through an injection under the skin very
slowly with the help of an electrical or mechanical gadget tied to the child. The
7cost of the gadget is around Rs 10,000 to 15,000. Thus, in thalassemia, there
is a vicious cycle of iron overload leading to oxidative stress with consequent
increase in hemolysis and increase in blood transfusion requirement causing
further iron overload and its toxicities on other organs. Replenishing
magnesium and antioxidants by administration of wheatgrass can break this
vicious cycle.
Some research workers have studied chlorophyll, one of the major ingredients
present in wheatgrass. Chlorophyll is not so unique in its chemical structure. It
is built around a porphyrin ring, which occurs in a variety of natural organic
molecules. The most interesting group of molecules which contain porphyrin
rings are those involved in cellular respiration, or the transportation and
consumption of oxygen. These include hemoglobin, myoglobin, and the
cytochromes. The chemical similarity between hemoglobin and chlorophyll
was first suggested by Verdel in 1855 (Carpenter 1949). One of the major
differences between chlorophyll and hemin is that chlorophyll contains
magnesium while the hemin molecule contains iron as its central atom. Owing
to the close molecular resemblance between chlorophyll and hemoglobin, it
was hypothesized that chlorophyll is nature's blood-building element for all
herbivorous animals and humans.
Some studies have indicated that feeding chlorophyll-rich foods to rats
stimulates the regeneration of red blood cells (Scott and Delor 1933).
Researchers were able to demonstrate that this effect was not due to the iron
or copper in the green foods (Rothemund et al., 1934). Hughes and Latner
(1936) fed several doses and forms of chlorophyll to anemic rabbits and found
that very small doses of purified chlorophyll or large doses of a crude
chlorophyll extract produced a very favorable effect on hemoglobin
regeneration. They suggested that the chlorophyll is acting as a physiological
stimulant of the bone marrow and is not really concerned with the actual
chemistry of regeneration of the porphyrin.
The deficiency of magnesium in serum or erythrocytes has also been reported
in human ?-thalassemia. These deficiencies may play a significant role in
8various cellular abnormalities characteristic of this disorder (De Franceschi et
al., 1998). The iron-induced liver damage in thalassemia may play a major
role in the depletion of lipid-soluble antioxidants like vitamin A and vitamin E
(Livrea et al., 1996). Degradation of chlorophyll following ingestion by humans
produces several chlorophyll derivatives, of which pheophytin, pyro-
pheophytin, and pheophorbide have been under study for their potential
medical benefits (Chernomorsky 1999). Pheophorbide-a showed antioxidant
activity against lipid auto-oxidation.  The extent of activity was comparable to
that of µ-tocopherol, a powerful and well-known antioxidant (Gentile 1991,
Nakamura 1996, Lee 1999). Considering the above facts, we hypothesized
that major ingredients of wheatgrass like chlorophyll, beta-carotene, vitamin
A, vitamin E, vitamin C, selenium, zinc, magnesium, iron, folic acid and
vitamin B12 may be useful in treatment of anemia and ß-thalassemia. A recent
report by Marvaha et al (2004) has provided an evidence to support this
hypothesis wherein in a pilot study it was reported that the administration of
wheatgrass significantly reduces blood transfusion requirement in thalassemic
patients. Therefore, one of the major objectives of the present project was to
evaluate clinical effects of wheatgrass in anemia and b-thalassemia (major).
Traditionally, wheatgrass has been used as an adjunct in treatment of
cancers. Wigmore (1985) suspected that wheatgrass is also useful as
anticancer preparation by virtue of its several components like chlorophyll,
P4D1 compound, abscisic acid and laetrile (vitamin B17). According to Te et al.,
(1997) chlorophyllin, which is obtained by hydrolysis of chlorophyll to remove
phytyl alcohol, is an efficient antimutagenic agent and has been used as a
dietary supplement or to diminish the intensity of the discomforting side
effects of cancer preventive therapy. It is possible that chlorophyllin may have
beneficial effects when used in combination with cancer preventive therapy.
More recently, the cancer chemopreventive properties of chlorophylls have
come to be recognized. Chlorophyll has been reported to exhibit anti-
mutagenic activity in short-term genotoxicity assays (Dashwood 1997).
Chlorophyll-rich plant extracts, as well as water solutions of a chlorophyll
derivative (chlorophyllin), dramatically inhibit the carcinogenic effects of
9common dietary and environmental chemicals (Kimm et al., 1982, Ong et al.,
1986). Using the standard Ames test, it has been shown that an extract of
wheat grass, when applied to known chemical mutagens (which cause cells to
become cancerous), decreased their cancer-causing ability by up to 99
percent (Li et al., 1978). Later studies by the same investigators showed that
several green vegetables provide anti-mutagenic protection from a number of
cancer causing chemicals (Li et al., 1980). This activity was found to be
proportional to the amount of chlorophyll in the vegetables (Lai 1978).
Apart from the use of wheatgrass juice in anemia and cancer, it has been
recommended that the topical application of wheatgrass juice is useful for
treatment of skin infections (Wigmore 1985). It has also been claimed that
wheatgrass juice may have antibacterial activity. Chlorophyll limits the growth
of many types of germs not by directly killing them, but by providing an
environment, which interferes with their growth especially against anaerobic
bacteria, those that do not require oxygen (Smith 1955). Chlorophyll solutions
provide significant relief of pain, reduction of inflammation, and the control of
odor for patients with serious mouth diseases (Gruskin 1940). Chlorophyll has
also been used successfully to treat chronic and acute sinusitis, vaginal
infections, and chronic rectal lesions (Gruskin 1940). In the light of these
reports we also made an attempt to evaluate anticancer and antibacterial
activity of wheatgrass.
As mentioned above, fresh wheatgrass has been proposed to be used as a
juice, which is prepared in a mixer/blender with addition of little water followed
by filtration through a cloth (Marwaha et al., 2004). In a chronic disease like
thalassemia, the drug treatment is of long duration, may even be for years. In
such a circumstances the factor of patient compliance becomes very
important. Outcome of the therapy will largely depend upon regular supply
(round the year and in all seasons) and acceptability of the drug by patient. As
a pharmaceutical scientist, preparation of a suitable dosage form is prime
area of research in the development of new drug formulations. In the present
investigation we decided to prepare suitable formulation that is as effective as
juice per se.
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Preparation of wheatgrass tablets was a challenge for us. We attempted to
use different drying techniques such as freeze drying, spray drying and shade
drying to prepare dried wheatgrass powder. In freeze-drying technique, fresh
wheatgrass was frozen to sub-zero temperature and subsequently subjected
to low-temperature heating (5o C -10o C) in vacuum to evaporate crystallized
water content. Dried wheatgrass was then milled to obtain powder. In spray-
drying technique, fresh wheatgrass was pressed in a hydraulic press to obtain
juice. The juice was then sprayed in aerosol form through a nebulizing nozzle
in a conical vessel from top. A hot air counter current (55o C) was passed from
bottom of the vessel. The nebulized juice settled on the bottom of the vessel
in the form of powder. In shade-drying technique, fresh wheatgrass was dried
at room temperature in a dark room. The dried wheatgrass after 3-4 days of
drying period was powdered in a mill.
It is well known that the stability of components present in wheatgrass, like
chlorophyll, beta-carotene, vitamin A, vitamin E, vitamin C etc. are adversely
affected upon exposure to changes in air, light, humidity and temperature.
Since, all of the above mentioned drying processes involve exposure of
wheatgrass to some of these variables, potency of wheatgrass powder
obtained at the end of each drying process might be different, consequently
affecting the therapeutic effectiveness and out come of the clinical trial.
Hence, we also evaluated the potency of dried wheatgrass powder, using UV
spectra and HPTLC methods.
It is well known that the contents of an herbal drug can be affected by
changes in species variety and choice of soil or fertilizer used. In order to
ascertain the most therapeutically potent verity of Wheat and best type of
fertilizer to grow wheatgrass, we carried out UV spectral and HPTLC analysis
of different verities of wheat grown in similar soil/fertilizer and same variety of
wheat grown in different soils/fertilizers.
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In nutshell the objectives of the present project were -
1. To carry out pharmacognostic study and phytochemical
standardization of different verities of Triticum grass (wheatgrass)
and crude extract using HPTLC fingerprinting.
2. To prepare tablets of wheatgrass and to evaluate the most
suitable method of drying the wheatgrass for the same.
3. To standardize various formulations of wheatgrass by HPTLC.
4. To evaluate effect of wheat variety and fertilizer on potentially
therapeutic contents in wheatgrass.
5. To evaluate effects and mechanism of action of wheatgrass in
treatment of anemia, b-thalassemia (major), cancer and bacterial
diseases.
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3. REVIEW OF LITERATURE
3.1 Pharmacognosy and phytopharmacology of wheatgrass
Taxonomical details -
 Kingdom Plantae – Plants
Subkingdom Tracheobionta – Vascular plants
Superdivision Spermatophyta – Seed plants
Division Magnoliophyta – Flowering plants
Class Liliopsida – Monocotyledons
Subclass Commelinidae –
Order Cyperales –
Family Poaceae – Grass family
Genus Triticum L. – wheat
Species T. aestivum
Wheat, a cereal grass of the Gramineae (Poaceae) family and of the genus
Triticum and its edible grain, is the world's largest cereal-grass crop. It has
been a food crop for mankind since the beginning of agriculture. The Middle
East is probably the area of origin, and wheat apparently spread throughout
Europe not later than the Stone Age. Historians believe it has been growing
since Paleolithic times and cultivated for at least 6,000 years. Its status as a
staple is second only to rice. One reason for its popularity is that, unlike other
cereals, wheat contains a high amount of gluten, the protein that provides the
elasticity necessary for excellent bread making. Although over 30,000
varieties of wheat exist, the two major types are bread wheat and durum
wheat. Global production of wheat is approximately 600 million tons; with
international trade approximately 100 million tons annually. Wheat is Asia's
second most important staple and has been growing much faster than rice.
Wheat now provides one-fifth of total developing country food supply, up from
15 % in the early 1970s. In 1992-94, developing countries accounted for 45 %
of world wheat production (551 million tons) and 46 % of world wheat area
(219 million ha).
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The wheat plant is an annual grass. It is mainly grown as a winter annual in
milder climates, with seeding in the fall and harvest from June through August
depending on the length of the winter. In areas with rigorous winter climates it
is mainly spring seeded. Planting is as early as soil can be worked, and
harvest is in late summer and early fall. In early growth stages the wheat plant
consists of a much-compressed stem or crown and numerous narrowly linear
or linear-lanceolate leaves. Leaves are mainly near glabrous. Buds in the leaf
axils below the soil surface grow into lateral branches termed tillers. From
both the main crown and the tillers, elongated stems develop later and
terminate in a spike or head in which the flowers, and finally the seed or grain,
develop. Stems of wheat reach from 18 inches to 4 or more feet in height
depending on kind and growing conditions.
Macroscopy (Triticum aestivum)
Triticum aestivum is a bisexual plant with bisexual spikelets and
hermaphrodite florets. Culm nodes are hairy, or glabrous. Culm internodes
are solid, or hollow. Leaves are auriculate with blades narrowly to broadly
linear. Leaves are 2–20 mm wide, flat, without cross venation and persistent.
Inflorescence is a single elongated spike. Rachides are hollow. Spikelets are
solitary; distichous and sessile. Female-fertile spikelets are 9–16 mm long,
laterally compressed and disarticulating above the glumes. Rachilla are
prolonged beyond the uppermost female-fertile floret. The rachilla extension is
incomplete florets. Hairy callus is absent. Callus is very short and blunt.
Glumes are two and more or less equal in size. They are shorter than the
adjacent lemmas and lateral to the rachis; without conspicuous tufts or rows
of hairs. Lower glume is 5–11 nerved. Upper glume is 5–11 nerved. Spikelets
are usually with incomplete florets. The incomplete florets are distal to the
female-fertile florets. The distal incomplete florets are usually 1, or 2 in
number. Female-fertile florets have lemmas similar in texture to the glumes.
Awns when present are much shorter than the body of the lemma or much
longer than the body of the lemma. Lemmas are hairy or hairless but scabrid.
Palea is present and is relatively long, entire or apically notched. Palea keels
are somewhat winged. Lodicules are membranous and ciliate. 3 stamens are
present. Anthers are not penicillate with 2–4.5 mm length. Ovary is hairy.
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Styles are free to their bases. Stigmas are 2 in number and white in color.
Fruit is free from both lemma and palea. It is medium sized or large i.e. up to
11 mm long, ellipsoid, longitudinally grooved, compressed dorsiventrally and
with hairs confined to a terminal tuft. Hilum is long and linear. Embryo is large
to small. Endosperm is hard; without lipid and contains only simple starch
grains. Embryonic leaf margins are meeting. Seedling has a short mesocotyl
and a tight coleoptile. First seedling leaf has a well-developed lamina. The
lamina is narrow and erect.
Microscopy (Triticum aestivum)
Leaf-blade epidermis has conspicuous costal zonation. Papillae are absent.
There are long-cells of similar wall thickness. Mid-intercostal long-cells are
rectangular and fusiform, having markedly sinuous walls. Microhairs are
absent. Stomata are common with 63–69 microns length. Subsidiaries are
parallel-sided or dome-shaped. Guard cells are overlapped by the
interstomatals. Intercostal short-cells are common (e.g. T. polonicum) or
absent or very rare. Crown cells are present. Costal zones have short cells.
Costal short-cells are predominantly paired (T. polonicum) or neither distinctly
grouped into long rows nor predominantly paired. Costal silica bodies are
horizontally elongated.
Transverse section of leaf blade shows parenchymatous cells without a
suberised lamella. Mesophyll has non-radiate chlorenchyma. Leaf blade has
distinct and prominent abaxial ribs of more or less constant size. Midrib is
conspicuous with one bundle only or has a conventional arc of bundles. The
lamina is symmetrical on either side of the midrib. Bulliform cells are present
in discrete and regular abaxial groups in the furrows). Many of the smallest
vascular bundles are unaccompanied by sclerenchyma. Combined
sclerenchyma girders are present (rarely) or are absent. Sclerenchyma is all
associated with vascular bundles.
Different species of wheat -
Wheat species differ from one another both morphologically and genetically.
Triticum species can be placed in three groups, according to whether their
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body cells contain 14, 28 or 42 chromosomes. The basic haploid number
being 7, these groups are described as Diploid, Tetraploid and Hexaploid
respectively. Diploid species include T. boeoticum (Wild Eincorn - most
ancient variety of wheat) and T. monococcum (Eincorn). T. boeoticum was
growing in Southwestern Asia before the advent of agriculture. T.
monococcum is now grown to a limited extent in the mountainous region of
Yugoslavia, Asia Minor and North Africa. Diploid species can be readily
crossed to yield Tetraploid group. Tetraploid species include T. dicoccum
(Emmer wheat, local variety -DDK) and T. durum (Durum wheat or Macaroni
wheat, local varieties - Bansi, Kathia, Khandwa, Raj 1555). T. dicoccum is one
of the most ancient of cultivated cereals. It was formerly grown in the United
States for feed on a limited acreage but now has substantially disappeared
from cultivation. It is grown to a limited extent in the nilgiri hills and the
neighboring areas and is preferred for the preparation of suji or rawa. T.
durum, next important species to T. aestivum, is used mainly for the
manufacture of semolina which is made into macaroni, spaghetti and related
products. Although high in gluten, T. durum is not good for baking. Instead, it
is often ground into semolina, the basis for excellent pasta, such as spaghetti
and macaroni. It is grown to a considerable extent in parts of Gujarat and
central peninsular India. It is preferred for preparation of vermicelli or sewian.
When crossed with Diploid species, Tetraploid species yield Hexaploid group.
Hexaploid species include T. aestivum (common wheat, bread wheat, local
varieties - Sharbati, Lal kanak, Lok1, GW 273). T. aestivum is the most
evolved and widely cultivated of all wheat species. It is high in protein (10-17
%) and yields flour rich in gluten, making it particularly suitable for yeast
breads. It is also preferred for the preparation of biscuits, cake and pastry
manufacture. In India, T. aestivum is the most widely grown wheat species.
The principal cultivated grasses are the cereal grains —wheat, rice, corn,
barley, oats, rye and millet (Baker 1978). Various researchers have known
that the cereal plant, at this young green stage, contains many times the level
of vitamins, minerals and proteins found in the seed kernel, or grain product of
the mature cereal plant. The nutrient content of these grasses varies with their
stage of growth and growing conditions, rather than with the species of cereal
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grass (Kahn 1985). The young germinated plant is a factory of enzyme and
growth activity. In the early stages of growth they store large amounts of
vitamins and proteins in the young blades. After jointing, the nutritional level in
the leaves drops rapidly while the fiber content increases rapidly. The jointing
stage is that point at which the internodal tissue in the grass leaf begins to
elongate, forming a stem. This stage represents the peak of the cereal plant's
vegetative development (Kohler 1944); factors involved in photosynthesis and
plant metabolism would be expected to increase up to this stage. Sucrose, the
simple carbohydrate found in table sugar, is the primary molecule from which
all organic (carbon containing) molecules are formed in the plant (Duffus and
Duffus 1984). At the appropriate times and rates, sucrose is converted into
amino acids (which make up all proteins), complex carbohydrates, lipids
(fats), and nucleic acids (DNA and RNA). The degree of conversion of sugars
to specific complex nutrients is dependent on the activity levels of specific
enzymes in the plant. Enzyme activity levels are dependent on the plant's
growth stage. Chlorophyll, protein, and most of the vitamins found in cereal
grasses reach their peak concentrations in the period just prior to the jointing
stage of the green plant. Although this period lasts for only a few days, cereal
grasses which are consumed, as food supplements should be harvested
precisely during this stage of the wheat or barley plant's development. After
the jointing stage, the stem forms branches and continues to elongate. The
chlorophyll, protein, and vitamin contents of the plant decline sharply as the
level of cellulose increases. Cellulose, the indigestible plant fiber, provides
structural stability for the growing stem.
Nutritional analysis of wheatgrass
Scientific reports on nutritional analysis of wheatgrass have been published
frequently in various journals (Kohler 1953, Hamilton et al., 1988, Laboratory
Analyses 1989). Also, several reputed companies involved in growing and
selling of wheatgrass have published analyses of wheatgrass. As is evident
from table 3.1 and table 3.2, wheatgrass is a rich source of chlorophyll,
various minerals like iron, magnesium, calcium, phosphorus, antioxidants like
beta carotene, insoluble dietary fibers while being low in fat content.
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Table – 3.1 Nutritional analysis of wheatgrass
Protein,                                        1.959  Calories,                                 21.0 Cal
 Carbohydrates total                    2.09  Moisture,                                     959
 Ash,                                            .0489;  Magnesium,                              24 mg;
Selenium,                                  <1 ppm; Potassium,                                  1 479;
 Zinc,                                            0.33g; Phosphorus,                               75.2g;
 Calcium,                                  24.2 mg; Sodium,                                  10.3 mg;
Iron,                                           061 mg;  Vitamin A                              427 ILI 9
Vitamin B1                                  08 mg, Vitamin B2,                             0.13 mg;
 Vitamin B3,                             0.11 mg; Vitamin B5,                              6.0 mg;
 Vitamin,                                96.0.2 mg, Vitamin B12,                           <1 mcg;
Vitamin C,                                3.65 mg; Vitamin E,                               15.2 IU;
 Folic Acid,                                 29 mcg;  Biotin,                                    10 mcg;
Dietary Fiber (total)                        0.1g;  Lecithin,food                           0.03 g;
Chlorophyll                               42.2 mg; Choline,                                92.4 mg;
Aspartic: Acid,                           260 mg; L-Arginine,                            135 mg.
All above constituents are present in per 100g juice.
Data based on scientific laboratory analysis by Irvine Analytical Laboratories
Inc., Irvine, CA, USA
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Sweet Wheat
Table 3.2 Major ingredients in sweet wheatgrass juice powder
Main Ingredients              Content %
Carbohydrates 23.5 Fat 3.7
Moisture 0 Protein 46.7
Ash (Minerals) 26.1
  Mineral & trace minerals mgs/gm
Boron .0055 Calcium 4.9
Chloride .49 Chromium .0012
Cobalt <0.0005 Copper .027
Fluoride .0065 Germanium <.011
Iodine <0.0005 Iron .051
Magnesium 4.4 Manganese .026
Molybdenum <0.0005 Nickel <0.0005
Phosphorous 29 Potassium 2.8
Selenium <0.0005
Silicon .16 Sodium .11
Tin <0.0005 Titanium <0.0005
Vanadium <0.0005 Zinc .066
  Vitamins mg/g
Biotin .00011 Choline .0011
Cyanocobalamin (B12 ) .00001 Folic Acid .0012
Inositol <0.011 Niacin (B3 ) .09
Panotothenic Acid .0196 Pyridoxine HCL B6 .0065
Riboflavin .0031 Thiamin (B1) .0098
Vitamin A (Retino)l 501 IU/Gm Vitamin C .185
Vitamin D <0.1 IU/Gm Vitamin E .02 IU/Gm
Others mg/g Chlorophyll 1.2
Cholesterol <0.01 Sugars 48
Essential Amino Acids mg/g
Isoleucine 15.8 Leucine 31.5
Lysine 22.6 Methionine 3.5
Phenylalanine 19.8 Proline 17.1
Threonine 14.8 Valine 22.1
Non-Essential Amino Acids mg/g
Alanine 24.8 Arginine 22.1
Aspartic Acid 46.9 Glutamine 77.4
Glycine 20.4 Histidine 7.4
Serine 15.9 Tyrosine 6.9
Source – EPA, USDA
19
Table 3.3 Comparison of contents of wheatgrass with other vegetables –
Wt. Protein Fiber Calcium Vit. A Iron Selenium Magnesium Potassium
Vegetable gr. gr. gr. mg. IU mg. mcg. Mg. mg.
Dehydrated
Wheatg
rass
100 25 17 515 66,080 57.1 99.7 197.5 1,425
Beets (raw) 100 1.7 0.8 17 22 0.7 - 23.3 339
Bib Lettuce
(raw) 100 1.3 0.5 35 964 2.1 - 9 264
Broccoli
(raw) 100 3.6 1.5 103 2,500 1.1 - 24 380
Cabbage
(raw) 100 0.9 0.8 34 90 0.3 1.5 13 163
Cauliflower 100 2.7 1 25 60 1.1 0.7 24 295
Celery, raw 100 0.9 0.6 39 266 0.3 - 21.6 39
Collards
(raw) 100 3.6 0.9 401 6,500 1 - 57 401
Corn
(cooked) 100 3.2 0.7 163 396 3 - 20 163
Cucumber
(raw) 100 0.9 0.6 25 245 1.1 0.1 11.2 158
Eggplant
(raw) 100 1.2 0.9 12 10 0.7 - 16 214
Green
Pepper
(raw)
100 1.3 1.4 9 425 0.8 0.6 18 213
Kale (raw) 100 4.2 1.3 179 8,900 0.5 - 37 318
Mushrooms
(raw) 100 2.7 0.8 6 5 0.8 12 10.8 406
Okra (raw) 100 2.4 1 249 520 0.6 - 41 -
Onions
(raw) 100 1.5 0.6 27 41 0.5 1.5 11.8 155
Peas (raw) 100 6.3 2 26 632 1.9 - 34.5 311
Potato
(raw) 100 2.2 0.8 7 5 0.6 - - 409
Radish
(raw) 100 1 0.7 28 5 1 4.2 14 290
Spinach
(raw) 100 3.5 0.6 97 8,109 3.2 - 80 471
Sweet
Potato
(baked)
100 1.6 1.2 31 3,400 0.7 - - 233
Tomato
(raw) 100 1.1 0.5 10 905 0.6 0.5 14.1 245
Turnips
(raw) 100 1 0.8 38 5 0.5 0.6 18.8 261
Source: Nutrition Almanac and published scientific papers on
cereal grass by Dr. George Kohler (Kohler 1944)
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Traditionally, wheatgrass has been used as a medicinal herb in India. In
western countries neutraceutical science is gaining momentum and
wheatgrass is now being advocated as a food supplement. A closer look at
table - 3.3 reveals that compared to most of the vegetables, which are part of
our daily food, wheatgrass has higher contents of all the nutritional factors and
minerals. Thus, wheatgrass is not just an herb or a food supplement, but it is
a complete food and may be taken daily, even by healthy people.
Medicinal uses of wheatgrass –
In today’ s fast lifestyle and fast-food world, deficiency of any or many of these
biochemical factors could easily occur culminating into a disease or disorder.
For example, as reported by Altura and Altura (1995), ‘ It is now becoming
clear that a lower than normal dietary intake of magnesium can be a strong
risk factor for hypertension, cardiac arrhythmias, ischemic heart disease,
atherogenesis and sudden cardiac death. Deficiency in serum magnesium is
often associated with arrhythmias, coronary vasospasm and high blood
pressure’ . wheatgrass juice, being a rich source of magnesium, may replenish
the deficiency of magnesium and improve the clinical picture.
Conversely, a disease state may cause deficiency of a nutrient. According to
Rude (1993), ‘ A large body of evidence demonstrates the prevalence and
adverse clinical consequences of magnesium deficiency in patients with
diabetes mellitus. It would be prudent for physicians who treat these patients
to consider magnesium deficiency as a contributing factor in many diabetic
complications and in exacerbation of the disease itself. Repletion of the
deficiency or prophylactic supplementation with oral magnesium may help
avoid or ameliorate such complications as arrhythmias, hypertension, and
sudden cardiac death and may even improve the course of the diabetic
condition’ . Regular intake of wheat grass juice could correct the secondary
magnesium deficiency and thus, may be helpful in averting long-term clinical
complications of diabetes mellitus.
The movement for the human consumption of wheatgrass began in the
western world in the 1930¹s and was initiated by Charles F. Schnabel, known
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as the father of wheatgrass (Anderson 1986). He said ‘ Fifteen pounds of
wheatgrass is equivalent to 350 pounds of the choicest vegetables.’ Later
Wigmore (1940) healed herself of cancer from the weeds she found in vacant
lots in Boston.  She began a study of natural healing modalities —and with the
help of a friend, Dr. Earp Thomas, she found that there are 4700 varieties of
grass in the world and all are good for man.
Dr. Wigmore reported that the “ wheatgrass” used in her program contain
abscisic acid and laetrile, both of which may have anti-cancer activity. It was
also reported that young grasses and other chlorophyll-rich plants are a safe
and effective treatment for ailments such as high blood pressure, some
cancers, obesity, diabetes, gastritis, ulcers, pancreas and liver problems,
fatigue, anemia, asthma, eczema, hemorrhoids, skin problems, halitosis, body
odor and constipation (Wigmore 1985).
Dr. Wigmore’ s opinions are based on her experiences with her guests at
Hippocrates. A few clinical studies have verified that some disease conditions
can be benefited by the use of wheatgrass. Remarkably, a relatively large
number of studies indicate that food factors and nutrients found in wheatgrass
may provide relief from many of the conditions claimed by Ann Wigmore.
In the following chapters, we have discussed the possible therapeutic
effectiveness and mechanisms of action of wheatgrass juice, in various
diseases.
Clinical studies on wheatgrass
Ulcerative colitis is a common and sometimes serious disorder of the large
intestine that can cause abdominal pain, diarrhea, and bleeding. Ben-Ayre et
al., (2002) reported that people taking wheat grass juice experience a
significant improvement of their ulcerative colitis symptoms on a scale that
measured overall disease activity, compared with people taking a placebo.
Wheat grass juice also significantly reduced the severity of rectal bleeding
and abdominal pain. The initial dose of wheatgrass juice, 20 ml (two-thirds of
an ounce) per day, was increased over a period of several days to a
maximum of 100 ml (3.5 ounces) per day. In addition to the positive results
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mentioned above, an examination of the colon (sigmoidoscopy) showed
improvement in 78% of the people receiving wheat grass juice, compared with
only 30% of those receiving placebo. No serious side effects were seen.
Although nausea was reported by 33% of the participants receiving wheat
grass juice, 41% noted an increase in vitality while taking the supplement.
A clinical pilot study was carried out by Marwaha et al., (2004) at the
Advanced Pediatric Centre, Postgraduate Institute of Medical Education and
Research, Chandigarh, India. It was reported that during period of wheatgrass
juice ingestion: all participants experienced lower blood transfusion
requirements, 50% had at least 25% reduction in transfusion requirements,
the mean interval between transfusions increased 29.5%, overall, hemoglobin
levels were not compromised by reduced transfusion volumes.
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3.2 Significance of antioxidants in wheatgrass -
Free radicals and oxidative stress -
Free radicals and reactive oxygen species (ROS) are short-lived reactive
chemical species having one or more electrons with unpaired spins. The roles
for such electronically activated species (e.g., superoxide and singlet oxygen)
in the normal function of cells and tissues and in the etiology of certain
diseases in man have been extensively studied. Radical generating
processes may be key components in the toxicity of many drugs (Reynolds et
al., 1980, Reynolds et al., 1981, Pryor 1980, McGinness et al., 1978,
McGinness et al., 1982) in antimicrobial defense (Babior 1982,
Hammerschmidt and Jacob 1982) and in inflammation (Kuehl et al., 1982).
The generation of reactive oxygen species (ROS) is a steady-state cellular
event in respiring cells.
             Figure 3.1 - Formation of reactive oxygen species -
In biologic systems molecular oxygen is reduced to water in four one-electron
steps. Reduction of molecular oxygen to superoxide, and of peroxide to
hydroxyl radical are "spin forbidden" and thus are slow unless catalyzed by a
heavy ion. Alternative spin-permitted pathways for the reduction of 02 include
interaction of molecular oxygen with the excited triple state of another
molecule to produce singlet oxygen from light or an excited state molecule
and jumps to a higher energy orbital on the same atom (Kuel et al., 1979).
Excited-state species produced may be highly reactive and participate in
reactions not unlike those of free radicals. Singlet oxygen, itself a strong
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oxidizing agent, may be responsible for some of the effects assigned to other
active oxygen species such as superoxide. Roles for singlet oxygen have also
been postulated in photosensitized reactions, and in antimicrobial defense
(Foote 1976).
Oxidative stress in pathological processes -
In addition to environmental causes such as oxygen (McLennon and Autor
1982), light, or ionizing radiation (Foote 1976) three physiological
circumstances result in extraordinarily high local fluxes of radical species: (1)
activation of the P-450-centered mixed function oxidase systems of
endoplasmic reticulum, (2) activation of NADPH oxidase in phagocytes in
response to antimicrobial defense and inflammation and (3) the presence of
extraordinarily high levels of compounds which can reduce oxygen directly in
auto oxidation reactions. Under such circumstances, the rate of active species
generation may exceed the local capacity of the antioxidant defense and may
contribute to injury.
Electron donors act as pro-oxidants by reducing less reactive species, such
as molecular oxygen and peroxide, to more reactive species via reactions,
which are typically mediated by the cyclical reduction/oxidation of transition-
metal ions. The reduction of peroxide to hydroxyl radical by ferrous iron is
known as Fenton's reaction." Peroxide and superoxide can also react in the
presence of a metal ion to produce hydroxyl radical and molecular oxygen.
This latter reaction is called the "Haber Weiss Reaction" (Crichton 1979).
Transition metal ions are remarkably good promoters of free radical reactions
(Hill 1981). Organisms use superoxide dismutases, catalase, and glutathione
peroxidase as protection against generation of reactive oxygen species.
Organisms also keep as many iron and copper ions as possible safely bound
in storage or transport proteins (Halliwell et al., 1988, Halliwell and Gutteridge
1986, Aruoma and Haliwell 1987). There is three times as much transferrin
iron-binding capacity in plasma as iron needing to be transported, so that
there are essentially no free iron ions in the plasma (Halliwell and Gutteridge
1986). Iron ions bound to transferrin cannot stimulate lipid peroxidation or
formation of free .OH radicals. The same is true of copper ions bound to the
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plasma proteins ceruloplasmin or albumin (Halliwell et al., 1988, Halliwell and
Gutteridge 1986, Aruoma and Haliwell 1987, Grootveld et al., 1989). The
value of this sequestration is shown by an inspection of the pathology suffered
by patients with iron-overload disease, in whom iron ion-citrate chelates
circulate in the blood (Grootveld et al., 1989). These patients can suffer liver
damage, diabetes, joint inflammation, and hepatoma, among other problems
(McLaren et al., 1983). Metal ion sequestration is an important antioxidant
defense. For example, recent papers have referred to ascorbic acid as a
major antioxidant in plasma. However, ascorbate can only exert antioxidant
properties in the absence of transition metal ions (Halliwell 1990).
Oxidative stress in thalassemia -
Sickle cell anemia, thalassemia, and glucose-6-phosphate-dehydrogenase
deficiency are all hereditary disorders with higher potential for oxidative
damage due to chronic redox imbalance in red cells that often results in
clinical manifestation of mild to serve hemolysis in patients with these
disorders. The release of hemoglobin, during hemolysis, and the subsequent
therapeutic transfusion lead to systemic iron overloading that further
potentiates the generation of ROS in thalassemia (Chan et al., 1999). The
synthesis and accumulation of excess normal globin chain (i.e. ?-chain in ?-
thalassemia and ?-chain in ?-thalassemia), within the red cell, lead to the
formation of unstable aggregates, which upon oxidation, due to oxidative
stress generated by iron overload, may precipitate and cause cell membrane
damage. These deformed cells undergo premature destruction either in the
bone marrow (extravascular hemolysis) or the peripheral circulation
(intravascular hemolysis) (Weatherall 1997, Festa 1985). There is also an
increase in erythropoietic activity in the bone marrow and in extramedullary
sites (i.e. liver, spleen and lymph nodes) in several forms of thalassemias
(e.g. ?-thalassemia major) (Weatherall 1997, Festa 1985). The ineffective
erythropoiesis and microcytic hypochromic anemia, described earlier, are
associated with a compensatory increase in the absorbance of dietary iron.
This may contribute to the iron overload that often results from blood
transfusion therapy. Further, our results point out that the iron-induced liver
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damage in thalassemia may play a major role in the depletion of lipid-soluble
antioxidants (Livrea et al., 1996).
Role of antioxidants -
Reactive oxygen species are constantly formed in the human body and
removed by antioxidant defenses. An antioxidant is a substance that, when
present at low concentrations compared to that of an oxidizable substrate
significantly delays or prevents oxidation of that substrate. Antioxidants can
act by scavenging biologically important reactive oxygen species
([O2].,[H2][O2], .OH, HOCl, ferryl, peroxyl, and alkoxyl), by preventing their
formation, or by repairing the damage that they do. In biological systems the
sources of the electrons are generally enzymes (e.g., NAD(P)H oxidase) and
reducing substances (electron-donors). Simplistically, electron-donors act as
antioxidants by (e.g.) reducing more reactive species such as trichloromethyl,
superoxide, or hydroxyl radicals to less reactive species such as chloroform,
peroxide, or water. Antioxidants come only from two sources - both natural:
endogenous or exogenous.
Endogenous Antioxidants -
Three important intracellular enzymes constitute antioxidant defense;
superoxide dismutase (SOD), catalase, and the GSH peroxidase/GSSG
reductase system. SOD catalyzes the dismutation of superoxide, catalase the
conversion of hydrogen peroxide to H2O and O2 (Willson 1979). Various
organelle specific isoenzymes of superoxide dismutase exist (Fridovich 1979).
The Zn-Cu SOD is cytoplasmic, while the Zn-Mn enzyme is chiefly
mitochondrial. Neither isoenzyme is found in high concentrations in
extracellular fluids (Fridovich 1979). GSH peroxidase transfers electrons from
GSH to reduce peroxides to water. The oxidized glutathione produced
(GSSG) is re-reduced back to GSH by glutathione reductase utilizing NADPH
produced by the HMP shunt acting as an enzyme cofactor (Carrell et al.,
1978).
The enzymatic production of active oxygen species by inflammatory cells may
contribute to the pathophysiology of leukocyte dependent inflammatory
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processes (Huber 1980). Further, peroxidase release from eosinophils may
play a similar role in inhibition of the inflammatory response while the
antioxidant properties of ceruloplasmin may also give this compound
antiinflammatory property. Production of active oxygen species by activated
phagocytes may also have a role in vascular (and other) damage following
endotoxin shock, burn-induced plasma volume loss and even in
atherosclerosis (Huber 1980).
It is not surprising that antioxidants, SOD (Huber 1980) and catalase (McCord
et al., 1982) should ameliorate inflammatory symptoms in human and animal
systems. This is of some clinical importance, since an antiinflammatory
pharmaceutical preparation rich in SOD ("orgotein") is used in veterinary
medicine and recently has been shown to be both effective and apparently
safe in the treatment of various inflammatory lesions in man. Catalase has
also been used in the treatment of arthritic disease in man with reported
success (Riu et al., 1971).
Exogenous antioxidants – antioxidants present in wheatgrass -
Beta-carotene -
Excited-state derivatives such as singlet oxygen and the excited triplet
(diradical) states of other molecules may be quenched by interactions with
conjugated diene systems such as those found in carotenes (Huber 1980),
tocopherols or the melanins (Forrest et al., 1974). Vitamin A, itself, can pose a
hazard to human health and even the risk of birth defects when taken in
excess. Its precursor, b-carotene, can be taken in virtually any quantity
without harmful effect. At the same time it provides the body with a store of
the raw material from which it produces vitamin A naturally according to
needs. b-carotene has been positively linked to increased protection against
many forms of cancer, including lung, bladder, rectal, oral and dermal (skin)
cancers.
Vitamin C -
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Vitamin C acts synergistically with vitamin E and assists not only in the
prevention of the formation of arterial cholesterol plaque but also, in sufficient
quantities, has been shown to actually assist in the chelation ("dissolving") of
existing cholesterol plaque thereby helping clear occluded (blocked) arteries,
particularly coronary. Vitamin C is also specifically known to assist in the
prevention of many forms of cancer, including pancreatic, rectal, cervical,
esophageal and oral cancer. It is also a powerful free radical scavenger and
thereby helps clean up the residues of cigarette smoke and other forms of air
pollution.
Vitamin E -
As well as the primary defenses (scavenger enzymes and metal-ion
sequestration), secondary defenses are also present. The cell membranes
and plasma lipoproteins contain µ-tocopherol, a lipidsoluble molecule that
functions as a chain-breaking antioxidant. Attached to the hydrophobic
structure of µ-tocopherol is an -OH group whose hydrogen atom is easily
removed. Hence, peroxyl and alkoxyl radicals generated during lipid
peroxidation preferentially combine with the antioxidant. instead of with an
adjacent fatty acid side chain. This therefore terminates the chain reaction,
whence the term chain-breaking antioxidant. It also converts the µ-tocopherol
into a new radical, tocopherol-O, which is poorly reactive and unable to attack
adjacent fatty acid side chains, consequently stopping the chain reaction.
Evidence exists (Esterbauer et al., 1989, Wefers and Sies 1988) that the
tocopherol radical can migrate to the membrane surface and reconvert to µ-
tocopherol by reaction with ascorbic acid (vitamin C). Both vitamin C and µ-
tocopherol seem to minimize the consequences of lipid peroxidation in
lipoproteins and in membranes, should this process begin (Wefers and Sies
1988). µ-tocopherol is t1he most effective lipid-soluble chainbreaking
antioxidant in vivo in humans (Ingold et al., 1986). The content of µ-
tocopherol in circulating low-density lipoproteins helps to determine their
resistance to lipid peroxidation and thus may affect the development of
atherosclerosis, a disease in which lipid peroxidation is involved (Gey et al.,
1987). Low plasma levels of µ-tocopherol and vitamin C correlate with an
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increased incidence of myocardial infarction and of some forms of cancer
(Gey et al., 1987). Vitamin E is present in small quantities in many foods but
its uptake is all too often inhibited by low-fat or no-fat diets as fats or oils are
the essential carriers of vitamin E without which absorption or uptake of this,
the most powerful of the antioxidant vitamins, is severely restricted. Vitamin E
is known to fight infection, promote healing and to assist in the prevention of
lung and gastro-intestinal (including bowel) cancer. It achieves this by again
preventing free radicals from entering cells where nuclear and DNA damage
would otherwise ensue.
Wheatgrass is rich in chlorophyll, magnesium, Iron, selenium, zinc, chromium,
and antioxidant vitamins like vitamins A, E, C, B12, folic acid, pyridoxine, host
of other minerals and amino acids, that have significant nutritious and
medicinal value. Since deformation of RBC, caused by oxidation of excess ?-
chains, is the main causative factor for hemolysis and therefore, increased
frequency of repeated blood transfusions in thalassemia; antioxidants and
magnesium present in wheatgrass may reduce the need of such repeated
transfusions.
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3.3 Significance of chlorophyll in health and disease -
The most important light-absorbing pigments, in the thyllakoid membrane of a
plant leaf, are the chlorophylls, green pigments with polycyclic, planar
structures resembling the protoporphyrin of hemoglobin, except that Mg+2, not
Fe+2, occupies the central position. The four inward oriented nitrogen atoms of
chlorophyll are coordinated with the Mg+2. The heterocyclic five-ring system
that surrounds the Mg+2 has an extended polyene structure, with alternating
single and double bonds. Such polyenes, characteristically show, strong
absorption in the visible region of spectrum; the chlorophylls exhibit high
molar absorption coefficients and are therefore well suited for absorbing
visible light during photosynthesis. Chloroplasts of higher plants always
contain two types of chlorophyll. One is invariably chlorophyll a, and the
second in many species is chlorophyll b, which has an aldehyde group
instead of a methyl group attached to ring II. Although both are green, their
absorption spectra are slightly different, allowing the two pigments to
complement each other’ s range of light absorption in visible region. Most
higher plants contain about twice as much chlorophyll a as chlorophyll b.
Chlorophyll itself is not a single molecule but a family of related molecules,
designated chlorophyll a, b, c, and d.  Chlorophyll a is the molecule found in
all plant cells and therefore its concentration is what is reported during
chlorophyll analysis. Chlorophyll d is found only in marine red algae, but
chlorophylls b and c are common in fresh water. Chlorophyll a and chlorophyll
b can be separated by shaking a light petroleum solution of chlorophyll with
aqueous methanol: chlorophyll-a remains in the light petroleum but chlorophyll
b is transferred into the aqueous methanol. Cholorophyll a is a bluish-green
solid and cholorophyll b is a dark green solid, both giving a green solution in
organic solutions. In natural chlorophyll there is a ratio of 3 to 1 (of a to b) of
the two components. In addition to chlorophylls, the thyllakoid membranes
secondary light absorbing pigments, together called the accessory pigments,
the carotenoids and phycobilins. Carotenoids may be yellow, red or purple.
The most important are beta-carotene, a red-orange isoprenoid compound
that is the precursor of vitamin A in animals, and the yellow carotenoid,
xanthophyll. The carotenoid pigments absorb light at wavelengths other than
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those absorbed by chlorophylls and thus are supplementary light receptors.
Phycobilins are linear tetrapyrroles that have the extended polyenes system
found in chlorophylls, but not their cyclic structure or central Mg+2. Examples
are phycoerythrin and phycocynin.
All the above-mentioned pigments allow plants to absorb energy from visible
light. In addition to this, chlorophyll has been reported to be useful in several
clinical conditions. Possibly, the presence of magnesium offers wide range of
therapeutically useful effects.
Degradation of chlorophyll following ingestion by humans produces several
chlorophyll derivatives, of which, pheophytin, pyro-pheophytin, and
pheophorbide have been under study for their potential medical benefits
(Chernomorsky 1999).  Magnesium is rather easily displaced from the
molecule of chlorophyll, when it is heated in the presence of organic acids.
Treatment of chlorophyll-a, with acid removes the magnesium ion replacing it
with two hydrogen atoms giving an olive-brown solid, pheophytin-a.
Pheophytins are much more stable than naturally occurring chlorophyll.
Hydrolysis of pheophytin-a splits off phytol and gives pheophorbide-a. Similar
compounds are obtained if chlorophyll b is used. Removal of the phytyl group
from the molecule of chlorophyll is catalyzed by the enzyme chlorophyllase,
found in some vegetables. Hydrolysis of the ester linkage yields a compound,
known as a chlorophyllide, which is water-soluble. Further degradation of
chlorophyllide produces pheophorbide. Thus, when a chlorophyll molecule
breaks down, a number of distinct pheophytins, chlorophyllides, and
pheophorbides will be produced, depending on the parent molecule.
Chlorophyll can also be reacted with a base, which yields a series of phyllins,
magnesium porphyrin compounds. Treatment of phyllins with acid gives
porphyrins. Numerous studies have shown that chlorophyll and Cu-
chlorophyllin, a water-soluble chlorophyll derivative, possess antimutagenic
and antigentoxic activities. Little information about the absorption and
metabolism of these compounds by humans is available. In vitro digestion has
been used to access the relative bioavailability of numerous minerals and
nutrients from different food matrices. The general consensus among
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researchers was that chlorophyll molecules were too large to be absorbed by
the body. But in recent studies, chlorophylls potential as a health promoter
has taken a leap forward (Chernomorsky 1999). In the study, artificial
digestion system, known as the Coupled In Vitro Digestion and Caco-2
Human Cell Model, showed that absorptive cells lining the small intestine
actually do uptake pheophytins chlorophyll derivatives such as pheophytins,
pyropheophytins and chlorophyllins formed during digestion of spinach puree.
Medicinal uses of chlorophyll –
Chlorophyll and anemia -
Chlorophyll is not so unique in its chemical make-up. It is built around a
porphyrin ring, which occurs in a variety of natural organic molecules. The
most interesting group of molecules which contain porphyrin rings are those
involved in cellular respiration, or the transportation and consumption of
oxygen. These include hemoglobin, myoglobin, and the cytochromes. The
chemical similarity between hemoglobin and chlorophyll was first suggested
by Verdel in 1855 (Carpenter 1949), and specifically demonstrated in the early
1920s. One of the major differences between chlorophyll and hemin is that
chlorophyll contains magnesium while the hemin molecule contains iron as its
central atom. The similarities between chlorophyll and heme are not limited to
appearance and function (Milgrom 1985). Chemists report that the synthesis
of heme by animals can occur in much the same way as the synthesis of
chlorophyll in plants (Battersby 1988). Owing to the close molecular
resemblance between chlorophyll and hemoglobin, it was hypothesized that
chlorophyll is nature's blood-building element for all herbivorous animals and
humans. This opinion was reinforced by the observation that animals, which
ate only leafy green plants, had ample amounts of hemoglobin in their red
blood cells (Patek 1936). Some studies have indicated that feeding
chlorophyll-rich foods to rats stimulates the regeneration of red blood cells
(Scott and Delor 1933). Researchers were able to demonstrate that this effect
was not due to the iron or copper in the green foods (Rothemund et al., 1934).
Drs. Hughes and Latner fed several doses and forms of chlorophyll to anemic
rabbits in 1936. Extremely small doses of purified chlorophyll or large doses of
a crude chlorophyll extract produced a very favorable effect on hemoglobin
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regeneration". They suggested that the chlorophyll is acting as a physiological
stimulant of the bone marrow and is not really concerned with the actual
chemistry of regeneration of the porphyrin (Hughes and Latner 1936).
Although green foods have long been considered useful for their "blood-
building" qualities, the chlorophyll found in green foods is itself valued for
many other therapeutic purposes. The number of surface conditions in which
chlorophyll has been successfully used would be unbelievable were they not
so well documented (Smith 1944).
Chlorophyll and cancer -
There is scientific evidence that chlorophyll and the nutrients found in green
foods offer protection against toxic chemicals and radiation. In 1980, Dr. Chiu
Nan Lai at the University of Texas Medical Center reported that extracts of
wheat grass and other green vegetables inhibit the cancer-causing effects of
two mutagens (benzopyrene and methylcholanthrene) (Lai et al, 1980). The
more chlorophyll in the vegetable, the greater the protection from the
carcinogen. Several laboratories have verified that chlorophyll can reduce the
ability of carcinogens to cause gene mutations in the last decade.
Chlorophyll-rich plant extracts, as well as water solutions of a chlorophyll
derivative (chlorophyllin), dramatically inhibit the carcinogenic effects of
common dietary and environmental chemicals (Kimm et al, 1982, Ong et al,
1986). Ames testing shows that chlorophyllin neutralizes the cancer-causing
action of mixtures of coal dust, tobacco, fried beef, red wine, and other
compounds. In this capacity, chlorophyllin is more effective than vitamin A,
vitamin C, or vitamin E against mutations induced by the same mixtures (Ong
et al, 1989, Ong et al, 1986). Chlorophyll and its related chemicals are being
investigated for potential protection against carcinogens, including the dietary
carcinogens found in cooked muscle meats (heterocyclic amines), smoked or
barbecued foods (polycyclic hydrocarbons), and peanut mold (aflatoxin)
(Zitgler 1995). Epidemiological evidence has suggested that diets containing
yellow-green vegetables are associated with protection against carcinogenic
effects and related mutagenic, clastogenic, and genotoxic activities (Sarkar
1994, Waladkhani 1998, Sarkar 1996).  Unlike other chemoprotective
phytochemicals, which are present naturally in small quantities in plants,
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chlorophyll is especially abundant in green leafy plants.  For example,
spinach can contain up to 5.7% chlorophyll on a dry-weight basis (Harttig
1998, Gentile 1991). Chlorophyll, ubiquitous to all green plants, and having
been shown to have medical value, has received tremendous interest as a
nutritional supplement.  However, some evidence suggests that the observed
medical effects of chlorophyll in plants are actually the result of the total effect
of the interaction between different components of the whole plant, in addition
to the sole effects of chlorophyll (Lea 1999, Waladkhani 1998). Other
phytochemicals that may work in therapeutic combination with chlorophylls
include carotenoids, flavonoids, indole, isothiocyanate, poyphenolic
compounds, protease inhibitors, sulfides, and terpens (Waladkhani 1998).
Epidemiological surveys have demonstrated that the frequent consumption of
fresh vegetables and fruit is associated with reduced risk of some cancers,
including gastrointestinal cancer in humans (Sarkar 1994, Nakamura 1996,
Sarkar 1996). Chlorophylls and chlorophyll-related products, both natural and
man-made, have been shown to support normal cellular function, as
demonstrated experimentally through in vitro, in vivo, and animal studies
(Higashi Okai 1998). Studies demonstrate that chlorophyll and chlorophyll-
related products support normal cellular health through anti-mutagenic
activity.  Studies have found that chlorophyll binds carcinogens and reduces
their uptake (Harttig 1998, Nakamura 1996). Chlorophylls have shown a
dose-related protective effect against carcinogens found in the human diet.
Chlorophylls form complexes with carcinogens while they are still in the
digestive tract, thereby limiting their bioavailability.  Chlorophylls also reduce
the binding of carcinogens to DNA in the liver (Zitgler 1995). Terwell and van
der Hoeven have shown through in vivo studies that chlorophyll and
chlorophyllin are inhibitors for the mutagenicity of cigarette smoke condensate
(Negishi 1989). Chlorophyllin has been used as a dietary supplement or to
diminish the intensity of the discomforting side effects of anticancer therapy.
The increase in micronuclei in bone marrow polychromatic erythrocytes in
response to anticancer therapy was reduced by concomitant chlorophyllin
treatment. We conclude that chlorophyllin may have beneficial effects when
used in combination with anticancer therapy (Te et al., 1997).
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Chlorophyll and its derivatives are also being studied in relation to
photodynamic therapy, a procedure that harnesses the energy of light to treat
certain diseases.  In photodynamic therapy, chlorophyll and its derivatives are
used as photosensitizers that kill cancer cells and act as antiviral agents (Lee
1990). Chlorophyll-related compounds have been effective in photodynamic
treatment of pancreatic cancer cells, gross leukemia virus and malignant
melanoma, in various in vitro, in vivo and animal studies (Fiedor 1993,
Rosenbach and Belkin 1996, Lee 1999).
Chlorophyll and inflammation -
In this century medical scientists have found chlorophyll to be effective in the
general fields of detoxification, deodorization, and the healing of wounds. The
power of chlorophyll as an effective deodorizing agent was first scientifically
demonstrated in the 1940s. In the decade that followed, toilet paper, diapers,
chewing gum, bed sheets, toothpastes, shoe liners, and a number of other
products containing various amounts of green coloring and crude chlorophyll
extracts began appearing on store shelves. In the wake of this "chlorophyll
hysteria", a number of researchers began serious investigation of the
therapeutic uses of chlorophyll (Smith 1955). The leaves and green parts of
plants have been used for centuries to accelerate wound healing. Among the
ancients, the greenest plants were chosen for health remedies (Smith 1944).
Chlorophyll has been recognized for its antinflammatory, antioxidant, wound
healing, and deodorant properties (Zitgler 1995, Nakamura 1996). The ideal
wound treatment stimulates repair of damaged tissues and inhibits the growth
of bacteria (Carpenter 1949). Chlorophyll does both! Even crude preparations
of chlorophyll are effective in stimulating the growth of healthy granuloma
tissue and fibroblasts —both on actual wounds and in laboratory cultures
(Smith 1955). Nakamura found that pheophorbide a, a naturally occurring
major degradation product of chlorophyll, had anti-inflammatory effects when
tested in animal studies. The anti-inflammatory effects have been linked to
inhibition of leukocyte activation, which is important to maintaining normal
tissue and cellular health (Nakamura 1996). Nenonen and others have found
that lactobacilli-rich and chlorophyll-rich drinks were associated with
decreased disease activity in arthritis (Nenonen 1998). In addition, the foul
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odors associated with surface wounds and ulcers rapidly disappear following
chlorophyll application (Gruskin 1940). The medical literature is replete with
reports demonstrating these effects. Surface wounds and sores due to
surgery, compound fractures, osteomyelitis (bone inflammation), decubitus
(bed sores), and routine cuts and scrapes all show fast and dramatic
improvement with the topical use of chlorophyll. Chlorophyll therapy has
saved limbs from amputation. Chlorophyll is also known to reduce the itching,
pain and local irritation of surface wounds (Smith 1955). Burns caused by
heat, chemicals, and radiation also heal faster with chlorophyll therapy,
whether or not they are infected. Chlorophyll was used to prolong the survival
of skin grafts before the development of the immune-suppressing drugs,
which are now used. The action of chlorophyll on wounds has a unique
feature. Most medicines become less effective with repeated use. In contrast,
an initial application of chlorophyll makes a wound more sensitive to its
healing benefits with repeated use (Smith 1955). Chlorophyll is considered to
have the most constant and marked effect of all agents for stimulating cell
proliferation and tissue repair (Smith 1955). Collings (1945) demonstrated that
the healing time of wounds is shorter with chlorophyll therapy than with
penicillin, vitamin D, sulfanilamide, or no treatment. Chlorophyll also
accelerates wound healing by reducing hemagglutination and inflammation.
When a tissue is injured, foreign substances in the blood generally cause
blood cells to clump together. This limits the amount of nutrients available for
repair of the injured tissue. When chlorophyll is administered to a wound, this
clumping is reduced, so the lag time associated with tissue repair is shortened
(Sack and Barnard 1955). Chlorophyll decreases swelling by reducing the
synthesis of fibrin (the protein associated with blood clot formation) (Miller et
al., 1960, Miller et al., 1958). This gives chlorophyll a mild blood thinning, or
heparin-like property, which can enhance the effectiveness of local immune
defenses. Chlorophyll has also been shown to be extremely effective in
speeding the healing of peptic ulcers and wounds, which develop internally in
the gastro-intestinal tract. Several studies document the use of chlorophyll in
the treatment of ulcers resistant to more conventional therapies. The results
are quite impressive. In the Offenkrantz study, 20 of the 27 patients with
chronic ulcers were relieved of pain and other symptoms in 24 to 72 hours
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(Offenkrantz 1950). Complete healing of the damaged tissues, as
demonstrated by X-ray examination, occurred in 20 of 24 cases within two to
seven weeks. These reports include case descriptions of dramatic recoveries
from severe, long standing problems. Chlorophyll has been cited as
therapeutic for inflammation of the ear, the mucous membrane of the nose,
and the sinuses (Duke 1992). Chlorophyll has also been found to be
supportive of normal kidney function, acceleration of wound healing, treatment
of ulcers, and reduction of fecal, urinary, and body odor in geriatric patients
(Duke 1992, Zitgler 1995).
European investigators report preliminary favorable results in the use of
chlorophyll in the treatment of pancreatitis. The chlorophyll is thought to
influence several enzymatic reactions, which complicate this disease
(Chernomorsky and Segelman 1988). Other intestinal diseases have also
been effectively treated with chlorophyll. Rafsky and Krieger (Rafsky and
Krieger 1948) report positive results obtained with the use of rectal implants of
chlorophyll solutions for the treatment of a variety of diseases of the colon
including spastic colitis, sigmoiditis, and ulcerative colitis. The majority of the
patients in the study showed definite improvement. Chlorophyll appears to
alter the metabolism of colonic bacteria. Its use is associated with reduced
formation of skatole, a substance formed by the bacterial breakdown of
proteins (Smith 1955).
Chlorophyll in gastrointestinal disorders -
Researchers observed a side benefit when chlorophyll was used to treat
peptic ulcers. Chlorophyll tended to "promote regularity" in the patients
studied (Offenkrantz 1950). According to several investigators, chlorophyll did
not act simply to stimulate bowel activity, as does a laxative. Rather, it
promoted bowel regularity, stimulating bowel action only when that action was
sluggish. The same effect was noted in a 1980 study of the use of
chlorophyllin (a water soluble chlorophyll derivative) to reduce body and fecal
odors in a geriatric nursing care facility (Young and Beregi 1980). It was found
that chlorophyll did reduce offensive odors, as anticipated, but also that it
promoted regular bowel movements in these patients. Chlorophyll use also
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reduced the amount of intestinal gas experienced by the patients. And, as
chlorophyll has no toxic side effects, the "gratifyingly good results" obtained
made it preferable to the use of "drastic laxatives". Today, patients to
deodorize the surfaces and contents of colostomies routinely use chlorophyll
tablets. Chlorophyll is also administered to incontinent patients to reduce
odors in health care facilities (Young and Beregi, 1980). Topical chlorophyll
ointments and solutions for healing and deodorizing wounds are still available,
as are chlorophyll-containing toothpastes and chewing gums.
Chlorophyll and oxidative stress -
Antioxidant activity of chlorophyll-related compounds, including chlorophyllin,
has been reported in several studies.  Nakamura (1996) found that the
naturally occurring chlorophyll derivative, pheophorbide a, showed antioxidant
activity against lipid auto-oxidation.  The extent of activity was comparable to
alpha-tocopherol, a powerful and well-known antioxidant (Gentile 1991,
Nakamura 1996, Lee 1999).
Chlorophyll and bacterial infections -
During the 1950s, many laboratories tested chlorophyll's power to kill germs.
The consensus of these reports was that, for the most part, chlorophyll is
bacteriostatic, and only slightly bacteriocidal. This means that chlorophyll
limits the growth of many types of germs not by directly killing them, but by
providing an environment, which interferes with their growth. It is particularly
effective against anaerobic bacteria, those, which do not require oxygen
(Smith 1955). Dentists and physicians have successfully used chlorophyll to
control mouth infections such as pyorrhea and Vincent's angina. Chlorophyll
solutions provide significant relief of pain, reduction of inflammation, and the
control of odor for patients with serious mouth diseases (Gruskin 1940). There
are several reported cases of the successful use of chlorophyll for bacterial
endocarditis, an infection of the tissue surrounding the heart (Smith 1944).
Chlorophyll has also been used successfully to treat chronic and acute
sinusitis, vaginal infections, and chronic rectal lesions (Gruskin 1940).
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Green plants are still used as healing agents by traditional health practitioners
throughout the world. But chlorophyll is used in a rather limited way in our
modern medical system. The enthusiasm with which chlorophyll was once
studied subsided with the development of antibiotics and steroid drugs. Dr. S.
A. Chernomosky, in a 1988 review article in the New Jersey Medical Journal,
states that the treatment of patients with slow-healing wounds is still
problematic, and that the increased use of chlorophyll compounds may offer a
useful alternative in this area (Chernomorsky and Segelman 1988).
Chlorophyll and radiation -
Green vegetables provide protection from radiation damage in test animals.
This information has been reported in the scientific literature since the early
1950s. Early reports showed that certain vegetables significantly reduced
mortality in rats exposed to lethal doses of X-rays (Spector and Calloway,
1959). Dark green broccoli offered more protection than the lighter green
cabbage. In a later study, the same vegetables were shown to reduce the
damage caused by radiation (Calloway et al., 1962). These protective effects
were more pronounced when even darker green vegetables such as mustard
greens and alfalfa leaves were used. When two or more of the green
vegetables were fed together, the positive resistance to radiation was
greatest.
Safety of chlorophyll ?
Chlorophyll has found diverse applications in both medicine and industry
(Duke 1992).  In response to recent concerns over the safety of chemical
additives used as food colorants, the food industry has witnessed a renewed
interest in using plant pigments as natural colorants. Chlorophyll, produced
mainly from grasses, is one of the top four pigments used in the food industry
for the coloring of food and drink ((Duke 1992, Lea et al., 1999). Chlorophyllin
is the man-made sodium, iron, or copper salt of chlorophyll in which the
central magnesium ion of chlorophyll is replaced by the metal ion.  In Japan,
chlorophyllin is used as a food additive for coloration (Negishi 1989).
Chlorophyll is of special interest to the food industry because of its recognized
safety.  Several in vivo experiments and animal experiments show chlorophyll
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to be safe (Sarkar 1996, Negishi 1997). Experiments report the absence of
adverse events and obvious toxicity at up to 5% chlorophyll in animal diets
(Furukawa 1998). In hundreds of experiments and trials on humans and test
animals, chlorophyll therapy has always been shown to have no toxic side
effects. Not just low toxicity, NO toxicity--whether ingested, injected or rubbed
onto a surface (Smith 1944). This fact alone makes chlorophyll one of the
most unique therapeutic substances known to medical science. In medicine,
chlorophyll has attracted great interest as a fundamental component of a
healthy diet and as a potential therapeutic agent (Sarkar 1996, Negishi 1989).
Several chlorophyll-related chemicals are also receiving attention:
chlorophyllin, the metal solution of chlorophyll, and several natural and
synthetic chlorophyll derivatives (Chernomorsky 1999, Hajri 1999, Gentile
1991).
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3.4 Significance of magnesium in health and disease -
The major electrolytes in the body are sodium, potassium, calcium,
magnesium, chloride, bicarbonate and phosphate. Magnesium is the most
abundant divalent cation in living cells and it plays a vital role in many cellular
processes (Wacker 1968, Flataian 1993, Fry and Proctor 1993). Average
adult body contains approximately 1000 mmol (2000 mEq/L) magnesium,
99% of which is in bone and the intracellular compartment (Abbott et al.,
1993, Rude 1993). Of the 1% remaining in the vascular space, 25% is bound
to proteins; it is the ionized 75% that exerts the physiological effect. Serum
magnesium is maintained in the normal range of 0.8-1.2 mmol/L (1.6 to 2.4
meq/L) by efficient renal conservation and the ability to draw on the
intracellular space for replacement ions, when intake falls. Consuming foods
high in oxalic acid, like spinach, cocoa, and tea, can inhibit the body’ s
processing of magnesium. Hypomagnesaemia is characterized by serum
magnesium level < 0.8 mmol/l. It may be caused by amphotericin B, cis-
platinum, diuretics, diarrhea, hypervitaminosis D, vitamin D-deficiency,
vomiting, hyperaldosteronism and aminoglycosides. Symptoms of magnesium
deficiency include tremor, hyperreactive reflexes, confusion and seizures.
Clinical deficiency of magnesium can be treated by administering MgSO4 (i v
0.15-0.25 mmol/kg/day) or Mg2O (300-600 mg PO BID-TID). The physiologic
function of magnesium  (along with calcium and phosphate) is to maintain
membrane potentials for nerve conduction and muscle contraction.
Magnesium is an essential nutrient, meaning that body needs it for healthy
functioning. It is found in significant quantities throughout the body and used
for numerous purposes, including muscle relaxation, blood clotting, and the
manufacture of ATP. Cytosol contains Mg+2, which binds to ATP and ADP. In
most enzymatic reactions that involve ATP as phosphoryl donor, the true
substrate is MgATP-2. Transfer of phosphate group in any biochemical
reaction in a cell requires presence of Mg+2. The phosphate groups of ATP,
ADP and glycolytic intermediates form complexes with Mg+2, and the
substrate binding sites of many of the glycolytic enzymes are specific for
these Mg-phosphate complexes. Thus, phosphated intermediates bind to
Mg+2 and form Mg-Phosphate complex. This complex binds to kinase or
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phosphorylase enzyme for further processing. Nearly all the glycolytic
enzymes require Mg+2 for activity (Lehninger 1993).
Several hundreds of enzymes, directly or indirectly, are (via the need of Mg-
ATP) dependent on Mg+2 (Wacker 1980). Thus, magnesium is a cofactor
required for activity of many important enzymes and other biomolecules
(Holoenzyme = Apoenzyme + Coenzyme + Metal ion (Mg+2)). Enzymes and
physiological processes, which require Mg+2 for their activity, are listed bellow:
-
Enzyme Function
· Hexokinase- - Glycolysis
· Glucokinase- -Glycogenesis, to lower BGL (faulty in
diabetes)
· Glycolytic enzymes- -affected in diabetes
· Phosphorylases- -Muscle Phosphorylase, Liver
Phosphorylase
· ATPases- -Na-K ATPase (excitability of muscles and
nerves)
· Ca ATPase - in sarcoplasmic reticulum -contraction and
relaxation of muscles
· Creatine Kinase- -Muscle contraction (Creatine phosphate +
ADP = ATP + Creatine)
· Phosphodiastrase -breakdown of cAMP and termination of
cAMP action
· Synthesis of LDL receptors -lowering of serum cholesterol
· Neurotransmitter release from nerve terminals (Ca+2 + ATP)
· Hormone release from exocrine glands, exocytosis (Insulin release)
· Synthesis of mRNA, DNA dependant- RNA polymerase (Insulin
synthesis)
· Synthesis of protein, Activation of amino acid, initiation and elongation
require Mg+2, (Insulin synthesis)
· DNA replication (immune response, Wound healing)
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· Phosphorylation of G-proteins (signal transduction)
· Phosphorylation of tyrosine kinase (Insulin signal transduction)
· Synthesis of Glut-4 (Insulin action- sensitivity)
· AMPA receptors (for glutamate) are coupled to Ca+2 channel, which is
normally blocked by Mg+2. Deficiency of Mg+2 would remove this block,
resulting in excitotoxicity.
Recently it has been reported that magnesium plays in the transmission of
hormones (such as insulin, thyroid, estrogen, testosterone, DHEA, etc.),
neurotransmitters (such as dopamine, catecholamines, serotonin, GABA,
etc.), and minerals and mineral electrolytes. It is concluded that it is
magnesium status that controls cell membrane potential and through this
means controls uptake and release of many hormones, nutrients and
neurotransmitters. It is magnesium that controls the fate of potassium and
calcium in the body. If magnesium is insufficient potassium and calcium will
be lost in the urine and calcium will be deposited in the soft tissues (kidneys,
arteries, joints, brain, etc.). Magnesium protects the cell from aluminum,
mercury, lead, cadmium, beryllium and nickel. Evidence is mounting that low
levels of magnesium contribute to the heavy metal deposition in the brain that
precedes parkinson's, multiple sclerosis and alzheimer's disease. It is
probable that low total body magnesium contributes to heavy metal toxicity in
children and is a participant in the etiology of learning disorders. Magnesium
is also an important component of plants. The most important light-absorbing
pigments in the thyllakoid membrane of a plant leaf are the chlorophylls,
green pigments with polycyclic, planar structures resembling the
protoporphyrin of hemoglobin, except that Mg+2, not Fe+2, occupies the central
position. The four inward oriented nitrogen atoms of chlorophyll are
coordinated with the Mg+2 (Lehninger 1993).
Medicinal uses of magnesium -
Magnesium has been called "nature's calcium channel–blocker." The idea
refers to magnesium's ability to block calcium from entering muscle and heart
cells. This may be the basis for magnesium's effects on migraine headaches
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and high blood pressure. Studies indicate that there may be a link between
low magnesium levels and thymus gland-cancer and diabetes. Diabetes
appears more frequently in areas of the country where the drinking water is
lower in magnesium. These two theories are more controversial and less clear
than the others. Some physicians feel that more premature babies are born to
women with low magnesium levels. Persons with kidney failure must be very
careful when taking any food or medication with magnesium because the
kidney clears excess magnesium from the body.
Magnesium and oxidative stress -
It is well known that magnesium plays a key role in oxidative metabolism in
the mitochondria (Jung et al., 1990). There is overproduction of NO in
magnesium deficiency. NO endogenously activates neutrophils to generate
Superoxide ions, which combine with NO to produce peroxynitrite radicals
(oxidative stress) to damage myocardium. Magnesium deficiency resulted in
70% decrease in plasma glutathione and 220% increase in TBARS levels in
rats (Tong et al., 1997). Part of the increased oxidative stress could be
contributed by increased NO production; simultaneous increases in
production of both Superoxide anions and NO would likely lead to the
formation of peroxynitrite which per se is highly reactive and might contribute
directly to depletion of glutathione (Beckman et al., 1990, Radi et al., 1994).
Increased oxidative stress is involved in cardiovascular injury during
Magnesium deficiency in the rat (Weglicki et al., 1992, Weglicki et al., 1994).
Increased free radical generation is involved in cardiovascular injury during
Magnesium deficiency and vitamin E provides protection against this injury
(Feedman et al, 1990). Several investigators have reported decrease in RBC
glutathione, during magnesium deficiency (Weglicki et al., 1994, Mak et al.,
1994, Mills et al., 1986).
Magnesium and inflammation -
Circulating levels of neutrophils increased 3-4 fold in Mg-deficient rats as
compared to magnesium-sufficient rats from 3rd week (Kurantsin et al., 1994).
Magnesium deficiency results in early elevation of neuropeptides (substance
P, CGRP) followed by later increases in inflammatory cytokines including
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gamma-interferon, IL-1, IL-6 and TNF-alpha in both rat and mice (Weglicki et
al., 1992, Weglicki et al., 1994, Weglicki and Phillips 1992, Weglicki et al.,
1992(a), Weglicki 1994(a)). As part of their proinflammatory activities, these
neuropeptides and cytokines might be able to activate a number of cells
including macrophages, neutrophils and endothelial cells to generate
oxyradicals and NO (Billingham 1987, Whicher et al., 1990, Mak et al., 1995,
Rock et al., 1995). Significant tissue inflammatory lesions occur only after 2
weeks of magnesium deficient diet (Weglicki et al., 1992, Weglicki et al.,
1994, Weglicki and Phillips 1992, Weglicki et al., 1992(a), Weglicki 1994(a)).
Magnesium and cardiovascular diseases -
Magnesium works with calcium and potassium to regulate blood pressure.
Several studies suggest that magnesium supplements can reduce blood
pressure in people with hypertension (Sanjuliani et al., 1996, Witteman et al.,
1994, Dyckner and Wester 1983, Henderson et al., 1986). A double-blind
placebo-controlled trial of 50 individuals with blockage in the arteries to the
heart (coronary artery disease) found that supplementation with magnesium
at 730 mg daily significantly improved exercise tolerance (Shechter et al.,
2000). In addition, a double-blind study of 42 individuals with heart disease
found that magnesium supplements reduced the tendency of the body to form
blood clots (Shechter 2000). Results indicate that hypomagnesaemia is
associated with decreased levels of Mg+2 and elevated levels of Ca+2 in the rat
heart and moreover internal Mg+2 is able to modulate the Ca+2 current through
L-type Ca+2 channel, which in turn may be involved in regulation of contractile
force in the heart. Mg+2 seems to play an important second messenger-
signalling role in the control of myocardial contractility possibly by regulating
cellular Ca+2 mobilization (Jaipaul et al., 1997). Magnesium deficiency or a
reduction of dietary intake of magnesium plays an important role in aeitiology
of diabetes and numerous cardiovascular diseases including thrombosis,
atherosclerosis, ischemic heart disease, myocardial infarction, hypertension,
arrhythmias and congestive heart failure in humans (Wallach 1987, Altura and
Altura 1986, Altura and Altura 1995, Maguire 1990, Woods 1991, Durlach and
Mareschi 1991, Elin 1987). Magnesium supplementation can bring about a
significant decrease in blood pressure and a stabilization of cardiac
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arrhythmias and acute myocardial infarction (Altura and Altura 1995, Woods
1991, Woods et al., 1992, Abraham 1987). The precise cellular mechanism(s)
by whereby magnesium can exert its useful effect on cardiac excitability and
contractility as well as on high blood pressure is not yet fully understood.
However, it is believed to act by a number of cellular pathways including
activation of enzymes and regulation of ion channel activities and transport
processes (Flataian 1993, Fry and Proctor 1993, Agus et al., 1989, Romani et
al.,1993, Murphy et al., 1991). Catecholamines can evoke marked Mg+2 efflux,
which is associated with a concomitant increase in force of contraction the
heart (Howarth et al., 1994, Hustler et al., 1995). Magnesium may also be
useful for improving blood pressure (Shechter et al., 2000, Sanjuliani et al.,
1996, Witteman et al., 1994) and preventing or treating coronary artery
disease (Dyckner and Wester 1983, Shechter et al., 2000). There is also
some evidence that magnesium may decrease the atherosclerosis risk
caused by hydrogenated oils, margarine-like fats found in many "junk" foods
(Kummerow et al., 1999). Hypomagnesaemia may lead to an impairment of
Ca+2 transporting processes in the heart resulting in an increase in heart Ca+2
content (Wacker 1968, Flataian 1993, Murphy et al., 1991). In human subject
hypomagnesaemia is often associated with electrolyte imbalace and severe
cardiovascular disorders including arrhythmias (Altura and Altura 1986, Altura
and Altura 1995, Woods 1991, Whang 1993). Reduction in either external or
internal ionized Mg+2 can result in a marked increase in Ca+2 influx through L-
type Ca+2 channels (Fry and Proctor 1993, Agus et al., 1989). Reduction in
ionised magnesium can result in sub-optimal performance of the Na-K-
ATPase pump (Skou 1979, Fischer and Giroux 1984) and Ca-ATPase pump
(Vormann et al., 1995). (Increase in (Na+)I, Na-Ca exchange in reverse,
increase in (Ca+2)I).
Magnesium and growth retardation -
Rats on low magnesium diet ate less food and grew more slowly than the
control rats on control magnesium diet. This reduction in growth has been
attributed to changes in insulin-like growth factor and growth hormone
accompanying magnesium deficiency (Dorup et al., 1991).
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Magnesium and migraine -
A recent double-blind study found that regular use of magnesium helps
prevent migraine headaches. In this 12-week trial, 81 people with recurrent
migraines were given either 600 mg of magnesium daily or placebo (Peikert et
al., 1996). By the last 3 weeks of the study, the treated group's migraines had
been reduced by 41.6%, compared to a reduction of 15.8% in the placebo
group. The only side effects observed were diarrhea (in about one-fifth of the
participants) and, less often, digestive irritation. Similar results have been
seen in other smaller double-blind studies (Taubert 1994, Facchinetti et al.,
1991). Several preliminary studies suggest that regular use of magnesium can
help prevent migraine headaches (Peikert et al., 1996, Taubert 1994,
Facchinetti et al., 1991).
Magnesium and kidney function -
Magnesium may also be useful for reducing the incidence of kidney stones
(Johansson et al., 1980). Magnesium inhibits the growth of calcium oxalate
stones in the test tube (Li et al., 1985) and decreases stone formation in rats
(Parivar et al., 1996). However, human studies have had mixed results. In one
2-year open study, 56 people taking magnesium hydroxide had fewer
recurrences of kidney stones than 34 people not given magnesium
(Johansson et al., 1980). In contrast, a double-blind (and, hence, more
reliable) study of 124 individuals found that magnesium hydroxide was
essentially no more effective than placebo (Ettinger et al., 1988).
Magnesium and premenstrual syndrome -
A 6-month double-blind placebo-controlled study of 50 women with menstrual
pain found that treatment with magnesium significantly improved symptoms
(Seifert et al., 1989). The researchers reported evidence of reduced levels of
prostaglandin F2µ, a hormone-like substance involved in pain and
inflammation. A double-blind placebo-controlled study of 32 women found that
magnesium taken from day 15 of the menstrual cycle to the onset of
menstrual flow could significantly improve premenstrual mood changes
(Facchinetti et al., 1991). Another small double blind preliminary study found
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that regular use of magnesium could reduce symptoms of PMS-related fluid
retention.73 In this study, 38 women were given magnesium or placebo for 2
months. The results showed no effect after one cycle, but by the end of two
cycles, magnesium significantly reduced weight gain, swelling of extremities,
breast tenderness and abdominal bloating (Facchinetti et al., 1991).
Preliminary evidence suggests that the combination of magnesium and
vitamin B6 might be more effective than either treatment alone (De Souza et
al., 2000). Preliminary double-blind trials suggest that magnesium may be
useful for dysmenorrhea (menstrual cramps) (Fontana and Hogg 1990,
Wagler et al., 1989) and symptoms of PMS (premenstrual syndrome),
including menstrual migraines (Facchinetti et al., 1991, Facchinetti et al.,(a)
1991).
Magnesium and diabetes -
Open trials suggest that magnesium might decrease symptoms of restless
legs syndrome (Hornyak et al., 1998, Popoviciu et al., 1993). Although there is
no direct evidence that magnesium helps people with diabetes, such
individuals are known to be deficient in magnesium (Elamin and Tuvemo
1990, Tosiello 1996, Eibl et al., 1995) and magnesium supplementation may
be a good idea on general principle. However, individuals with severe kidney
disease should take magnesium supplements only on their physician's advice.
Wheatgrass is rich in magnesium content hence, it may replenish body’ s
depleted level of magnesium. From the forgoing discussion on benefits of
magnesium supplementation in various pathological conditions, wheatgrass
may offer potential therapeutic uses.
49
3.5 Pathophysiology and treatment of thalassemia -
Thalassemia is one of the most common groups of genetic blood disorder.
The word thalassemia was derived from two Greek words - Thalassa meaning
the sea and haima meaning blood. Thomas Benton Cooley (1871-1945) was
the first American physician to describe the clinical presentation and features
of unexplained severe anemia and hence it was coined Cooley's anemia.
Countries like Italy, Greece and Cyprus have the highest frequency of
thalassemia cases in the world. There exists a thalassemic "belt" that includes
the Mediterranean passing through West and Central Asian countries like
Turkey, Iran, Afghanistan onto Pakistan and India and passes on to the South
East Asian countries like Indonesia, Burma and Thailand. There are an
estimated 240 million carriers of thalassemia in the world. India has the
largest pool of numbering around 30 million (every 8th carrier of thalassemia
is an Indian). The distribution of ß-thalassemia gene is not uniform in the
Indian subcontinent. The highest frequency of ß-thalassemia trait is reported
in Gujarat (10-15%), followed by Sindh (10%), Tamil Nadu (8.4%),
Maharashtra (7.04%), Punjab (6.5%) and South India (4.3%) (Varawalla et al.,
1991, Balgir 1996, Sukumaran and Master 1974 ). The condition is
uncommon south of Vindhyas. Very high rates have been found in certain
communities such as Sindhis 12.4% and in Lohana Gujratis 13.6 %. The
reason is attributed to intra-caste and intra-community marriages. It is
estimated that every year about 10,000 children are born in India with the
disorders. A staggering sum of Rs. 150 crores is required to be spent every
year, in terms of cost of ideal maintenance of these children (Varawalla et al.,
1991).
The thalassemias are characterized by impaired production of one or more
polypeptide chains of globin. Any of the four polypeptides (?, ?,?,  ) that
occur in normal hemoglobin may be involved. However, the most prevalent
thalassemia syndromes are those that involve diminished or absent synthesis
of the ?- or ?-globin chains of HbA1 (Weatherall 1997, Jandl 1987, Steinberg
1988).
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Two distinct types of globin chains (each with its individual heme molecule)
combine to form hemoglobin. One of the chains is alpha (µ). The second
chain is "non-alpha". With the exception of the very first weeks of
embryogenesis, one of the globin chains is always alpha. A number of
variables influence the nature of the non-alpha chain in the hemoglobin
molecule. The fetus has a distinct non-alpha chain called gamma (g). After
birth, a different non-alpha globin chain, called beta (b), pairs with the alpha
chain. The combination of two alpha chains and two non-alpha chains
produces a complete hemoglobin molecule (a total of four chains per
molecule). The combination of two alpha chains and two gamma chains form
"fetal" hemoglobin, termed "hemoglobin F" i.e. (µ2g2). With the exception of
the first 10 to 12 weeks after conception, fetal hemoglobin is the primary
hemoglobin in the developing fetus. The combination of two alpha chains and
two beta chains form "adult" hemoglobin, also called "hemoglobin A" i.e.
(µ2b2). Although hemoglobin A is called "adult", it becomes the predominant
hemoglobin within about 18 to 24 weeks of birth.
The pairing of one alpha chain and one non-alpha chain produces a
hemoglobin dimer (two chains). The hemoglobin dimer does not efficiently
deliver oxygen, however. Two dimers combine to form a hemoglobin tetramer,
which is the functional form of hemoglobin. Complex biophysical
characteristics of the hemoglobin tetramer permit the exquisite control of
oxygen uptake in the lungs and release in the tissues that is necessary to
sustain life. The genes that encode the alpha globin chains are on
chromosome 16. Those that encode the non-alpha globin chains are on
chromosome 11. Multiple individual genes are expressed at each site.
Pseudogenes are also present at each location. The alpha complex is called
the "alpha globin locus", while the non-alpha complex is called the "beta
globin locus". The expression of the alpha and non-alpha genes is closely
balanced by an unknown mechanism. Balanced gene expression is required
for normal red cell function.
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Human hemoglobins -
Embryonic hemoglobins –
Gower 1- zeta(2), epsilon(2)
Gower 2- alpha(2), epsilon (2)
Portland- zeta(2), gamma (2)
Fetal hemoglobin -
Hemoglobin F- alpha(2), gamma(2)
Adult hemoglobins -
hemoglobin A1- alpha(2), beta(2) - 97%
hemoglobin A2- alpha(2), delta(2) – 2.5%
hemoglobin F- alpha(2), gamma(2) – 0.5%
Genetics of thalassemia -
Figure – 3.2 Schematic representations of the globin gene loci
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Alpha globin locus -
Each chromosome 16 has two alpha globin genes that are aligned one after
the other on the chromosome. For practical purposes, the two alpha globin
genes (termed alpha1 and alpha2) are identical. Since each cell has two
chromosomes 16, a total of four alpha globin genes exist in each cell. Each of
the four genes produces about one-quarter of the alpha globin chains needed
for hemoglobin synthesis. The mechanism of this coordination is unknown.
Promoter elements exist 5’ to each alpha globin gene. In addition, a powerful
enhancer region called the locus control region (LCR) is required for optimal
gene expression. The LCR is many kilobases upstream of the alpha globin
locus. The mechanism by which DNA elements so distant from the genes
control their expression is the source of intense investigation. The transiently
expressed embryonic genes that substitute for alpha very early in
development, designated zeta, are also in the alpha globin locus.
Beta globin locus -
The genes in the beta globin locus are arranged sequentially from 5' to 3'
beginning with the gene expressed in embryonic development (the first 12
weeks after conception; called epsilon). The beta globin locus ends with the
adult beta globin gene. The sequence of the genes is: epsilon, gamma, delta,
and beta. There are two copies of the gamma gene on each chromosome 11.
The others are present in single copies. Therefore, each cell has two beta
globin genes, one on each of the two chromosomes 11 in the cell. These two
beta globin genes express their globin protein in a quantity that precisely
matches that of the four alpha globin genes. The mechanism of this balanced
expression is unknown.
The lower panel shows the alpha globin locus that resides on chromosome
16. Each of the four alpha globin genes contributes to the synthesis of the
alpha globin protein. The upper panel shows the beta globin locus. The two
gamma globin genes are active during fetal growth and produce hemoglobin
F. The "adult" gene, beta, takes over after birth.
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Molecular biology -
Each globin gene consists of a string of nucleotide bases divided into 3 coding
sequences termed exons and 2 noncoding regions known as introns or
intervening sequences. Three other regions, known as regulatory regions,
also exist in the 5’ noncoding or flanking region of each globin gene.
The first is the promoter, which plays a major role in the transcription of the
structural genes. The second region is the enhancer, which has an important
role in promoting erythroid-specific gene expression, as well as in
coordinating the changes in globin gene activity at different stages of
development (embryonal, fetal, adult). Enhancers are able to influence gene
expression, despite being located some distance away from the gene itself,
and, unlike the promoter, they can stimulate transcription irrespective of their
orientation relative to the transcription start site. Finally, master regulatory
sequences, known as locus control regions (in the beta globin gene family)
and HS40 (in the alpha gene complex), are responsible for activating the
genes in erythroid cells.
Each of these regulatory sequences has a modular structure, consisting of
short nucleotide motifs that act as binding sites for transcriptional activator or
suppressor molecules. Such molecules activate or suppress gene expression
in different cell types at different stages of development. Transcription of a
certain gene is achieved by an initiation complex formed of certain proteins
and a number of transcription factors, which interact with binding sites on the
promoters and other regulatory sequences of the relevant genes.
When a gene is transcribed, mRNA is synthesized from one of the gene’ s
DNA strands by the action of RNA polymerase. The initial product is a large
mRNA precursor. Both exons and introns are initially present on this mRNA
precursor; the introns ultimately are subsequently eliminated, and the exons
are spliced together in the nucleus. At this stage, the mRNA, which also has
been modified at both 5’ and 3’ ends, moves to the cytoplasm to act as a
template for the production of globin chains.
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Carrier molecules (transfer RNA [tRNA]) transport amino acids to the mRNA
template. Each amino acid has a specific tRNA, which also contains 3 bases
(anticodon), complimentary to the mRNA codons for that amino acid. The
position of each amino acid in the globin chain thus is established by its
corresponding triplet code (codon) in the globin gene. The CUG codon
(cytidine/uridine/guanosine), for example, encodes the amino acid leucine,
while the AAA codon (adenosine/adenosine/adenosine) encodes lysine.
When a tRNA molecule carries the initial amino acid to the template, directed
by codon-anticodon base pairing, globin chain synthesis begins.
Once the first tRNA is in place, a complex is formed between several protein
initiation factors and the subunit of the ribosome that is to hold the growing
peptide chains together on the mRNA as it is translated. A second tRNA
moves in alongside, and a new amino acid is bound to the first with a peptide
bond, resulting in a peptide chain 2 amino acids long. This process continues
from left to right until a specific codon for termination is reached. At this point,
the completed peptide chain drops off the ribosome-mRNA complex, and the
ribosomal subunits are recycled. The globin chain is now ready to join a heme
molecule and 3 other globin chains to form an Hb molecule.
The developmental switches from embryonic to fetal and then to adult Hb
production are synchronized throughout the different organs of hematopoiesis
(yolk sack, liver, bone marrow), which function at various stages of
development. Even though the mechanism of such switches is not understood
clearly, the globin gene promoter is known to contain information that
specifies developmental stages of transcription.
Molecular pathology -
Mutations resulting in beta or alpha thalassemia are similar in principle but
different in their patterns. More than 150 different mutations are known to
result in various types of beta thalassemia. Major deletions are unusual (in
contrast to alpha thalassemia), and most of the encountered mutations are
either single base changes, small deletions, or insertions of 1-2 bases at a
critical site along the gene. These mutations occur in both exons and introns.
55
For example, in a "nonsense" mutation, a single base change in the exon
generates a "stop" codon in the coding region of the mRNA, resulting in
premature termination of globin chain synthesis. This leads to the production
of short, nonviable beta chains. Conversely, in the "frame shift" mutation, one
or more bases on the exon are lost or inserted, resulting in a change in the
reading frame of the genetic code or the production of a new stop codon.
RNA splicing mutations are fairly common and represent a large portion of all
mutations resulting in beta thalassemia. These mutations corrupt the splicing
process. The importance of precise splicing in the quantitative production of
stable functional mRNA cannot be overemphasized. Slippage by even one
nucleotide changes the reading frame of the mRNA. Specific consensus
sequences exist at both ends of the RNA introns (at the junction with the
exons); these motifs include GT in the 5’ (left end or donor site) consensus
sequence and AG in the 3’ (right end or acceptor site) consensus sequence.
Such sequences are obligatory for correct splicing, and a single substitution at
the invariant GT or AG sequence prevents splicing altogether and results in
beta-0 or alpha-0 thalassemia. Mutations in the other members of the
consensus sequences, even though still highly conserved, result in variable
degrees of ineffective beta globin production, causing milder types of beta
thalassemia.
Mutations in exon sequences may activate a "cryptic" splice site. For example,
in exon 1 of the beta globin gene, a consensus sequence that resembles a
sequence in IVS-1 has been identified as the site for several distinct
mutations, resulting in a gene that carries the features of both thalassemia
and hemoglobinopathy at the same time (quantitatively and qualitatively
abnormal Hb production). This type of mutation represents a clear link
between the thalassemias and the hemoglobinopathies, and accordingly,
these are labeled "thalassemic hemoglobinopathies." Thus, mutations at
codon 19 (A to G), 26 (G to A), and 27 (G to T) —all in exon 1 —result in
reduced production of mRNA (thalassemia), due to inefficient splicing, and an
amino acid substitution, encoded by the mRNA that is spliced and translated
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(albeit inefficiently) into protein. The resulting abnormal Hbs are Malay, E and
Knossos respectively.
The flanking regions of the beta globin gene are also sites for various
mutations. A single base substitution involving the promoter element, for
example, can down-regulate beta globin gene transcription, resulting in a mild
form of beta thalassemia. Conversely, a mutation affecting the 3’ end of the
beta globin mRNA can interfere with it’ s processing, resulting in a severe form
of beta thalassemia.
Clearly, many different beta thalassemia mutations exist, and compound
heterozygosity frequently is encountered. The resulting laboratory findings
may lead to confusion. An example is the patient who manifests symptoms of
beta thalassemia major without an elevated HbA2. The explanation for such a
situation is often co-inheritance of beta and delta thalassemia. Delta/beta
thalassemia further is divided into (delta/beta+) or (delta/beta-0). In the first
type, a misalignment in the delta-beta genes during meiosis results in the
production of fused delta/beta genes, a process responsible for the production
of an Hb variant termed Hb Lepore. The fused delta/beta gene is under the
control of a delta-globin gene promoter region (the beta gene promoter is
deleted in the process). Since the delta gene promoter carries mutations that
lead to ineffective transcription, the fused delta/beta chains are produced in
limited amounts, resulting in thalassemia. This is in addition to the
hemoglobinopathy.
Conversely, in delta/beta-0 thalassemia, a large deletion takes place in the
beta globin gene cluster, removing both the delta and the beta genes, which
also can extend to involve all globin genes on chromosome 11, thus
producing (epsilon, gamma, delta, and beta-0) thalassemia.
Alpha Thalassemia -
Alpha thalassemia occurs when one or more of the four alpha chain genes
fails to function. Alpha chain protein production, for practical purposes, is
evenly divided among the four genes. With alpha thalassemia, the "failed"
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genes are almost invariably lost from the cell due to a genetic accident. ?-
thalassemia has four manifestations, which correlate with the number of
defective genes. (i) Silent carrier state. (ii) Mild alpha-thalassemia. (iii)
Hemoglobin H disease. (iv) Hydrops fetalis. Since the gene defect is almost
invariably a loss of the gene, there are no "shades of function" to obscure the
matter as occurs in beta thalassemia.
Silent carrier state -
This is the one-gene deletion alpha thalassemia condition. People with this
condition are hematologically normal. They are detected only by sophisticated
laboratory methods.
Mild alpha-thalassemia ?
These patients have lost two alpha globin genes. They have small red cells
and a mild anemia. These people are usually asymptomatic. Often,
physicians mistakenly diagnose people with mild alpha-thalassemia as having
iron deficiency anemia. Iron therapy, of course, does not correct the anemia.
Hemoglobin H disease ?
These patients have lost three alpha globin genes. The result is a severe
anemia, with small, misshapen red cells and red cell fragments. These
patients typically have enlarged spleens. Bony abnormalities particularly
involving the cheeks and forehead are often striking. The bone marrow works
at an extraordinary pace in an attempt to compensate for the anemia. As a
result, the marrow cavity within the bones is stuffed with red cell precursors.
These cells gradually cause the bone to "mold" and flair out. Patients with
hemoglobin H disease also develop large spleens. The spleen has blood-
forming cells, the same as the bone marrow. These cells become hyperactive
and over expand, just as those of the bone marrow. The result is a spleen
that is often ten-times larger than normal. Patients with hemoglobin H disease
often are small and appear malnourished, despite good food intake. This
feature results from the tremendous amount of energy that goes into the
production of new red cells at an extremely accelerated pace. The constant
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burning of energy by these patients mimics intense aerobic exercise; exercise
that goes on for every minute of every day.
Hydrops fetalis ?
This condition results from the loss of all four alpha globin genes. The affected
individual usually succumbs to the severe anemia and complications before
birth.
Beta thalassemia -
The fact that there are only two genes for the beta chain of hemoglobin makes
ß-thalassemia simpler to understand than ?-thalassemia (Rund and
Rachmilewitz 1995). Unlike ?-thalassemia, ß-thalassemia rarely arises from
the complete loss of a ?-globin gene. The ?-globin gene is present, but
produces little ?-globin protein. The degree of suppression varies. The type of
thalassemia usually carries the name of the under-produced chain(s). The
reduction varies from a slight decrease to complete absence of production.
For example, when beta chains are produced at a lower rate, the thalassemia
is termed beta+, whereas beta0 thalassemia indicates a complete absence of
production of beta chains from the involved allele. As per the clinical
manifestations, ß-thalassemia is classified in to three categories, (i)
Thalassemia minor, or thalassemia trait (ii) Thalassemia intermedia (iii)
Thalassemia major.
Thalassemia minor or thalassemia trait -
These terms are used interchangeably for people who have small red cells
and mild (or no) anemia due to thalassemia. These patients are clinically well,
and are usually only detected through routine blood testing. Physicians often
mistakenly diagnose iron deficiency in people with thalassemia trait. Iron
replacement does not correct the condition. The primary caution for people
with beta-thalassemia trait involves the possible problems that their children
could inherit if their partner also has beta-thalassemia trait. These more
severe forms of beta-thalassemia trait are outlined below.
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Thalassemia intermedia ?
Thalassemia intermedia is a confusing concept. The most important fact to
remember is that thalassemia intermedia is a description, and not a
pathological or genetic diagnosis. Patients with thalassemia intermedia have
significant anemia, but are able to survive without blood transfusions. The
factors that go into the diagnoses are: 1. The degree to which, the patient
tolerates the anemia. 2. The threshold of the physician to transfuse patients
with thalassemia. With regard to the tolerance of the anemia, most patients
with thalassemia have substantial symptoms with a Hb of much below 7 or 8
gm/dl. With hemoglobins of this level, excess energy consumption due to the
profound hemolysis can produce small stature, poor weight gain, poor energy
levels, and susceptibility to infection. Further, the extreme activity of the bone
marrow produces bone deformities of the face and other areas, along with
enlargement of the spleen. The long bones of the arms and legs are weak
and fracture easily. Patients with this clinical condition usually do better with
regular transfusions. The need for regular transfusions would then place them
under the heading of thalassemia major (see below). On the other hand,
some patients with marked thalassemia can maintain hemoglobin of about 9
to 10 gm/dl. The exercise tolerance of these patients is significantly better.
The question then becomes whether the accelerated bone marrow activity
needed to maintain this level of hemoglobin causes unacceptable side effects
such as bone abnormalities or enlarged spleen. This is a judgment decision.
Some physicians to prevent these problems, even if they are slight, would
transfuse a given patient at the critical borderline. The patient then would be
clinically classified as having thalassemia major. Another physician might
choose to avoid the complications of chronic transfusion. The same patient
then would be clinically classified as thalassemia intermedia. The patient has
thalassemia that is more severe than thalassemia trait, but not so severe as to
require chronic transfusion as do the patients with thalassemia major. A
patient can change status. The spleen is enlarged in these patients. The
spleen plays a role in clearing damaged red cells from the blood stream.
Since all of the red cells in patients with severe thalassemia have some
degree of damage, clearance by the spleen accelerates the rate of cell loss.
Therefore the bone marrow has to work harder to replace these cells. In some
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patients, removal of the spleen slows the rate of red cell destruction just
enough, that they can manage without transfusion, and still not have the
unacceptable side-effects. In this case, the patient converts clinically from
thalassemia major to thalassemia intermedia.
Thalassemia major ?
This is the condition of severe thalassemia in which chronic blood
transfusions are needed. In some patients the anemia is so severe, that death
occurs without transfusions. Other patients could survive without transfusions,
for a while, but would have terrible deformities. While transfusions are life
saving in patients with thalassemia major, transfusions ultimately produce iron
overload. Chelation therapy, usually with the iron-binding agent,
desferrioxamine (Desferal), is needed to prevent death from iron-mediated
organ injury.
Cellular pathophysiology -
As discussed earlier, the basic defect in all types of thalassemia is
imbalanced globin chain synthesis. However, the consequences of
accumulation of the excessive globin chains in the various types of
thalassemia are quite different. In beta thalassemia, excessive alpha chains,
unable to form Hb tetramers, precipitate in the RBC precursors and, in one
way or another, produce most of the manifestations encountered in all of the
beta thalassemia syndromes. This is not the situation in alpha thalassemia.
The excessive chains in alpha thalassemia are gamma chains earlier in life
and beta chains later on. Both are able to form homotetramers that, although
relatively unstable, nevertheless remain viable and able to produce soluble Hb
molecules such as Bart (4 gamma chains) and H (4 beta chains). These basic
differences in the 2 main types of thalassemia are responsible for the major
differences in their clinical manifestations and severity.
In b-thalassemia, the synthesis and accumulation of excess normal ?-globin
chain within the red cell, lead to the formation of unstable aggregates, which
upon oxidation, due to oxidative stress generated by iron overload, may
61
precipitate and cause cell membrane damage. These deformed cells undergo
premature destruction either in the bone marrow (extravascular hemolysis) or
the peripheral circulation (intravascular hemolysis) (Weatherall 1997, Festa
1985). This means that both hemolysis and ineffective erythropoiesis cause
anemia in the patient with beta thalassemia. The ability of some red cells to
maintain the production of gamma chains, which are capable of pairing with
some of the excessive alpha chains to produce HbF, is advantageous.
Binding some of the excess alpha chains undoubtedly reduces the symptoms
of the disease. The elevated HbF increases oxygen affinity leading to hypoxia,
which, together with the profound anemia, stimulates the production of
erythropoietin. As a result, severe expansion of the ineffective erythroid mass
occurs leading to severe bone expansion and deformities. Both iron
absorption and metabolic rate increase, adding more symptoms to the clinical
and laboratory manifestations of the disease. The large numbers of abnormal
red cells processed by the spleen, together with its hematopoietic response to
the anemia if untreated, results in massive splenomegaly, leading to
manifestations of hypersplenism.
Management of ß-thalassemia major (Cooley's Anemia) requires patients to
have life-long regimen of regular blood transfusions coupled with iron
chelation therapy (Modell 1994, Cao et al., 1997). The frequency of blood
transfusion requirement increases with growing age. On an average
transfusion is required every fortnight. Blood transfusion produces on long
term, serious and unavoidable side-effects because with each unit of blood
transfused 200 to 250 mg of iron gets deposited in the heart, liver, pancreas
and other glands in the body. This may lead to heart failure, cirrhosis of liver,
diabetes mellitus and malfunctioning of other glands. Generally, regular blood
transfusions and iron chelation treatment with desferrioxamine are initiated
early in life; therefore, the patients and their families have to sustain regular
treatment throughout their childhood, adolescent, and adult years (Olivieri et
al., 1994, Zurlo et al., 1989).
Biochemistry of Iron –
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Iron is the most important component of haemoglobin, the molecule of which
contains four iron atoms. Approx. 2–5 g iron is normally present in the human
body, depending on body weight. Some two-thirds of this quantity are
incorporated into haemoglobin (100 ml blood contains approx. 15 g
haemoglobin), about one-fifth is stored in the tissues, about one-tenth is
contained in all types of cells as a component of various enzymes, and
approx. 5% is bound in myoglobin; only about 2% circulates in the plasma. An
average daily diet contains roughly 10–20 mg iron, but of this quantity the
body normally absorbs only as much as is required to offset the amount of
iron excreted each day, i.e. about O.5–1.O mg. Iron is absorbed from the gut
by the cells of the intestinal mucosa in its non-poisonous bivalent form. It then
either passes into the blood, where it becomes bound in its trivalent form to
the iron-binding protein transferrin  (siderophilin), or, alternatively, it is retained
in the mucosal cells in the form of ferritin. Under normal circumstances, the
iron in transferrin is made available to the erythropoietic cells for the synthesis
of haemoglobin. Iron supplied to the body in excessive quantities becomes
stored chiefly in the liver and in the reticulo-endothelial system, either as
ferritin or as haemosiderin.
Iron overload -
In untransfused patients with severe ß-thalassemia, abnormally regulated iron
absorption results in increases in body iron burden that may, depending on
the severity of erythroid expansion, vary between 2 and 5 grams per year
(Pippard et al., 1997, Pootrakul et al., 1988). Regular transfusions may double
this rate of iron accumulation. Although most clinical manifestations of iron
loading do not appear until the second decade of life in inadequately chelated
individuals, evidence from serial liver biopsies in young patients indicates that
the deleterious effects of iron are mediated much earlier. After approximately
one year of transfusions, iron is deposited in parenchymal tissues, where it
may cause significant toxicity as compared to that within reticuloendothelial
cells (Hershko et al., 1998). As iron loading progresses, the capacity of serum
transferrin, the main transport protein of iron, to bind and detoxify iron may be
exceeded. Thereafter, the non-transferrin-bound fraction of iron within plasma
may promote generation of free hydroxyl radicals, propagators of oxygen-
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related damage (Hershko et al., 1998). The effectiveness of an iron-chelating
agent depends in part on its ability to bind non-transferrin bound plasma iron
over sustained periods of time, thereby ameliorating iron-catalyzed toxicity of
free radicals.
Clinical impact of iron overload in thalassemia -
Cardiac complications ?
The commonest cause of death in cases of thalassemia major is heart failure.
In the absence of chelating therapy, iron accumulation results in progressive
dysfunction of the heart, liver and endocrine glands (Olivieri and Brittenham
1997). In response to iron loading, human myocytes in vitro upregulate the
transport of non-transferrin-bound iron (Parkes et al., 1993), thereby possibly
aggravating cardiac iron loading. Extensive iron deposits are associated with
cardiac hypertrophy and dilatation, myocardial fiber degeneration and, rarely,
fibrosis (Buja and Roberts 1971). In many patients abnormal function is
observed in the absence of symptoms (Fiorillo et al., 2000). In transfused,
unchelated patients, symptomatic cardiac disease is observed after about ten
years following the start of transfusions (Wolfe et al., 1985) and may be
aggravated by myocarditis (Kremastinos et al., 1996) and pulmonary
hypertension (Aessopos et al., 1995, Du et al., 1997). Survival is determined
by the magnitude of iron loading within the heart (Brittenham et al., 1994,
Olivieri et al., 1994).
Liver damage -
Iron-induced liver disease is a common cause of death in transfused patients
(Zurlo et al., 1989). Within two years following the start of transfusions,
collagen formation (Iancu et al., 1977) and portal fibrosis (Thakerngpol et al.,
1996) are observed; in the absence of chelating therapy, cirrhosis may
develop in the first decade of life (Witzleben and Wyatt 1961, Jean et al.,
1984). As in cultured heart cells, upregulation of transport of non-transferrin-
bound iron is observed in cultured hepatocytes (Parkes et al., 1995), possibly
aggravating iron loading in vivo.
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Endocrinal disorders -
In cases of thalassemia major, increasingly severe impairment of the
endocrine system can be observed as the years go by and as more blood
transfusions are administered. Iron deposition in the interstitial tissues and in
the secreting cells of the endocrine glands results in disorders such as
diabetes mellitus, hypothyroidism, hypoparathyroidism, hypoadrenalism, and
hypogonadism. Already during the early stages of the disease, involvement of
the µ and b cells in the pancreas manifests itself in the form of disorders
affecting insulin secretion and glucose tolerance. In transfused patients, iron
loading within the anterior pituitary results in disturbed sexual maturation in
approximately 50% of males and females. Diabetes mellitus is observed in
about 5% of adults (Cavallo-Perin et al., 1995). Chronic iron deposition also
damages the thyroid, parathyroid, adrenal glands, and exocrine pancreas
(Magro et al., 1990, Sklar et al., 1987, Gullo et al., 1993) and may provoke
pulmonary hypertension, right ventricular dilation, and restrictive lung disease
(Tai et al., 1996, Piatti et al., 1997). Hypofunction of the adrenal cortex may
give rise quite early on to an increase in melanin production and skin
pigmentation, as well as to the appearance of low voltage waves in the ECG,
which, however, are unaccompanied by any evidence of organic damage to
the heart. Growth retardation in patients with thalassemia major can occur for
a number of reasons, depending on how the patient is managed. A poorly
transfused or non-transfused patient has severe anemia, with or without
multiple infections and accompanied by failure to thrive25. A child on regular
transfusions without iron chelation therapy will have stunting as a result of the
iron overload. In this case, the poor growth results from the effect of iron on
pituitary function, leading to a lack of puberty, and/or from poor liver function
and a consequent interference with somatomedin metabolism, leading to
short stature. Desferal treatment itself, if too intensive, has been reported to
result in short stature.
Hyperbilirubinaemia and gallstones -
The severe hemolysis occurring in thalassemia major gives rise to
hyperbilirubinaemia, which in turn leads to bilirubinuria, a condition causing
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dark brown discoloration of the urine; after the fourth year of life it may also
result in the formation of gallstones, the incidence of which rises to 75% by
the 15th year of life. In addition, this hemolysis leads to an increase in the
serum concentrations of various substances released as the erythrocytes
break down, e.g. lactic dehydrogenase, alkaline phosphatase, glutamic acid,
uric acid, and iron. One consequence of the damage sustained by the liver is
deficiencies affecting blood coagulation factors.
Splenomegaly -
The important functions of the spleen are summarized below: A) Immune
functions, including clearance of particulate matter and microorganisms and
generation of humoral and cellular response to foreign antigens. B)
Sequestration of normal and abnormal cells. C)Regulation of portal blood
flow. D) Site of extramedullary erythropoiesis. Increased erythrocyte
production, coupled with increased phagocytosis and storage of stroma from
broken down erythrocytes, leads to hyperplasia of the reticulo-endothelial
system. Splenomegaly produces enlargement of the abdomen, which may
eventually assume massive proportions. Hypersplenism is defined as a
condition in which the spleen removes circulating red blood cells,
granulocytes and platelets in excessive quantity. Hypersplenism is diagnosed
if the following criteria are fulfilled: 1) pancytopenia 2) normal or hypercellular
bone marrow 3) splenomegaly and 4) correction of cytopenia after
splenectomy.
Sexual development -
Sexual development in these patients shows a stronger correlation with bone
age rather than with chronological age. Delayed sexual development – like
the other complications such as cardiac lesions, diabetes mellitus, and liver
cirrhosis – seems to be largely caused by the hemosiderosis; however,
menstruation and spermatogenesis appear to be normal in some patients.
Skeletal changes and facial appearance -
Changes occurring in the skeleton are due to chronic over activity of the bone
marrow, which results in widening of the medullary spaces. Included among
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these changes are osteoporosis, thinning of the cortex, and trabecular
atrophy. Owing to such lesions, deformities of the spinal column tend to occur,
as well as pathological bone fractures in response to minor injuries25.
Excessive prominence of the cheekbones, forehead, and parietal eminence,
coupled with depression of the root of the nose, gives the face a characteristic
Asiatic appearance. Premature fusion of the epiphyses in the long bones
often leads to shortening or angulation of the limbs. Arthropathy, synovitis,
and arthralgia of the knees and ankles, together with oedema of the ankles
and feet, are attributable to a combination of secondary haemosiderosis and
hyperuricaemia.
Assessment of body iron burden -
Both direct and indirect means for the assessment of body iron are available;
no single indicator or combination of indicators is ideal for the evaluation of
iron status in all clinical circumstances. The measurement of plasma or serum
ferritin is the most commonly used indirect estimate of body iron stores
(Brittenham et al., 2001). Interpretation of ferritin levels may be complicated by
a variety of conditions that alter concentrations independently of changes in
body iron burden, including ascorbate deficiency, fever, acute infection,
chronic inflammation, acute and chronic hepatic damage, hemolysis and
ineffective erythropoiesis (Brittenham et al., 2001). Serum iron, transferrin,
transferrin saturation and transferrin receptor concentration, or urinary iron
excretion following an infusion of DFO do not quantitatively reflect body iron
stores. The availability of a simple assay for monitoring non-transferrin-bound
plasma iron could provide a useful measurement of iron status but has not
been applied widely (Breuer et al., 2001). A variety of studies have been
directed at imaging tissue iron by computed tomography, nuclear resonance
scattering, and magnetic resonance imaging. Measurement of hepatic iron
concentration is the most quantitative, specific, and sensitive method for
determining body iron burden Breuer et al., 2001). Iron in biopsy samples is
assessed most frequently using atomic absorption spectroscopy.
Treatment of thalassemia -
Blood transfusion therapy -
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The combination of transfusion and iron chelation is now the reference
treatment for thalassemia. This combination gives a marked improvement in
survival, growth and sexual development if started at the right time and
followed diligently. The standard policy is to maintain hemoglobin between 10
and 14 g/dl, if the blood supply permits. If adequate individual records are
kept, the optimal transfusion therapy can be determined for each patient's
clinical condition. One drawback of blood transfusion is that it exposes the
patient to risk. Thus it is vital to improve blood safety continually and, find
ways of reducing transfusion requirements.
Objectives of transfusion -
When the diagnosis of thalassemia major is clear-cut, regular transfusions
should be started without delay. The transfusion scheme should keep the Hb
level in the normal range, the current recommendation being to maintain a
mean Hb = 10 -12 g/dl. Super-transfusion regimen, in which the mean Hb =
13g/dl, and Hyper-transfusion, maintaining a mean Hb = 12g/dl are also
advocated. This scheme prevents 1. chronic hypoxemia 2. secondary bone
change by reducing compensatory bone marrow hyperplasia 3. growth
perturbation, whereas promotes normal physical activity 4. hypervolemia,
which places a strain on the heart 5. early development of splenomegaly and
hypersplenism, by reducing the number of abnormal RBC reaching the spleen
and 6. excess gastro-intestinal iron absorption, which contributes to iron
overload.
Amount of blood needed for transfusion -
The amount of blood needed for transfusion is estimated in relation with the
patient’ s age and his clinical status. The total volume of blood fluctuates
between 10-20ml / kg of body weight and the hematocrit of the RC (red cell)
component may influence this calculation (60-75%). It is estimated that 3ml
RCs / kg of body weight increase Hb per 1g/dl. A blood volume greater than
20ml / kg per transfusion must be avoided. However, the calculations are
misleading for low-transfused patients (mean Hb=10g/dl or less) because
they have a greatly expanded blood volume. To evaluate transfusion in such
patients both the pre-transfusion and the post-transfusion Hb must be
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measured routinely. Moreover, low-transfused patients are at risk for
circulatory overload and therefore they have to be transfused with small
volumes of RC but more frequently (8-12 days).
Transfusion rate -
The rate at which blood can be transfused without overloading the circulation
depends on the patient’ s Hb level and cardiovascular status, and RC
component used. When there is no cardiac problem: It is acceptable to give 5-
7,5ml RC/Kg/ hour. If it is necessary to transfuse volumes > 20ml/Kg the
transfusion must be given over 3-4 hours. When cardiac failure is present or
Hb level < 5g/dl: No more than 5ml /Kg/ hour should be transfused on any one
occasion, and infusion rate should not exceed 2ml /Kg / hour.
Transfusion interval -
The pre-transfusion Hb level required to maintain the recommended mean Hb
= 12-12,5 g/dl, varies with the transfusion interval. In practice, the interval
between transfusions varies from 2-4 weeks and it is well supported in well-
being patients.
Personalizing the treatment -
1. The pre-transfusion Hb should be high enough (10-11g/dl) to inhibit marrow
hypersensitivity. The exact level of pre-transfusion Hb can vary with
Thalassaemia mutations involved, the patient’ s age, and the presence or
absence of the spleen.
2. The post-transfusion Hb should not rise above 16g/dl. Higher levels
increase blood viscosity, reduce tissue oxygenation and increase the risk of
thrombosis. Moreover, blood consumption increases and iron overload is
accelerated.
3. Transfusion interval is usually influenced by pragmatic considerations, such
as the distance from a patient’ s home to the center, and the wish to minimize
the social and psychological disturbance of repeated hospital visits.
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4. To avoid waste of blood, the transfusion interval is also usually adjusted to
allow the transfusion of a whole number of units (for small children, special
pediatric blood bags are available).
Transfusion reactions in thalassemic patients -
Acute -
After infusion of only few millilitres of blood:
1. Hemolytic (AHTR) Intravascular: result from transfusion of ABO
incompatible RCs (clerical error) and can be life-threatening.
2. Anaphylactic: Immediate hypersensitivity, occurs among patients who have
a congenital deficiency in IgA. It begins mildly but can progress to shock and
death.
3. Embolic: Air embolism is a concern, if air enters the system when
containers or tubing are changed. Patient symptoms may include cough,
dyspnea, chest pain and shock.
Steps to be followed:
1. Stop the transfusion immediately and maintain IV access with normal
saline.
2. Perform clerical check of labels, forms and patient identification. If an error
has been made, undertake then an immediate search to locate it and avert
putting another patient at risk.
3. Report reaction to blood bank personnel.
4. Draw a post-transfusion sample and urine sample and send it along with
the unused blood product and its administration set to the blood bank.
Towards the end or after the completion of the transfusion -
 1. Circulatory Overload: Transfusion that proceeds at too fast a rate may lead
to congestive heart failure and pulmonary edema.
2. TRALI: should be considered whenever recipient experiences acute
respiratory difficulties without evidence of cardiac involvement.
3. Metabolic: Hyperkalaemia may arise when RBC are transfused at the end
of storage, when they lose their intracellular potassium.
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4. FNHTR: occurs in about 1% of the transfusions. It is defined as an increase
in To >  1oC, without any other medical explanation. It may be caused by
antileukocyte antibodies present in the recipient’ s plasma or to infusion of
cytokines produced by leucocytes during component storage. It may be
reduced by antipyretics and prevent by leucopoor RC components < 1 x 106
WBC/unit.
5. Allergic (urticarial): Characterized by local redness, itching and hives. It is
the result of either foreign allergen in the donor plasma, with which the
recipient antibodies react, or transfused donor antibodies, which combine with
recipient allergens. It may be reduced with antihistamines.
DELAYED:
After some days or weeks:
1. Alloimmune Hemolytic Extravascular (DHTR): an anamnestic response
leads to antibody production and clinical symptoms in about 3-7 days post-
transfusionally. The most common alloantibodies are in Rhesus (anti-D, anti-
Cw, anti-E, anti-c, anti-C). Symptoms may be mild (fever, chills and moderate
jaundice) to severe, depending on the hemolytic effect of antibody attachment
to the surface of the RCs. Moreover, there is a failure of expected therapeutic
response.
2. Viral Contamination: The risk varies between the different countries. It
depends on transfusion screening programme, as well as the carrier rates of
infection in the donor populations. The prevention of HIV and Hepatitis C are
of great importance.
3. Parasitic Contamination: Malaria, Leishmaniose.
Iron chelating therapy -
Iron overload may be treated or prevented with a chelating agent capable of
complexing with iron and promoting its excretion. The only iron-chelating
agent presently available for clinical use in the US is desferrioxamine
(Desferal).
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Desferrioxamine (Desferal) ?
Desferrioxamine is a chelating agent with a strong affinity for iron. Discovered
in 1960 as a result of work undertaken conjointly in the laboratories of Ciba
and of the Swiss Federal Institute of Technology in Zürich, it was introduced in
1963. The active substance of Desferal is desferrioxamine B, an iron-
chelating compound derived from ferrioxamine B, which is an iron-bearing
metabolite produced by Actinomycetes (Streptomyces pilosusEttlinger et al.)
and belongs to the group of the sideramines. Desferrioxamine B is present in
Desferal in the form of the methane sulphonate, a chain molecule of the
following structure:
Trivalent iron reacts with desferrioxamine B to form ferrioxamine B, an
octahedral iron complex:
Subcutaneous infusion at a daily dose 40 mg/kg over 8-12 hours has become
the standard schedule of delivery for over 20 years.
Biodistribution and metabolism -
DFO is hydrophilic, and this property together with its high molecular weight
means that uptake into cells and subcellular compartments is generally slow
relative to hydroxypyridinones (such as deferiprone), taking several hours for
equilibration (Hoyes et al., 1993, Cooper et al., 1996)). Uptake into
Desferrioxamine B Ferrioxamine B
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hepatocytes is rapid, however, probably by a facilitated process, making
access to intrahepatic iron relatively efficient (Porter et al., 1988). Due to the
positive charge of both DFO and FO, egress from cells by diffusion will be
slow (Singh et al., 1990). DFO is relatively stable for several hours in plasma,
and the majority of metabolism takes place within hepatocytes by oxidative
deamination of the N-terminus, yielding metabolite B as the predominant
product (Singh et al., 1990). The iron free form of metabolite B can diffuse
back into plasma rapidly, due to its negative charge (Singh et al., 1990),
where it is rapidly cleared from plasma (t1/2 = 1.3 hours) and eliminated in the
urine (Lee et al., 1993).
Clinical toxicity -
Toxicity from DFO in thalassemia major is unlikely provided that doses do not
exceed 40 mg/kg/day, that DFO is not introduced at too young an age (see
below), and that the dose is reduced as iron loading falls. Systemic reactions
with fever, muscle aches and arthralgia are uncommon and anaphylaxis may
occasionally occur.
Infections –
There is an increased risk of Yersinia infection in iron overload, and this risk
increases further with DFO treatment as Yersinia does not make a natural
siderophore and uses iron from FO to facilitate its growth (Robins-Browne and
Prig 1985). Patients who present with diarrhea, abdominal pain or fever
should stop DFO until appropriate stool samples, blood cultures and
serological testing can reasonably exclude Yersinia infection. The growth of
other organisms (e.g. Klebsiella) may also be facilitated by FO and it is wise to
withhold DFO in a febrile patient until the source of the fever has been
identified.
Deferiprone -
Pharmacology and pharmacokinetics ?
Deferiprone (1,2 dimethy-3-hydroxypyridin-4-one) is a member of a family of
hydroxypyridin-4-one (HPO) chelators (Hider et al., 1982) that require three
molecules fully to bind Fe+3, each molecule providing two co-ordination sites
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(bidentate chelation). The pM of deferiprone for Fe+3 (pM = 20) is less than
that of DFO, which reflects the lower stability of the iron-chelate complex.
Other metals such as Ga, Al3+ and In3+ are bound tightly with relative affinities
for other metals being Cu2+ > Zn 2+ > Ca 2+ > Mg 2+ (Hider et al., 1994). The
molecular weight of deferiprone is approximately one-third that of DFO and
this together with its neutral charge and relative lipophilicity account for its
rapid absorption from the gut. These same properties also allow more rapid
access by deferiprone and related HPOs to intracellular iron (Porter et al.,
1988), to labile intracellular iron (Zanninelli et al., 1997) as well as more rapid
access to intra-lysosomal iron pools and to iron containing enzymes
(Abeysinghe et al., 1996, Cooper et al., 1996).
Deferiprone appears in plasma within 5 to 10 minutes of ingestion, the peak
concentrations (Cmax) occurring within 1 hour, reaching levels in excess of
300 µM after oral ingestion of a 50 mg/kg dose (Kontoghiorghes et al., 1990,
Al-Refaie et al., 1995). However, these levels are short-lived with an
elimination t1/2 of 1.52 hours. Unlike DFO, where approximately half of iron
excretion is fecal, there is little fecal iron excretion with deferiprone
(Kontoghiorghes et al., 1988, Collins et al., 1994, Olivieri et al., 1990).
Metabolism -
Deferiprone is metabolized to the inactive glucuronide that is the predominant
form recovered in the urine (Lange et al., 1993).
Toxicities –
Neutropenia and agranulocytosis: Agranulocytosis is the most serious
unwanted effect of this drug so far identified. This was initially reported in 3-
4% of patients treated with deferiprone; mild neutropenia was found in an
additional 4% (Al-Refaie et al., 1992, Al-Refaie et al., 1995).
Arthropathy: Painful swelling of the joints, particularly the knees, occurs in 6-
39% of patients (Cohen et al., 2000, Agarwal et al., 1992). This complication
usually but not always resolves after stopping therapy. Arthritis was the most
common side effect in the Indian study in which many of the patients were
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heavily iron overloaded (Agarwal et al., 1992). Other unwanted effects include
nausea (8%), zinc deficiency (14%) and fluctuation in liver function tests
(44%) (Al-Refaie et al., 1995).
Liver fibrosis: In a retrospective analysis, fibrosis was reported to progress in
5 of 12 patients on deferiprone and in none of 12 age-matched control
subjects receiving regular DFO (Olivieri et al., 1998).
Role of ascorbic acid in chelation therapy -
Patients on chelation therapy have been demonstrated to have some degree
of vitamin C deficiency. This has been attributed in part to increased
catabolism. Administration of vitamin C increases the urinary excretion of iron
and raises both serum iron and ferritin levels. This probably is related to the
fact that vitamin C slows down the conversion of ferritin to hemosiderin,
leading to the availability of more chelatable iron. Conversely, vitamin C
enhances iron-mediated peroxidation of membrane lipids, leading to
significant toxicity, mostly cardiac dysfunction in patients who are receiving
large doses of vitamin C supplementation in addition to chelation therapy. For
this reason, only small doses should be administered to enhance chelation (3
mg/kg/d at the start of infusion of the chelator). Large doses should be
avoided.
Vitamin E deficiency –
Vitamin E deficiencies have been reported in patients with severe
thalassemia. Some of the hemolysis in this population even was attributed to
peroxidation of the membrane lipids by an iron-mediated free radical effect.
As an antioxidant, vitamin E is expected to decrease cell toxicity.
Folic acid deficiency –
This deficiency is a common complication in patients with thalassemia, mainly
due to the extreme demand associated with the severe expansion of the
marrow. Other causes, such as poor absorption and intake, also can
contribute to folate deficiency. For this reason, folic acid (1 mg/d) has been
recommended as a supplement for this patient population.
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Hematopoietic stem cell transplantation –
HSCT only is recommended for selected patients. It is the only known curative
treatment for thalassemia. Poor outcome after HSCT correlates with the
presence of hepatomegaly and portal fibrosis and with ineffective chelation
prior to transplant. Event-free survival for patients who have all 3 features is
59%, compared to 90% for those who lack all 3. Even though blood
transfusion is not required after a successful transplant, chelation therapy
continues to be needed in certain individuals to remove excessive iron. The
optimal time to start such treatment is a year after the successful HSCT.
Parents and/or caregivers of patients with severe thalassemia frequently are
confronted with the question of choosing between standard therapy and
HSCT. The 15-year cardiac disease-free survival for patients on standard
therapy exceeds 90% and is similar for those without risk factors having
undergone HSCT. Long-term outcome for transplant patients, including
fertility, is not known. The cost of long-term standard therapy is known to be
higher than the cost of transplant. The possibility of developing cancer after
HSCT also should be considered. In many centers, the donor has to be a
matched sibling with or without thalassemia trait.
Gene therapy –
This therapy is a very attractive therapeutic modality, the efficacy of which
remains to be demonstrated.
Surgical Care –
The principal surgical procedure used for many patients with thalassemia is
splenectomy. The spleen is known to contain a large amount of the labile
nontoxic iron (i.e. storage function) derived from sequestration of the released
iron. The spleen also increases RBC destruction and iron distribution (ie,
scavenger function). These facts always should be considered before the
decision is made to proceed with splenectomy. If the spleen acts as a store
for nontoxic iron, thereby protecting the rest of the body from this iron, early
removal of the spleen may be harmful (liver cirrhosis has been described in
such individuals). Conversely, when the spleen becomes hyperactive, leading
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to excessive destruction of RBCs and thus increasing the need for frequent
blood transfusions, resulting in more iron accumulation, splenectomy is
justified. Furthermore, if the labile iron pool in the spleen becomes the target
for the action of the deferoxamine (ie, removing the nonharmful pool and
leaving the toxic one), then splenectomy is justified even more. The goal in
this confusing dilemma always should be to achieve a negative iron balance,
which in many patients has been possible by continuous administration of
subcutaneous deferoxamine. Several criteria are used to aid in the decision
for splenectomy; a practical one suggests that splenectomy may be beneficial
in patients who require more than 200-250 ml/kg of PRBC per year to
maintain an Hb level at 10 g/dl. The risks associated with splenectomy are
minimal, and many of the procedures now are performed by laparoscopy.
Postsplenectomy risk of infections with encapsulated organisms and malaria
in endemic areas is always a concern. The problem is minimal at the present
time, since presplenectomy immunizations and postsurgical prophylactic
antibiotics have decreased the rates of such complications significantly.
Traditionally, the procedure is delayed whenever possible until the child is
aged 4-5 years or older. Aggressive treatment with antibiotics always should
be administered for any febrile illness while awaiting the results of cultures.
Prenatal DNA testing -
Successful prevention programs in different parts of the world have resulted in
an impressive decline in the number of patients with severe forms of
thalassemia. Ferrara, Cyprus, Sardinia, Greece, and the United Kingdom
were among the first to report a significant decline in the birth rate of children
with thalassemia major. Many other regions with more limited resources are
following their steps with remarkable success. In addition to the effective
prenatal diagnosis adopted in the countries mentioned, other measures such
as premarital screening programs, genetic counseling, and restrictions on
issuing marriage certificates and licenses also proved to be effective. Since
many of the countries where thalassemia prevails are poor and cannot afford
sophisticated preventive programs, more practical approaches clearly are
needed.
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Screening of school children, pregnant women, and individuals visiting public
health facilities is effective in identifying individuals at risk who require further
testing. A simple CBC, with emphasis on the red cell counts and indices,
including the MCV, MCH, and RDW, is the main component of such screening
processes. Those suspected to be positive are checked for elevated HbA2,
HbF, or both for confirmation. In some situations, this simple method is not
adequate, and further testing; including analyses of globin chain synthesis
must be performed to reach a final diagnosis.
Investigational agents known to increase HbF level -
In the past few years, several new approaches to the treatment of
thalassemia have included marrow or stem cell transplantation, the use of
young red blood cells ("neocytes" for transfusion), maintenance of a higher
pre-transfusion hemoglobin level, new iron chelators and the use of drugs
such as hydroxyurea, 5-AzaC and butyrate compounds to elevate fetal
hemoglobin (HbF).
Fetal hemoglobin or HbF (µ2g2), which has a substantially higher affinity for
oxygen than adult hemoglobin, develops in the fetus during the last six
months of gestation. As both mother and fetus share the same blood supply,
fetal hemoglobin essentially draws off oxygen from the mother’ s blood. This
enables the fetus to survive in the uterus. After birth, fetal hemoglobin levels
fall rapidly and in the adult represents less than one percent of total
hemoglobin in the body. Thus, total adult hemoglobin comprises of HbA1 -
µ2b2 (97%), HbA2 - µ2d2 (2.5%) and HbF - µ2g2 (0.5%). It has been found that
stimulation or induction of fetal hemoglobin in thalassemia can improve the
patient’ s clinical condition.
Increased transcription of fetal hemoglobin requires an open chromatin
configuration dictated by –
1. DNA hypomethylation ?
The g-globin gene promoter has been shown to be nonmethylated at a CpG
residue during fetal development; this dinucleotide sequence becomes
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methylated (mCpG) postnatally when g-globin gene expression is silenced
(Vander-Ploeg and Flavell 1980). Early studies demonstrated that treatment of
tissue culture cells with the cytidine analog 5-azacytidine (5-azaC) led to
cellular differentiation and DNA hypomethylation (Jones and Taylor 1980).
Incorporation of 5-azaC into baboon DNA resulted in a 40- to 70-fold increase
in g-globin gene expression in the adult (DeSimone et al., 1982), and to
hypomethylation of the g -globin promoter (Lavelle et al., 1986). These early
studies led to clinical trials of this analog in sickle cell anemia and ß-
thalassemia (Ley et al., 1983, Ley and Anagnou 1983, Dover et al., 1983,
Charache et al., 1983) that demonstrated significant increases in HbF levels
(10%–25%), F cells (30%–40%), and total hemoglobin (1–3 g/dL) in patients
receiving 5-azaC. When a 5-azaC analog incorporates into DNA as 5-aza-2-
deoxycytidine, it covalently binds DNA methyltransferase (DNMT), thereby
depleting DNMT concentration (Juttermann and Jaenisch 1994, Creusot et al.,
1982). This decrease in DNMT results in DNA hypomethylation as DNMT is
required for maintenance of the methylation pattern during replication.
Patients treated with 5-azaC analogs show global hypomethylation.
2. Increased histone acetylation -
Histone proteins are found attached to DNA allowing long chromosomal
strand to fold and stack on itself (i.e. formation of chromatin) when
transcription is not in progress. Transcription requires an open chromatin
configuration dictated by specific patterns of histone acetylation of amino
acids in amino terminal histone. For example, histone acetylation is required
for an active chromatin configuration, and acetylated histone does not
associate with DNA having mCpG dinucleotides (Eden et al., 1998). The level
of acetylation is, to a large extent, dependent on histone deacetylase (HDAC)
activity. Butyrate exerts its effect by increasing histone acetylation and
opening up the chromatin structure of the promoter of the g-globin gene.
Mechanism of induction of HbF by butyrate is that it Inhibits histone
deacetylases and thereby increasing histone acetylation, which opens up the
chromatin structure and makes DNA more accessible to transcription factors.
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This results in increased transcription of the g-globin gene by making its DNA
more accessible to transcription factors.
3. Histone methylation -
There is a third level of regulation related to DNA methylation, and that is
histone methylation. Histone methylation can have an activating or
suppressing effect depending upon which amino acids are methylated, and
the number of methyl groups added.
The current hypothesis is that histone modifications and DNA methylation may
influence each other. It has also been shown that there is a direct connection
between the enzymes that methylate DNA and methylate histones (Fuks et
al., 2003). Thus DNA methylation appears to be central in transcriptional
regulation. This cross talk suggests that inhibitors of DNMT and HDAC may
collaborate to activate transcription (Bird 2001).
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4. Materials and Methods
4.1 Pharmacognostic studies
Identification of wheat variety and growing of wheatgrass -
Certified samples of three major species of wheat viz. Triticum aestivum,
Triticum durum and Triticum dicoccum were acquired form Wheat Research
Center, Gujarat Krushi University, Junagadh, Gujarat. The authenticity of
these certified samples was also confirmed by comparing their morphological
characters with the description mentioned in different standard texts and
floras (Percival 1974). Voucher specimens were deposited at B. K. Mody
Government Pharmacy College, Rajkot, Gujarat. These wheat varieties were
grown in plastic trays as per the standard procedure described below
(Wigmore 1985).
Procedure for growing wheatgrass -
1. Adequate quantity of unpolished wheat grain were soaked overnight in
water in a container.
2. On the next day, the soaked wheat-grain were spread on the surface of
the soil filled in plastic trays. Care was taken so that the grains did not
touch one another.
3. A thin layer of soil was sprinkled on the wheat grains.
4. The tray was covered with a newspaper to provide darkness, which
helps the sprouting.
5. The tray was kept in a covered balcony.
6. Next day the tray was uncovered to spray on some water and was
covered again with the newspaper.
7. Step 6 was repeated everyday until sprouting took place, after which
the tray was left uncovered and watered everyday for 8 days.
8. On 9th day the wheatgrass was harvested by cutting it with a clean pair
of scissors about 1/2" above the surface of the soil.
To characterize and differentiate among the three varieties of wheatgrass, all
three varieties of the grass were subjected to microscopic study, which
included transverse sections, surface preparations and powder study. For
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powder study the grass was cleaned and dried in a dark place for four days. It
was powdered, passed through 40# and stored in airtight bottles.
4.2 Phytochemical Studies
Extraction Process -
For preparation of methanolic extract, 100 gram of fresh wheatgrass was
crushed thoroughly, using mortar and pestle. The crushed wheatgrass was
completely exhausted by adding small quantities of methanol and filtering off
every time in a successive manner, to yield final volume of 1 liter. The
methanolic extracts of different varieties of fresh wheatgrass, and also dried
wheatgrass powders, obtained from different types of drying processes, were
prepared by above-mentioned procedure. These extracts were subjected to
thin layer chromatography.
Thin-Layer Chromatography and HPTLC finger printing -
Samples of different methanolic extracts and methanolic solutions of
reference standards chlorophyll a, chlorophyll b and b carotene were used for
TLC and HPTLC. Suitably diluted sample solutions were spotted on pre-
coated silica gel 60 F254 TLC plates (E. Merck) using CAMAG Linomat IV
Automatic Sample Spotter. The plates were developed in the solvent system
consisting of Hexane: Acetone (65:35). The plates were dried at room
temperature and scanned using CAMAG TLC scanner 3 at UV 254 and 354
nm and Rf values, absorption spectra of resolved bands were recorded.
4.3 Estimation of antibacterial activity -
Preparation of Extract -
Fresh Wheatgrass was crushed and the juice was filtered through filter paper
(undiluted juice). Fresh Wheatgrass was also extracted in acetone and
methanol separately. The extracts were concentrated and dried by
evaporating the solvent. The anti-microbial activity of the undiluted juice and
extracts was studied by agar-well diffusion method (Pelczar et al., 1993) at
the concentration of 2.7 g/ml were tested against Bacillus subtilis,
Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli,
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Pseudomonas aeruginosa, Kleibsella pneumoneae, Bacillus megaterium,
Bacillus cereus and Salmonella typhimurium.
Activation of strain and preparation of plate -
A loop full of the test strain was inoculated in 25ml of nutrient broth and
incubated for 24 hours on a rotary shaker so as to activate the given test
bacterial strain. The Mueller Hinton Agar No. 2 (Hi-media) was prepared for
the study of in-vitro antibacterial activity by agar diffusion method
(Pharmacopoeia of India). Agar well diffusion method (Perez et al., 1990) was
performed.22 ml of the Mueller Hinton Agar No. 2 media was poured into the
100mm diameter Petri-plate (Hi-media). The test bacterial culture (0.2 ml) was
also added along with the media into the Petri plate.
Microbiological Assay -
Inoculation of the test strain was done by the pour-plate technique. The media
is autoclaved at 121 lbs pressure.0.2ml of the activated strain was inoculated
into the media with the help of an auto pipette when it reached 40-42 C
temperatures. Shaking the sugar tube in between the palms will make the
sugar tubes temperature reach somewhere between 40-42 C. Now the
activated test bacterial strain (0.2 ml) is inoculated into the media. Again the
tubes are rotated in between the palms for the proper homogenization of the
bacterial in the media. The complete procedure of the plate preparation was
done in the laminar airflow to maintain strict sterile and aseptic condition. After
the inoculation the plates were kept for solidification. The solidification of the
media took about 30 – 45 minutes. After the media got solidified, a ditch was
made in the plates with the help of a sterile cup-borer (8.5mm). After
introducing the cup-borer, with the help of a sterile forceps the agar beads
were removed, form a well in the agar plate and 0.1ml of the test compound
was introduced into the well. The inoculation of the crude drug was done with
the help of auto pipette (Glaxo). The plates were kept for incubation for 24-36
hours depending upon the test bacterial strain used. The inhibitory activity of
the compounds in various solvents was determined by comparing the sizes of
inhibition zones of the different compounds in different solvents with those of
the controls. The controls were those solvents in which the test compound is
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dissolved. The positive result was determined by deducting the control
(solvent) activity with that of the test (compound). The experiment was done in
triplicates.
Media (1) Used:
N – Broth was used for activation of the test bacterial strains.
Media Composition:
Peptic digest of animal tissue - 0.5 %
NaCl - 0.5 %
Beef extract - 0.15 %
Yeast extract - 0.15 %
Distilled water - 100 ml
Media (2) used:
Mueller Hinton Agar No. 2 was used for the antimicrobial susceptibility test.
Media Composition:
Casein acid hydrolysate - 1.75 %
Beef heart infusion - 0.2 %
Starch, soluble - 0.15 %
Agar - 1.7 %
Distilled water - 100 ml
4.4 Estimation of antiproliferative activity–
Seeds of green grams, groundnuts and wheat were soaked in sufficient
quantity of distilled water (control) in 5 petridishes each, overnight. Similarly,
all three varieties of seeds were soaked in Wheatgrass juice prepared
traditionally in water. Next day, the seeds were sown in small bowls filled with
plain soil. The left over quantity of distilled water or Wheatgrass juice, used for
soaking the seeds, was added to the soil of each bowl in corresponding
manner. Seeds were allowed to germinate for 5 days with addition of sufficient
quantity of distilled water to all the bowls, daily. On 6th day, the number of
seeds germinated in each bowl was counted. Sprout length less than 2 mm
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were not considered in counting. The experiment was repeated 5 times and
average was reported.
4.5 Preparation of dried Wheatgrass powder -
For preparation of dried Wheatgrass powder (to be used for manufacturing of
Wheatgrass tablets) different drying techniques were used such as freeze-
drying, spray drying and shade drying. In freeze drying technique, fresh
wheatgrass was frozen to sub-zero temperature and subsequently subjected
to low-temperature heating (5 oC -10 oC) in vacuum to evaporate crystallized
water content. Dried wheatgrass was then milled to obtain powder. In spray-
drying technique, fresh wheatgrass was pressed in a hydraulic press to obtain
juice. The juice was then sprayed in aerosol form through a nebulizing nozzle
in a conical vessel from top. A hot air counter current (55 oC) was passed from
bottom of the vessel. The nebulized juice settled on the bottom of the vessel
in the form of powder. In shade-drying technique, fresh wheatgrass was dried
at room temperature in a dark room. The dried wheatgrass after 3-4 days of
drying period was powdered in a mill.
4.6 Preparation of wheatgrass tablets -
Wheat grains of Triticum durum variety were acquired and sown in plain soil
without using any type of fertilizer. The wheatgrass was grown under specially
constructed shades. The grass was harvested after 8 days from sprouting and
shade-dried in well-ventilated dark rooms for 4 days. Dried wheatgrass was
powdered in a mill. Tablets of wheatgrass were manufactured in a
pharmaceutical tablet unit by adding suitable binders and excipients.
4.7 Clinical trial of wheatgrass on patients with anemia -
The clinical trial of wheatgrass on anemia was carried out at Ayurved Hospital
working under Civil Hospital, Rajkot. Necessary permission for conducting the
clinical trial was obtained from the concerned ethical committee. 20 anemic
patients, visiting the hospital were enrolled for the trial, after taking informed
consent.
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Twenty patients suffering from anemia whose age ranged from 15 to 50 years
were included in the trial. The patients were given wheatgrass tablets with
dosage regimen of 2 tablets (wheatgrass powder 250 mg.) 3 times in a day for
1 month. Blood samples were collected at the start and at the end of period of
clinical trial (i.e. 1-month period). The samples were analyzed for hemoglobin
content by using standard method (Sahli’ s Hemoglobinometer) while, Total
RBC count, Total WBC count, Neutrophil count, Lymphocyte count and Total
lymphocyte count were recorded by using automatic cell counter – Model KX-
21 – Sysmex.
4.8 Clinical trial of wheatgrass on patients with b-thalassemia
(major) -
The clinical trial of wheatgrass on b-thalassemia was carried out at K. T.
Children Hospital working under Civil Hospital, Rajkot. Necessary permission
for conducting the clinical trial was obtained from the concerned ethical
committee. Thalassemic patients, visiting K. T. Children Hospital regularly for
blood transfusion and registered at the hospital were enrolled for the trial,
after taking informed consent.
Twenty patients suffering from b-thalassemia (major) whose age ranged from
8 to 20 years were included in the trial. The patients of this group were given
wheatgrass tablets with dosage regimen of 2 tablets (wheatgrass powder 250
mg.) 3 times in a day for 9 months. Blood samples were collected at the start,
after 6 months and at the end of period of clinical trial (i.e. 9 months period).
The samples were analyzed for hemoglobin content by using standard
method (Sahli’ s Hemoglobinometer) while, Total RBC count, PCV, MCV,
MCH, MCHC, Total WBC count, Neutrophil count, Lymphocyte count,
Eosinophil count, Basophil count and Total lymphocyte count were recorded
by using automatic cell counter – Model KX-21 – Sysmex.
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We also estimated Serum iron, Serum magnesium, Serum ferritin and
Thiobarbituric acid reacting substances (TBARS).
4.9 Estimation of serum magnesium -
Serum magnesium was estimated by Calmagite Dye method.
Principle -
Magnesium ions react with Caimagite to produce a red complex, which is
measured spectrophotometrically at 530 nm. Intensity of the color produced is
directly proportional to magnesium concentration in the serum. To eliminate
the interference of calcium during estimation, EGTA is included in the reagent.
Heavy metal interference is prevented by the presence of cyanide and a
surfactant system is included to remove protein interference.
Kit contents -
Reagent 1: Magnesium color reagent - Calmagite: 0.006° o w/v, Stabilizer:
1% w/v
Reagent 2: Ethylaminoethanol: 6%, EGTA: 1.18 mM, Potassium cyanide:
0.10%
Reagent 3: Magnesium Standard - Magnesium salt: 2 meq/l
Preparation of working reagent -
Ten volumes of Color reagent (Reagent 1) were mixed with one volume of
Buffer reagent (Reagent 2). The mixture (working reagent) was prepared
as per requirement for the day.
Procedure -
Pipette into Test Tubes Blank Standard Test
Magnesium working
reagent
1.0 ml 1.0 ml 1.0 ml
Standard - 10 ml -
Sample - - 10 ml
Distilled water 10 ml - -
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All solutions were mixed and incubated at room temperature (22-28°C) for 10
min. The absorbance of the Test (AT), Standard (AS) and Blank (AB) were read
against distilled water at 530 nm (520 - 530 nm).
Calculations -
Magnesium conc. (meq/l) = (AT- AB) x 2 (As – AB)
4.10 Estimation of serum iron–
Principle –
Transferrin-bound iron is released at an acid pH and reduced from ferric ion to
ferrous ion. These ions react with frrozine to form a violate-colored complex,
which is measured spectrophotometerically at 560 nm. The absorbance
measured at this wavelength is proportional to serum iron concentration.
Reagents –
Iron buffer reagent – Hydroxylamine hydrochloride 220 mM in acetate buffer,
pH 4.5 with surfactant.
UIBC buffer reagent – Tris 500 mM, pH 8.1 with surfactant, Sodium azide
0.05% (w/v) as preservative.
Iron color reagent – Ferrozine 16.7 mM in hydroxylamine hydrochloride
Iron standard (500 ug/dl) – Ferrous chloride in hydroxylamine hydrochloride.
Procedure –
Couvettes were labeled as blank, standard and sample. Table of setup
instructions listed bellow, was followed.
Total iron -
Reagents Test Sample blank
Iron buffer 1ml 1 ml
Sample 200 ul Ul
Color reagent 20 ul -
Color was added and incubated for 10 minutes at 37 c.
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Spectrophotometer was zeroed at 560 nm with reagent blank.
Absorbencies of all tubes were read and recorded.
Calculation –
A = Absorbance
STD = Standard
Total Iron (ug/dl) = (ATest – Ablank) X conc./ AStd – Ablank
4.11 Estimation of Serum Ferritin–
Serum Ferritin was estimated using Access Immunoassay System a product
of Beckman Coulter.
Principle –
Access Ferritin assay is a two-site immunoenzymatic (‘ sandwich’ ) assay. A
sample is added to a reaction vessel with goat anti-ferritin-alkaline
phosphatase conjugate and paramagnetic particles coated with goat anti-
mouse: mouse anti-ferritin complexes. Serum or plasma (heparin) ferritin
binds to the immobilized monoclonal anti-ferritin on the solid phase, while the
goat anti-ferritin enzyme conjugate reacts with different antigenic sites on the
ferritin molecules. After incubation in a reaction vessel, separation in a
magnetic field and washing remove materials not bound to the solid phase. A
chemiluminescent substrate, Lumi-phos* 530, is added to the reaction vessel
and light generated by the reaction is measured with a luminometer. The light
production is directly proportional to the concentration of ferritin in the sample.
The amount of analyte in the sample is determined from a store multi-point
calibration curve.
Procedure –
Ferritin assay was performed using automatic analyzer as per the Access
Immunoassay System manual.
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4.12 Estimation of free radicals (Thiobarbituric acid reacting
substances)–
Lipid peroxidation product (MDA) was estimated by thiobarbituric acid reaction
method (Ohkawa et al., 1979).
Procedure -
1.0 ml sample was mixed with 0.2 ml 4% (w/v) sodium dodecyl sulphate
(SLS). 1.5 ml 20% acetic acid in 0.27M HCl (pH 3.5) and 1.5 ml of 0.8%
thiobarbituric acid (pH 7.4). Mixture was heated in hot water bath at 85oC for 1
hr and after centrifugation at 1200 g for 10 minutes; intensity of pink color was
read against reagent blank at 532 nm. The amount of MDA (TBA reactive
material) was calculated using molar extinction coefficient 1.56 x 105 M-1.Cm-1
and has been reported as n moles of MDA per mg protein.
4.13 Statistical analysis–
Results are presented as mean ± SEM. Statistical differences between the
means of the various groups were evaluated using student’ s paired ‘ ?  test.
Data were considered as statistically significant at ‘ P’ value of 5% (P   0.05).
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5. RESULTS
5.1 Pharmacognostic Studies
Macroscopical features -
In our investigation, certified samples of three major species of wheat viz.
Triticum aestivum, Triticum durum and Triticum dicoccum were used to grow
wheatgrass in plastic trays as per the standard procedure. In conformation
with the description in literature; the leaves were near glabrous, auriculate,
with blades narrow to broadly linear, 2–20 mm wide, flat and without cross
venation (Percival 1974). The leaf blade was linear and parallel–veined with
mid rib projecting on the back, continuing someway along the sheath. In T.
Dicoccum the hairs on the swollen base of leaf were longer than those of
other species. The longest leaves were possessed by T. durum.
Microscopical studies -
Microscopic studies of transverse sections, surface preparations and powder
studies of three varieties of wheatgrass viz Triticum aestivum, Triticum durum
and Triticum dicoccum were conducted using high-resolution microscope.
The structure of wheatgrass leaf showed elaborate epidermis with
characteristic stomata and trichomes, green assimilating parenchyma,
conducting vascular bundles and longitudinal strands of fibrous stereome or
supporting tissue.
The epidermis of the blade of the leaf was found to be composed of a number
of diverse elements arranged in parallel rows along the long axis. Some of the
individual rows consisted entirely of elongated cells placed end to end, each
cell, with convex cutinised outer wall 4-5 m thick, appearing in longitudinal
section as a narrow rectangle 150-300 m long and 15-20 m wide. In other rows
characteristic lines of long cells alternating with stomata were also present,
and, except T. durum, trichomes or hairs of various lengths were found
scattered along the rows at more or less at regular intervals. The trichomes or
hairs were always unicellular. To the right and left of the central line were
rows of long cells interspersed with hairs. Parallel to these, at the base of the
Surface preparations of different species of Triticum -
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ridge, there were single or double lines of stomata. In the furrow between two
ridges was a band of three to seven rows of elongated cells, whose walls
were thinner and not so distinctly parallel to each other are bulliform cells or
motor cells (Figure 5.1 – 5.3).
Figure 5.1 Surface preparation of Triticum durum
1
2
3
4
Figure 5.2 Surface preparation of Triticum dicoccum
2
3
4
5
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On the upper surface of the leaf there was a series of longitudinal ridges or
ribs, the lower surface being almost flat. The epidermal cells covering the
ridges differed in form and arrangement from those over the furrows and
along the edge of the leaf. Running along the summit of each ridge there was
a single row of elongated thick-walled and pitted cells alternating with hairs.
On the flank of the ridge, right and left of the central line, there were three to
five rows of long cells interspersed with short one and hairs. Parallel to these,
at the base of the ridge, were single or double lines of stomata. In the furrow
between two ridges there was a band of three to seven rows of elongated
cells, whose walls were thinner. They were not distinctly parallel to each other
are bulliform cells or motor cells. The trichomes or hairs were always
unicellular, and varied in length and stoutness. Some of them were blunt on
1. Unicellular trichome
2. Stereome fiber
3. Double raw of stomata
4. Rows of motor cells
5. Calcium oxalate crystal
Figure 5.3 Surface preparation of Triticum aestivum
2
3
4
1
Transverse section of Triticum leaf (General description) - -
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the edges of older leaves where as others were short and stout, 20-30 m long,
with fine curved points rendering the surface scabrid. On the leaves of T.
aestivum, ample numbers of hairs were present, while in T. dicoccum and T.
durum they were sparsely distributed on the surface of the leaf. These were
usually more on the upper epidermis than the lower epidermis. Each stoma
on the leaf consisted of four cells, the two guard cells being narrow, with
specially thickened walls round the stomatal pore and thin-walled widely
dilated ends: the pore when closed appears as a narrow slit 30-40 m long. The
ratio of the number of stomata on the upper and lower epidermis respectively
was about 10:7. In the transverse section the pores of the stomata were seen
to be in communication with large intracellular cavities in the mesophyll,
called lacune.  The parenchyma of the leaf consists chiefly of thin-walled
assimilating tissue, containing lenticular chloroplasts 4.5-6m in diameter. The
cells of the chlorophyll-containing tissue in the central part of the leaf were
much more irregular in shape and are loosely packed, with large intracellular
spaces between them. Chloroplasts were present especially present in the
subepidermal layers. In each cell on the outside of stereome, and between
the vascular bundles, there was a single crystal or cluster of crystals of
calcium oxalate. Vascular bundles were somewhat nearer to the lower
surface than the upper surface of the leaf. All vascular bundles were
collateral, with the xylem towards the upper surface of the leaf and the
phloem bellow. In the xylem there were one or two vessels 20 m in diameter
with annular or spiral thickening with narrow elliptical pits. Each bundle was
surrounded by an inner and outer sheath; the former (the ‘ mestome’ )
enclosed the vascular strand, and was composed of elongated thick-walled
cells; the outer or ‘ parenchyma sheath’ was more conspicuous and consisted
of thin-walled cells, almost circular in transverse section. Above and bellow
the bundles, and arranged parallel with them along the leaf were strands of
stereome or supporting tissue consisting of sclerenchymatous fibers.
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Differentiating characters among transverse sections of leaf of various
Triticum species -
Transverse section of T. durum leaf -
Trichomes were almost absent or very rare but stomata were more in number
than other verities. Lower epidermal cells had more motor cells in comparison
to upper one. Lower portion of median vein was more bulging than other
species. Xylem vessels were more in number than in other species. Outer
sheath of vascular bundles were incomplete (Figure 5.4 and 5.7).
Transverse section of T. dicoccum leaf -
Motor cells were not seen clearly. Outer sheath of vascular bundle was
incomplete and parenchymatous cells of the sheath were smaller than other
species. Xylem vessels were 2-3 in number. Each ridge had almost one row
of simple pointed trichomes (Figure 5.5 and 5.8).
Transverse section of T. aestivum leaf -
It had more number of trichomes than other species, mostly in lower
epidermis. Motor cells were clearly seen, almost equal in size on both the
sides. The parenchymatous cells of outer bundle sheath were larger and also
more in number than other verities. The cells of epidermis were nearly circular
in shape. The medial vein was broader than other species. Xylem vessels
were 4-5 in number. Outer sheath of vascular bundle was complete (Figure
5.6 and 5.9).
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1. Ridge
2. Vascular Bundle
3. Outer epidermis
4. Inner epidermis
5. Trichome
Transverse sections (Diagrammatic) of different species of Triticum -
Figure 5.6 Transverse section (Diagrammatic) of Triticum aestivum
3 41 2 5
Figure 5.5 Transverse section (Diagrammatic) of Triticum dicoccum
3 41 2 5
Figure 5.4 Transverse section (Diagrammatic) of Triticum durum
3 41 2
96
Transverse sections (Cellular) of different species of Triticum -
Figure 5.7 Transverse section (Cellular) of Triticum durum
1 53 7 92 64 8 10
1211
Figure 5.8 Transverse section (Cellular) of Triticum dicoccum
1 5
3
7
2
64 8 10
12
11
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Powder characters of Triticum aestivum –
Epidermal cells in surface view were elongated and rectangular having few
numbers of stomata. Trichomes were simple, uniseriate, unicellular and long
with pointed end and swollen bases. Smaller ones were hook-shaped with
broad base while longer trichomes were more in number than smaller ones.
Fibers were scattered here and there, found as single or in groups. They were
thin-walled and lignified. Vessels were single or together in groups of  2-3,
pitted, reticulated and annular type. Pitted vessels were more in number
(Figure 5.10).
Triticum durum differed in trichomes only, which were simple, unicellular and
uniseriate but were smaller in size than T. aestivum. Fibers were more in
number and reticulated vessels were almost absent (Figure 5.11).
1. Epidermis   2. Motor cells   3. Stomata   4. Lacuna   5. Xylem
6. Phloem   7. Inner sheath of vascular bundle   8. Outer sheath of
vascular bundle 9. Mesophyll   10. Parenchyma   11. Guard cell
12. Stereome
12. Stereome
e
Figure 5.9 Transverse section (Cellular) of Triticum aestivum
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Characteristics of various species of Triticum powder -
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5.2 Phytochemical Studies
5.2.1 Phytochemical analysis -
The shade-dried powder of wheatgrass, used in our study, was analyzed at
Sathyam Analytical Laboratory, Bombay. In the phytochemical analyses
wheatgrass was found to be rich in chlorophyll, various minerals like iron,
magnesium, calcium, phosphorus, antioxidants like beta-carotene and
insoluble dietary fibers while, the fat content was very low (Table - 5.1).
Table – 5.1
Phytochemical Analysis of Wheatgrass Powder
Sr. No. Constituent Quantity
1. Moisture 4.4 %
2. Ash 4.15 %
3. Protein 25.2 %
4. Fat 1.75 %
5. Crude fiber 0.29 %
6. Carbohydrates 52.4 %
7. Calories 390 kcal/100 gm
8. Calcium 32 mg/100 gm
9. Phosphorus 850 mg/100 gm
10. Chlorophyll 5.12 %
11. Iron 43.5 mg/100 gm
12. Magnesium 1455 mg/100 gm
13. Zinc 97.8 mg/100 gm
14. Beta Carotene 10.9075 I. U./100 gm
15. Soluble dietary fibers 0.3545 %
16. Insoluble dietary fiber 64.54 %
17. Total dietary fiber 65.56 %
5.2.2 Thin layer chromatography -
TLC of methanolic extracts of Standard b Carotene, fresh wheatgrass, shade-
dried wheatgrass powder, freeze-dried wheatgrass powder, spray-dried
wheatgrass powder showed, in all, 13 spots at different Rf values (Fig 5.10)
viz. (1) 0.07(Light green), (2) 0.21(Yellow), (3) 0.27(Grey), (4) 0.35(Yellow),
(5) 0.40(Yellow), (6) 0.47(Light green), (7) 0.54(Yellow), (8) 0.57(Green), (9)
0.61(Blue green), (10) 0.64(Light grey), (11) 0.69(Light grey), (12) 0.74(Grey),
(13) 0.92(Orange). By comparing standard Rf values and colors reported in
literature, out of 13 spots representing 13 different components of
wheatgrass, seven components at spot number 4, 7, 8, 9, 11, 12 and 13 were
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identified as xanthophyll c, xanthophyll a, chlorophyll b, chlorophyll a,
pheophytin b, pheophytin a and beta carotene respectively (Table - 5.2)
(Figure 5.13).
         Table – 5.2
Spot
No.
Color of
the spot
Rf value
(calculated)
Rf value
(Reported)
Component
(Identified)
1. Light green 0.07 --- Unknown
2. Yellow 0.21 --- Unknown
3. Grey 0.27 --- Unknown
4. Yellow 0.35 0.32 Xanthophyll c
5. Yellow 0.40 --- Unknown
6. Light green 0.47 --- Unknown
7. Yellow 0.54 0.53 Xanthophyll a
8. Green 0.57 0.58 Chlorophyll b
9. Blue green 0.61 0.62 Chlorophyll a
10. Light grey 0.64 --- Unknown
11. Light grey 0.69 0.69 Pheophytin b
12. Grey 0.74 0.75 Pheophytin a
13. Orange 0.92 0.91 b carotene
Figure 5.13 TLC of Methanolic extracts of B, W, Sh, Fr and Sp
B = Standard b Carotene         W = Fresh wheatgrass Juice
Sh = Shade-dried wheatgrass powder
Fr = Freeze-dried wheatgrass powder
Sp = Spray-dried wheatgrass powder
B W ShW Fr FrSh SpSp
1
2
3
4
5
6
7
8
9
11
12
13
10
Spot
No.
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Chlorophyll a was found to be present in the maximum quantity in fresh
Wheatgrass. The degraded product pheophytin was the least in fresh
wheatgrass extract. The content of chlorophyll was least in spray-dried
powder. The shade dried powder showed maximum quantity of pheophytin.
Except chlorophyll a, 12 components were found present in shade-dried
powder. Spot no. 4, 5, 6, 9 and 10 were absent in freeze-dried and spray-
dried powders. b-Carotene was present in all formulations. Thus, shade
drying, the natural method of drying, was found to preserve all components of
wheatgrass and hence, the most suitable one.
5.2.3 HPTLC finger printing of wheatgrass formulations (qualitative) -
Based on the resolution, as observed in UV light at 254 nm and at 354 nm,
the solvent system containing hexane: acetone (60: 40) was found to be the
most suitable one. Chromatograms of methanolic extracts of standard b
Carotene, fresh wheatgrass, shade-dried wheatgrass powder, freeze-dried
wheatgrass powder, spray dried wheatgrass powder were subjected to
HPTLC study. The chromatograms were scanned in combined as well as in
individual modes at 254 nm and 354 nm wavelengths (Fig 5.14 to 5.25).
Among individual chromatograms of wheatgrass formulations (Fig 5.16-5.19),
the chromatogram of fresh wheatgrass extract (Fig 5.16) exhibited poor
resolution in hexane: acetone solvent system. This may have happened due
to the fact that there was presence of water content in the fresh grass,
whereas the extracts of other formulations were prepared from dried powders.
Spot number 1 and 2 showed maximum prominence in chromatogram of
spray-dried powder. Low RF values of these two constituents in the non polar
solvent system indicate their polar and therefore water soluble and
thermostable character. It is possible that high temperature (55 oC) used in
preparation of spray-dried powder resulted in degradation of non polar and
thermolabile constituents of Wheatgrass, resulting into dominance of
thermostable and watersoluble constituents. In consonance with TLC study, in
qualitative HPTLC also, the chromatogram of shade dried powder (Fig 5.17)
showed maximum number of peaks indicating that shade drying method, the
natural method of drying, preserved all components of Wheatgrass.
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Figure 5.15 HPTLC (Qualitative) - Chromatogram of b carotene at
354 nm wavelength
Figure 5.16 HPTLC (Qualitative) - Chromatogram of Fresh
wheatgrass at 354 nm wavelength
Figure 5.14 HPTLC (Qualitative) - Combined (overlapping)
chromatograms of B, W, Sh, Fr and Sp at 354 nm wavelength.
Std. B. carotene
 Fresh wheatgrass
 Shade dried powder
 Freeze dried powder
 Spray dried powder
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Figure 5.17 HPTLC (Qualitative) - Chromatogram of shade-dried
powder at 354 nm wavelength
Figure 5.18 HPTLC (Qualitative) - Chromatogram of freeze-dried
powder at 354 nm wavelength
Figure 5.19 HPTLC (Qualitative) - Chromatogram of spray-dried
powder at 354 nm wavelength
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Figure 5.21 HPTLC (Qualitative) - Chromatogram of b carotene at 254
nm wavelength
Figure 5.22 HPTLC (Qualitative) - Chromatogram of Fresh wheatgrass
at 254 nm wavelength
Figure 5.20 HPTLC (Qualitative) - Combined chromatograms of B, W,
Sh, Fr and Sp at 254 nm wavelength
Std. B. carotene
 Fresh wheatgrass
 Shade dried powder
 Freeze dried powder
 Spray dried powder
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Figure 5.23 HPTLC (Qualitative) - Chromatogram of shade-dried
powder at 254 nm wavelength
Figure 5.24 HPTLC (Qualitative) -Chromatogram of freeze-dried
powder at 254 nm wavelength
Figure 5.25 HPTLC (Qualitative) - Chromatogram of spray-dried
powder at 254 nm wavelength
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Since the chromatogram of shade dried powder exhibited best resolution and
maximum number of prominent peaks, individual spots (components) were
scanned at 254 nm wavelength to obtain their spectra. Some of these spectra
were used for identification of the components of wheatgrass (Fig 5.26-5.38).
Figure 5.26 HPTLC (Qualitative) - UV spectra of spot 1 at 254 nm
wavelength
Figure 5.27 HPTLC (Qualitative) - UV spectra of spot 2 at 254 nm
wavelength
Figure 5.28 HPTLC (Qualitative) - UV spectra of spot 3 at 254 nm
wavelength
Individual spectra of components of Wheatgrass -
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Figure 5.29 HPTLC (Qualitative) - UV spectra of spot 4 at 254 nm
wavelength
Figure 5.30 HPTLC (Qualitative) - UV spectra of spot 5 at 254 nm
wavelength
Figure 5.31 HPTLC (Qualitative) - UV spectra of spot 6 at 254 nm
wavelength
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Figure 5.32 HPTLC (Qualitative) - UV spectra of spot 7 at 254 nm
wavelength
Figure 5.33 HPTLC (Qualitative) - UV spectra of spot 8 at 254 nm
wavelength
Figure 5.34 HPTLC (Qualitative) - UV spectra of spot 9 at 254 nm
wavelength
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Figure 5.35 HPTLC (Qualitative) - UV spectra of spot 10 at 254 nm
wavelength
Figure 5.36 HPTLC (Qualitative) - UV spectra of spot 11 at 254
nm wavelength
Figure 5.37 HPTLC (Qualitative) - UV spectra of spot 12 at 254 nm
wavelength
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The quantitative HPTLC was carried out on wheatgrass formulations for
presence of various constituents. For this purpose methanolic extracts were
prepared at maximum concentration. Considering the weight of fresh
wheatgrass as 100% the yields of shade dried, freeze dried and spray dried
powders were found to be 10%, 6% and 10% respectively at the end of drying
process. For quantitative estimation, methanolic extracts of equivalent
amounts of these formulations were subjected to quantitative HPTLC along
with those of different species of wheatgrass. Chromatograms (tracks) of the
formulations or species were recorded (Table - 5.3).
Table – 5.3
Figure 5.38 HPTLC (Qualitative) - UV spectra of spot 13 at 254 nm
wavelength
5.2.4 HPTLC fingerprinting of wheatgrass species and formulations
         (Quantitative) -
Track no. Extract
1 Standard b carotene
2 T. durum fresh grass (compost fertilizer)
3 T. durum traditional juice
4 T. durum shade-dried powder
5 T. durum freeze dried powder
6 T. durum spray dried powder
7 Gel
8 T. aestivum fresh grass (compost fertilizer)
9 T. dicoccum fresh grass (compost fertilizer)
10 T. durum (plain soil)
11 T. durum (Organic fertilizer )
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Figure 5.39 HPTLC (Quantitative) - Combined chromatograms of
various extracts at 254 nm wavelength (Table 5.2)
1
2
3
4
5
6
7
89
11
10
Track
No.
Figure 5.40 HPTLC (Quantitative) - Chromatogram of track 1 at
254 nm wavelength
Figure 5.41 HPTLC (Quantitative) - Chromatogram of track 2 at
254 nm wavelength
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Figure 5.42 HPTLC (Quantitative) - Chromatogram of track 3 at
254 nm wavelength
Figure 5.43 HPTLC (Quantitative) - Chromatogram (Quantitative)
Of track 4 at 254 nm wavelength
Figure 5.44 HPTLC (Quantitative) - Chromatogram of track 5 at
254 nm wavelength
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Figure 5.45 HPTLC (Quantitative) - Chromatogram of track 6 at
254 nm wavelength
Figure 5.46 HPTLC (Quantitative) - Chromatogram of track 7 at
254 nm wavelength
Figure 5.47 HPTLC (Quantitative) - Chromatogram of track 8 at
254 nm wavelength
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Figure 5.48 HPTLC (Quantitative) - Chromatogram of track 9 at
254 nm wavelength
Figure 5.49 HPTLC (Quantitative) - Chromatogram of track 10 at
254 nm wavelength
Figure 5.50 HPTLC (Quantitative) - Chromatogram of track 11 at
254 nm wavelength
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Area under curve of different components were measured in chromatogram
(track) of each formulation or species (Fig. 5.39 – 5.50) and analyzed for
comparison with that of fresh wheatgrass (Table – 5.4 - 5.7). Since all the
constituents of wheatgrass could not be identified, the AUCs of only
chlorophyll, pheophytin and beta-carotene were used for the purpose of
comparison.
Wheatgrass grown from three major varieties of wheat, when subjected to
quantitative HPTLC analysis revealed that Triticum aestivum had lowest
contents (76.8%) as compared to the contents of Triticum durum (86.92%)
and Triticum dicoccum (100 %) varieties (Table – 5.4) (Figure 5.51). Thus, the
data indicate that wheatgrass grown from tetraploid species of wheat,
especially Triticum dicoccum and T. durum, are more suitable for medicinal
use as compared to the hexaploid species i.e. T. aestivum or common wheat.
Table – 5.4
Effect of wheat variety on contents of wheatgrass (HPTLC)
Wheat variety AUC(Chlorophyll)
AUC
(Pheophytin)
AUC
(B-carotene) Total AUC
% AUC to
T. dicoccum
T. dicoccum
(fresh grass) 27994.2 5648.5 1805.7 35448.4 100.00
   T. durum
(fresh grass) 21531.8 6938.3 2340.6 30810.7 86.92
T. aestivum
(fresh grass) 22464.4 2772.7 1987.9 27225 76.80
Fig. 5.50 Effect of Wheat Variety On Contents of
Wheatgrass
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When subjected to quantitative HPTLC analysis, contents of wheatgrass
(Triticum durum) grown in organic fertilizer (91.36%) and that of wheatgrass
grown in compost fertilizer (92.05%) were nearly similar while the contents of
wheatgrass grown in plain soil (100%) were highest among the three (Table –
5.5) (Figure 5.52). Thus, presence of a fertilizer seems to hamper or interfere
with the sensitive phytochemical processes being carried out in the young
growing grass in early stages of growth.
Table – 5.5
Effect of fertilizer on contents of wheatgrass (HPTLC)
Fertilizer AUC(Chlorophyll)
AUC
(Pheophytin)
AUC
(B.carotene)
Total
AUC
% AUC to
plain soil
Wheatgrass grown in
plain soil 28263.2 3341.6 1866.4 33471.2 100.00
Wheatgrass grown
with compost fertilizer 21531.8 6938.3 2340.6 30810.7 92.05
Wheatgrass grown
with organic fertilizer 26879.1 1946.5 1755 30580.6 91.36
Fig. 5.51 Effect of Fertilizer On Contents Of Wheatgrass
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When wheatgrass juice prepared by traditional method was subjected to
quantitative HPTLC analysis, it was found to have 96.7% contents
considering the contents of methanolic extract of fresh wheatgrass as 100%
(Table – 5.6) (Figure 5.53). Thus, the traditional method seems to be the best
method for wheatgrass therapy compared to any formulations of wheatgrass
(Table - 5.6) that were made in our study.
Table – 5.6
Evaluation of traditional method of wheatgrass therapy (HPTLC)
Method AUC(Chlorophyll)
AUC
(Pheophytin)
AUC
(B.carotene)
Total
AUC
% AUC to
meth. ext.
Meth. Extract of fresh
wheatgrass 21531.8 6938.3 2340.6 30810.7 100.00
Fresh wheatgrass
juice prepared by
traditional method
20530.4 7059.6 2203.9 29793.9 96.70
When subjected to quantitative HPTLC analysis spray-dried powder of
wheatgrass was found to have lowest contents (21.66%) as compared to the
contents of freeze-dried powder (46.68%) and shade-dried powder (87.75%)
considering the contents of methanolic extract of fresh wheatgrass as 100%
(Table – 5.7) (Figure 5.54). Thus, the potency of wheatgrass appears to be
maintained at a substantially higher level in shade drying technique compared
to other two techniques.
Fig. 5.49 Evaluation of traditional method of wheatgrass
therapy (HPTLC)
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Table – 5.7
Evaluation of wheatgrass formulations (HPTLC)
Formulation AUC(Chlorophyll)
AUC
(Pheophytin)
AUC
(B.carotene)
Total
AUC
% AUC to
meth. ext.
Meth.extract of fresh
wheatgrass 21531.8 6938.3 2340.6 30810.7 100.00
Shade-dried powder 18282.4 6136.6 2617.4 27036.4 87.75
Freeze-dried
powder 8376.4 2673.2 3332.8 14382.4 46.68
Spray-dried powder 2421.7 1085.7 3166 6673.4 21.66
Meth. extract = Methanolic extract of fresh wheatgrass
Shade-dried = Shade-dried tablets
Freeze-dried = Freeze-dried tablets
Spray-dried = Spray-dried tablets
AUC = Area under curve
Chloro. = Chlorophyll
Pheo. = Pheophytin
B-caro. = Beta-carotene
Total = Total of AUC of Chlorophyll, Pheophytin, Beta-carotene
Traditional juice = Fresh Wheatgrass juice prepared by traditional method
Plain soil = Wheatgrass grown in plain soil
Compost fertilizer = Wheatgrass grown with compost fertilizer
Organic fertilizer = Wheatgrass grown with organic fertilizer
Fig. 5.52 Evaluation of Wheatgrass Formulations (HPTLC)
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Figure 5.55 Display of freeze dried wheatgrass powder, tablets and bottle
pack
Figure 5.56 Display of spray-dried wheatgrass powder, tablets and bottle pack
Various wheatgrass formulations (dried powders), tablets prepared wherefrom
and market packs, prepared for the first time in our study, now commercially
available in market (Figure 5.55 ? 5.57) -
5.3 Wheatgrass formulations and tablets -
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Formulation data of wheatgrass tablets -
Wheatgrass powders obtained after shade drying, freeze drying and spray
drying were used to make tablets using suitable excipients and binders. The
preparations were done in pharmaceutical company and the method has
been kept secret for the purpose of patent registration. Random samples of
these tablets were subjected to analysis of pharmaceutical parameters (Table
5.8). There was consistency in weight of these tablets. Among the three types
of tablets, spray dried tablets exhibited hygroscopic character and showed
least hardness (3.2 kg/cm2) compared to those of freeze dried tablets (4.5
kg/cm2) and shade dried tablets (5.3 kg/cm2). Spray dried tablets also showed
least friability (1.11%) compared to those of freeze dried tablets (2.36%) and
shade dried tablets (2.71%). Freeze dried tablets showed lowest dissolution
rate (55.69%) compared to those of shade dried tablets (66.15%) and spray
dried (73.96%). Shade dried tablets disintegrated at the fastest rate (12.25
min.) compared to spray dried tablets (15 min.) and freeze dried tablets
(17min.) (Table 5.8).
Figure 5.57 Display of shade-dried wheatgrass powder, tablets and bottle pack
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Table – 5.8 Comparative characteristics of tablets prepared from
different forms of wheatgrass formulations -
Sr. No. Freeze-dried
Tablet
Wt. in mg
Shade-dried
Tablet
Wt. in mg
Spray-dried
Tablet
Wt. in mg
1 0.430 1.1100 0.5771
2 0.438 1.2258 0.5482
3 0.459 1.2109 0.5786
4 0.410 1.1354 0.5825
5 0.427 1.1621 0.5538
6 0.445 1.0088 0.5477
7 0.457 1.1858 0.5700
8 0.396 1.1777 0.5805
9 0.380 1.2116 0.5640
10 0.450 1.1999 0.5690
Average wt. in mg 0.4292 1.1549 0.5670
Disintegration time 17 min. 12.25 min. 15 min.
Dissolution rate 55.69 % 66.15 % 73.96 %
Friability 2.36 % 2.71 % 1.11 %
Hardness kg./cm2 4.5 kg./cm2 5.3 3.2
5.4 Antibacterial activity -
The in-vitro antibacterial activity of undiluted juice as well as acetone and
methanolic extracts of wheatgrass was studied by agar – well diffusion
method. Acetone and methanolic extracts did not show any kind of
antibacterial activity. Fresh and undiluted wheatgrass juice exhibited mild
antibacterial activity against Staphylococcus aureus, Bacillus cereus,
Salmonella typhimurium and Kleibsella pneumoneae at 2.7 gm/ml
concentration. In terms of zone of inhibition, the diameter of the zone was
found to be 12.1, 12.4, 13.2 and 12.2 % respectively (Table 5.9).
Staphylococcus aureas causes skin lesions such as boils, styes, and
furuncles. Availability of excess iron in body e.g. in thalassemia, increases
host susceptibility to K pneumoniae and S. typhimurium infections.
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Table – 5.9
Sr. No. Bacteria
Undiluted
juice
Acetone
Extract
Methanol
Extract
1 Bacillus subtilis - ve - ve - ve
2 Staphylococcus aureus 12.1 - ve - ve
3 Staphylococcus epidermidis - ve - ve - ve
4 Escherichia coli - ve - ve - ve
5 Pseudomonas aeruginosa - ve - ve - ve
6 Bacillus cereus 12.4 - ve - ve
7 Bacillus megaterium - ve - ve - ve
8 Salmonella typhimurium 13.2 - ve - ve
9 Kleibsella pneumoneae 12.2 - ve - ve
Agar-well diameter=8.5 mm
Results are expressed as inhibitory zone in mm.
Diameter of zone of inhibition (mm): - < 8.5; + = 12-16
5.5 Antiproliferative activity–
Comparison of seed germination rates of different seeds in presence of
wheatgrass juice and distilled water revealed that the rates were considerably
reduced in presence of wheatgrass juice. There was 50% reduction in the rate
of wheat germination while those of green gram and groundnut were inhibited
to the extent of 70% and 90% respectively. The antiproliferative activity
exhibited by wheatgrass juice may be a clue to further investigation for
possible anticancer activity of wheatgrass.
5.6 Clinical trial of wheatgrass on patients with anemic
condition–
After 1-month treatment with wheatgrass, hemoglobin % (Hb gm%) was
significantly increased (before treatment: 11.75 ± 0.245, after treatment: 12.63
± 0.307), while RBC count was significantly decreased (before treatment: 4.72
± 0.132, after treatment: 4.37 ± 0.087). The decrease in RBC count indicates
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that wheatgrass may have suppressed haemopoietic process while rise in
hemoglobin content indicates stimulation of hemoglobin synthesis in individual
RBC. WBC count (before treatment: 8.615 ± 0.593, after treatment: 7.725 ±
0.44), TLC (before treatment: 2.6615 ± 0.083, after treatment: 2.483 ± 0.12),
neutrophils count (before treatment: 6.22 ± 0.151, after treatment: 6.08 ± 0.17)
and lymphocyte count (before treatment: 3.225 ± 0.162, after treatment: 3.37
± 0.186) were not affected to any significant level (Table – 5.10) (Figure 5.58).
This shows that either wheatgrass has no effect on body’ s defense
mechanism or the duration of treatment i.e.1 month, was insufficient for such
an effect.
Table – 5.10
Effect of one month treatment with wheatgrass on patients with anemia
with respect to various hematological parameters -
Parameter Before Treatment After Treatment
Hb (gm%) 11.75 ± 0.245 12.63 ± 0.307*
RBC (/cmm) 4.72 ± 0.132 4.37 ± 0.087*
WBC (/cmm) 8615 ± 593 7725 ± 440
Total Lymphocyte
Count (/cmm) 2661.5 ± 83 2483 ± 120
Neutrophil (%) 62.2 ± 1.51 60.8 ± 1.7
Lymphocyte (%) 32.25 ± 1.62 33.7 ± 1.86
               * Significantly different from initial value (P<0.05)
Fig 5.1 Effect of Wheatgrass on patients with anemic condition
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5.7 Clinical trial of wheatgrass on patients with b thalassemia
(major)–
Table – 5.11
Profile of patients in the treatment group (ß-thalassemia (major) -
After 9 months treatment with wheatgrass, Hemoglobin % (Hb gm%) in
normal-range subgroup (i.e. Male-13.5-18 gm%, F–12-16 gm%) was
significantly decreased (before treatment: 12.87 ± 0.10, after treatment: 10.77
± 0.36). RBC count in normal-range subgroup (Male-4.5-6.5/cmm, Female-
4.2-5.4/cmm) was also significantly decreased (before treatment: 4.55 ± 0.13,
after treatment: 3.74 ± 0.20). Decrease in hemoglobin content and RBC count
indicate possible haemopoietic suppression. The decrease in reticulocyte
count was highly significant. Reticulocyte count in abnormal-range subgroup
was significantly decreased (before treatment: 10.8 ± 2.55, after treatment:
2.8 ± 1.21). Decrease in reticulocyte count after wheatgrass treatment is an
indication of increase in tissue oxygenation and improvement in
erythropoiesis. Mean corpuscular volume (MCV) in normal-range subgroup
was significantly increased (before treatment: 86.26 ± 1.06, after treatment:
77.02 ± 2.58) and that in abnormal-range subgroup was also significantly
increased (before treatment: 77.63 ± 0.94, after treatment: 82.99 ± 1.74).
Mean corpuscular hemoglobin concentration (MCHC) in abnormal-range
subgroup was significantly increased (before treatment: 28.85 ± 1.06, after
treatment: 32.63 ± 1.06) (Table 5.12) (Figure 5.59). Positive changes in MCV
and MCHC reflect correction of both hypochromia and microcytosis, thus
exhibiting reversal of abnormal condition in thalassemia.
Total number of patients 20
Patients below 12 years age 8
Patients above 12 years age 12
Patients with S. Ferritin below 2500 (low iron load) 7
Patients with S. Ferritin above 2500 (high iron load) 13
Patients with spleen 13
Patients without spleen (spleenectomized) 7
Male/Female 12/8
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Table – 5.12
Effect of wheatgrass on patients with b-thalassemia (major) with respect
to changes in parameters related to erythropoetic activity -
Parameter Normal Value Subgroup
Number
of
patients
Mean value before
treatment with
wheatgrass
Mean value after
treatment with
wheatgrass
Normal 3 12.87 ± 0.10 10.77 ± 0.36 *Hb gm % M - 13.5-18F – 12-16 Abnormal 17 8.68 ± 0.54 8.83 ± 0.43
Normal 8 4.55 ± 0.13     3.74 ± 0.20 **
RBC m/cmm M - 4.5-6.5F - 4.2- 5.4 Abnormal 12 3.08 ± 0.21 3.28 ± 0.19
Normal 7 1.06 ± 0.06 1.00 ± 0.00Reticulocyte% 0.1-2 Abnormal 4 10.80 ± 2.55    2.80 ± 1.21 *
Normal 0 - -PCV % 42-50 Abnormal 20 29.49 ± 1.83 28.22 ± 1.39
Normal 6 86.26 ± 1.06   77.02 ± 2.58 *MCV cu mic 82-92 Abnormal 14 77.63 ± 0.94   82.99 ± 1.74 *
Normal 6 28.29 ± 0.16  26.73 ± 0.48 *MCH pic gm 27-31 Abnormal 17 24.96 ± 0.56 26.34 ± 0.49
Normal 12 33.83 ± 0.51 32.60 ± 0.42MCHC % 32-36 Abnormal 8 28.85 ± 1.06  32.63 ± 1.06 *
* Significantly different from initial value (P<0.05)
** Significantly different from initial value (P<0.01)
Fig 5.49 Effect of Wheatgrass on patients with b-thalassemia (major) w ith respect
to changes in parameters related to erythropoetic activity
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After 9 months treatment with wheatgrass, eosin count (Eosin %) in abnormal
-range subgroup was significantly decreased (before treatment: 3.22 ± 1.14,
0.33 ± 0.22) (Table – 5.13) (Figure 5.60). Reversal of eosinophilia may be an
indicator of detoxifying or antiallergic property of wheatgrass.
Table – 5.13
Effect of wheatgrass on patients with b-thalassemia (major) with respect
to changes in parameters related to natural defense mechanism of body-
Parameter NormalValue Subgroup
Number of
patients
Mean value before
treatment with
wheatgrass
Mean value after
treatment with
wheatgrass
Normal 11 273182 ± 12107.5 285091 ± 29245.2Platelet 1.5-4.5 Abnormal 2 199000 ± 126572.1 258000 ± 154149.3
Normal 12 6008.3 ± 485.84 5769.2 ± 457.19WBC/cmm 4000-10000 Abnormal 8 13875.0 ± 2902.79 16057.1 ± 2033.11
Normal 7 62.14 ± 1.11 58.71 ± 2.63Neutro % 60-70 Abnormal 13 51.69 ± 2.04 54.23 ± 3.39
Normal 1 23.00 ± 0.00 43.00 ± 0.00Lympho % 20-30 Abnormal 19 40.00 ± 1.83 40.53 ± 2.00
Normal 13 1963.85 ± 132.08 2293.92 ± 161.40Total
lympho
Count
800-3000 Abnormal 7 5274.00 ± 916.94 6968.29 ± 1364.91
Normal 1 2.18 ± 0.36 0.64 ± 0.23Eosin % 1.0-4.0 Abnormal 9 3.22 ± 1.14   0.33 ± 0.22 *
* Significantly different from initial value (P<0.05)
Fig 5.50 Effect of Wheatgrass on patients with b-thalassemia (major) with respect
to changes in parameters related to natural defense mechanism of the body
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After 9 months treatment with wheatgrass, serum ferritin was significantly
decreased (before treatment: 6846 ± 1222, after treatment: 3877 ± 676)
indicating decrease in iron load. In absence of substantial rise in hemoglobin
content, the only possible explanation for decreased iron load is increased
excretion of iron. Treatment with wheatgrass had no influence on serum
magnesium, serum iron and TBARS (Table 5.14) (Figure 5.61). These, data
indicate that although wheatgrass treatment increases hemoglobin content of
RBC in thalassemia, the mechanism of action is neither iron or magnesium
supplementation nor replenishment of antioxidants.
Table – 5.14
Effect of wheatgrass on patients with b-thalassemia (major) with respect
to changes in parameters related to mechanism of action of wheatgrass-
Parameter Normal Value Subgroup Number ofpatients
Mean value
before treatment
with wheatgrass
Mean value after
treatment with
wheatgrass
Normal 3 130.00 ± 12.25 274.00 ± 46.68S. iron mic/dl 90-150 Abnormal 14 225.51 ± 15.57 229.68 ± 22.34
S. ferritin ng/dl 12-140 Abnormal 16 6846 ± 1222 3877 ± 676*
Normal 18 1.93 ± 0.10 1.92 ± 0.05S. mag meq/l 1.3-2.5 Abnormal 1 3.54 ± 0.00 2.48 ± 0.00
Normal 0TBARS x105
M/cmm 1.3-2.5 Abnormal 12 0.63 ± 0.05 0.60 ± 0.05
* Significantly different from initial value (P<0.05)
b61Fig 5.5  Effect of Wheatgrass on patients with b-thalassemia (major)with respect to changes in parameters related to mechanism of action
of Wheatgrass
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After 9 months treatment with Wheatgrass, different parameters in patients of
above 12 years age group showed significant changes. In this group, the
hemoglobin content in normal range subgroup was significantly decreased
(before treatment: 12.86 ± 0.1, after treatment: 10.77 ± 0.36). RBC count in
normal range subgroup was significantly decreased (before treatment: 4.54 ±
0.14, after treatment: 3.71 ± 0.22). Reticulocyte count in abnormal range
subgroup was significantly decreased (before treatment: 10.8 ± 2.55, after
treatment: 2.8 ± 1.21). MCV in normal range subgroup was significantly
decreased (before treatment: 86.73 ± 1.37, after treatment: 76.2 ± 3.52).
MCHC in normal range subgroup was significantly increased (before
treatment: 28.43 ± 1.37, after treatment: 33.34 ± 1.28). Total lymphocyte
count in normal range subgroup was significantly increased (before treatment:
1768.5 ± 151.04, after treatment: 2351.8 ± 157.97). In bellow 12 years age
group, the serum iron content in normal range subgroup was significantly
increased (before treatment: 149 ± 2.83, after treatment: 287 ± 7.78).
Comparison of the effects of wheatgrass treatment in patients of both these
age groups revealed that patients of above 12 years age group had
experienced more beneficial effects of wheatgrass treatment compared to the
patients of below 12 years age group. (Table 5.15- 5.17).
Table – 5.15
Comparison of effects of wheatgrass on patients of different age groups
with b-thalassemia (major) with respect to changes in parameters related
to erythropoetic activity -
Parameter Subgroup Below 12 years age group Above 12 years age group
Before After Before After
Normal - - 12.86 ± 0.1 10.77 ± 0.36 **Hb gm %
Abnormal 9.13 ± 0.18 8.63 ± 0.41 8.43 ± 0.7 8.94 ± 0.62
Normal 4.57 ± 0.0 3.93 ± 0.0 4.54 ± 0.14 3.71 ± 0.22 **RBC m/cmm
Abnormal 3.34 ± 0.23 3.28 ± 0.19 2.89 ± 0.3 3.28 ± 0.3
Normal 1.0 ± 0.0 1.0 ± 0.0 1.08 ± 0.08 1 ± 0.0Reti.- PM %
Abnormal - - 10.8 ± 2.55 2.8 ± 1.21 *
Normal - - - -PCV %
Abnormal 27.85 ± 2.7 26.92 ± 1.36 30.19 ± 2.33 28.77 ± 1.88
Normal 85.30 ± 1.42 78.65 ± 2.9 86.73 ± 1.37 76.2 ± 3.52 **MCV cu mic
Abnormal 74.53 ± 2.17 80.63 ± 4.2 78.87 ± 0.67 83.93 ± 1.66
Normal - - 28.29 ± 0.23 26.73 ± 0.63MCH pic gm
Abnormal 25.61 ± 0.56 25.67 ± 0.94 24.61 ± 0.79 26.7 ± 0.53
Normal 34.36 ± 0.88 32.97 ± 0.36 33.56 ± 0.6 32.42 ± 0.59MCHC %
Abnormal 30.09 ± 0.01 30.48 ± 0.31 28.43 ± 1.37 33.34 ± 1.28 *
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* Significantly different from initial value (P<0.05)
** Significantly different from initial value (P<0.01)
Table – 5.16
Comparison of effects of wheatgrass on patients of different age groups
with b-thalassemia (major) with respect to changes in parameters related
to natural defense mechanism of the body –
  * Significantly different from initial value (P<0.05)
Table – 5.17
Comparison of effects of wheatgrass tablets on patients of different age
groups with b-thalassemia (major) with respect to changes in parameters
related to mechanism of action of wheatgrass -
    ** Significantly different from initial value (P<0.01)
Parameter Subgroup Below 12 years age group Above 12 years age group
Before After Before After
Normal 284250± 23495 221000 ± 9753 266857 ± 12884 321714 ± 39421Platelet
Abnormal - - 258000 ± 154149 199000 ± 126572
Normal 6383 ± 536 6166 ± 740 5633 ± 781 5833 ± 343WBC
/cmm Abnormal - - 14025 ± 2639 14275 ± 2724
Normal 62.67 ± 2.18 62.33 ± 2.13 61.75 ± 1.02 56 ± 3.79Neutro %
Abnormal 50.33 ± 2.6 55.0 ± 0.82 52.1 ± 2.52 54 ± 4.4
Normal 30 ± 0.0 40 ± 0.0 28.25 ± 1.52 34.5 ± 4.26Lymph. %
Abnormal 42 ± 3.3 40 ± 2.15 44 ± 2.45 42.5 ± 2.5
Normal 2276 ± 166 2345 ± 343 1768.5 ±151.04 2351.8 ± 157.97 *Total
lympho.
Count Abnormal 3744 ± 0.0 2970 ± 0.0 7505 ± 1483 6034 ± 960
Normal 1.75 ± 0.45 1 ± 0.35 0.8 ± 0.34 1 ± 0.3Eosin %
Abnormal 7 ± 2.12 1.5 ± 0.35 6.5 ± 1.06 0.5 ± 0.35
Parameter Subgroup Below 12 years age group Above 12 years age group
Before After Before After
Normal 149 ± 2.83 287 ± 7.78 ** 124.33 ±10.71 231 ± 57.91S. ironmic/dl Abnormal 281 ± 32.51 258 ± 56.79 225.8 ± 13.9 221.84 ± 27.48
Normal 1.85 ± 0.07 1.87 ± 0.04 1.95 ± 0.11 1.95 ± 0.07S. mag
meq/l Abnormal 1.96 ± 0.57 1.89 ± 0.03 3.54 ± 0.0 2.48 ± 0
Normal - - - -TBARS
X105 M/cm Abnormal 0.68 ± 0.09 0.45 ± 0.01 0.61 ± 0.08 0.66 ± 0.06
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6. DISCUSSION
Wheatgrass has been traditionally used, since ancient times, to treat various
diseases and disorders. Presently, there are a number of wheatgrass
suppliers, in almost all cities of India, supplying fresh wheatgrass daily to their
regular customers who use it as a traditional remedy against various ailments
and also as a health tonic. There are several claims that wheatgrass is a safe
and effective treatment for ailments such as high blood pressure, some
cancers, obesity, diabetes, gastritis, ulcers, anemia, asthma and eczema
(Wigmore 1985). Scientific reports on nutritional analysis of wheatgrass have
been published (Kohler 1953, Hamilton et al., 1988, Laboratory Analyses
1989). These reports and the chemical analyses undertaken reveal that
wheatgrass is rich in chlorophyll, minerals like magnesium, selenium, zinc,
chromium, antioxidants like beta-carotene (pro-vitamin A), vitamin E, vitamin
C, antianemic factors like vitamin B12, Iron, folic acid, pyridoxine and many
other minerals, amino acids and enzymes, which have significant nutritious
and medicinal value (Chan et al., 1999).
Thalassemia is one of the most common groups of genetic blood disorder. b-
thalassemia is characterized by impaired production of b globin chain. The ?-
globin gene is present, but produces little ?-globin protein (Weatherall 1997,
Jandl 1982, Steinberg 1988). The synthesis and accumulation of excess
normal ?-globin chain within the red cell, lead to the formation of unstable
aggregates, which upon oxidation, due to oxidative stress generated by iron
overload, precipitates and cause cell membrane damage. These deformed
cells undergo premature destruction either in the bone marrow (extravascular
hemolysis) or the peripheral circulation (intravascular hemolysis) (Festa
1985). Management of ß-thalassemia major (Cooley's Anemia) requires
patients to have life-long regimen of regular blood transfusions coupled with
iron chelation therapy. Blood transfusion produces on long term, serious and
unavoidable side-effects because with each unit of blood transfused 200 to
250 mg of iron gets deposited in the heart, liver, pancreas and other glands in
the body. This may lead to heart failure, cirrhosis of liver, diabetes mellitus
and malfunctioning of other glands. Generally, regular blood transfusions and
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iron chelation treatment with desferrioxamine are initiated early in life;
therefore, the patients and their families have to sustain regular treatment
throughout their childhood, adolescent, and adult years (Olivieri et al., 1994,
Zurlo et al., 1989). Data indicate that dietary magnesium supplementation
improves some of the characteristic cellular function abnormalities of b-
thalassemia. The deficiency of magnesium in serum or erythrocytes has also
been reported in human  ?-thalassemia. These deficiencies may play a
significant role in various cellular abnormalities characteristic of this disorder
(De Franceschi et al., 1998). Thus, in thalassemia, there is a vicious cycle of
iron overload leading to oxidative stress with consequent increase in
hemolysis and increase in blood transfusion requirement causing further iron
overload and its toxicities on other organs.
In a chronic disease like thalassemia, the drug treatment is of long duration,
may even be for years. In such a circumstances the factor of patient
compliance becomes very important. Outcome of the therapy depends upon
regular supply (round the year and in all seasons) and acceptability of the
drug by patient. Recently, Marvaha et al (2004) reported an improvement in
the patients using wheatgrass juice. About 100 ml of freshly extracted wheat
grass juice was consumed daily. There was decrease in requirement of blood
transfusion to atleast 25% in 19 patients. No specific variety of wheat grass
was used. Poor compliance, indiscipline in intake and an insufficient duration
of intake in 14 of 38 patients (37%) could be attributed to lack of positive
effect observed in some cases. The process of growing, harvesting and
extracting juice was too laborious, especially in summer months for most
parents of defaulters’ . Thus, we could forsee non-compliance of the patients
as a major hurdle in our tiral. As a pharmaceutical scientist, preparation of a
suitable dosage form is prime area of research in the development of new
drug formulations. Hence, in the present investigation we decided to prepare
suitable formulation that is as effective as juice per se. While preparing dry
wheatgrass powder for manufacture of tablets, it was noticed that the potency
of the powders from different batches was affected by wheat species, fertilizer
used to grow wheatgrass and the method adopted for drying or extraction.
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Therefore, it was decided to carry out complete profiling of wheatgrass
formulation (i.e. preformulation studies) by ascertaining most suitable species
of wheat, fertilizer used to grow wheatgrass and also the method of extraction
to prepare the powder.
Wheat species differ from one another both morphologically and genetically.
Triticum species can be placed in three groups, according to whether their
body cells contain 14, 28 or 42 chromosomes. The basic haploid number
being 7, these groups are described as Diploid, Tetraploid and Hexaploid
respectively (Percival 1974). Diploid species comprises of Triticum boeoticum
or Wild Eincorn, which is the most ancient variety of wheat and T.
monococcum Eincorn. T. monococcum is now grown to a limited extent in the
mountainous region of Yugoslavia, Asia Minor and North Africa. Diploid
species can be readily crossed to yield Tetraploid group. Tetraploid species
comprises of T. dicoccum or emmer wheat and T. durum or macaroni wheat.
T. dicoccum is one of the most ancient of cultivated cereals today. It was
formerly grown in the United States for feed on a limited acreage but now has
substantially disappeared from cultivation. T. durum, next important species to
T. aestivum, is used mainly for the manufacture of semolina which is made
into macaroni, spaghetti and related products (Percival 1974). It is grown to a
considerable extent in parts of Gujarat and central peninsular India. When
crossed with Diploid species, Tetraploid species yield Hexaploid group.
Hexaploid species comprises of T. aestivum or common wheat is the most
highly evolved and widely cultivated of all wheat species. In India, T. aestivum
is the most widely grown wheat species.
In our investigation, certified samples of three major species of wheat viz.
Triticum aestivum, Triticum durum and Triticum dicoccum were acquired form
the Wheat Research Center, Gujarat Krushi University, Junagadh, Gujarat.
These wheat varieties were grown in plastic trays as per the standard
procedure. Microscopic studies of transverse sections, surface preparations
and powder studies of the three species of wheatgrass were conducted using
high-resolution microscope. In conformation with the description in literature
(Percival 1974); the leaves were mainly near glabrous, auriculate, with blades
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narrowly to broadly linear; broad to narrow; 2–20 mm wide; flat; without cross
venation (Percival 1974). The leaf blade was linear and parallel –veined with
mid rib projecting on the back continuing someway along the sheath. In T.
Dicoccum the hairs on the swollen base of leaf were longer than those of
other species. The longest leaves were possessed by T. durum.
Observations in microscopic studies of different species also confirmed
characteristics reported in literature (Percival 1974). In transverse section, the
wheatgrass leaf showed 1. elaborate epidermis with characteristic stomata
and trichomes 2. the green assimilating parenchyma, 3. the conducting
vascular bundles, and 4. longitudinal strands of fibrous stereome or
supporting tissue. The upper surface of the leaf showed a series of
longitudinal ridges or ribs, the lower surface being almost flat. At the summit
of each ridge was a single row of elongated thick-walled and pitted cells
alternating with hairs. The trichomes or hairs were always unicellular, and
vary much in length and stoutness. On the leaves of T. aestivum, ample
numbers of hair were present, while in T. dicoccum and T. durum they were
sparsely distributed on the surface of the leaf. Stomata were observed at the
base of the ridge arranged in single or double lines. Each stoma on the leaf
consists of four cells, the two guard cells being narrow, with specially
thickened walls round the stomatal pore and thin-walled widely dilated ends.
Pores of the stomata are seen to be in communication with large intracellular
cavities in the mesophyll, called lacune. The ratio of the number of stomata on
the upper and lower epidermis respectively is about 10:7, the number on the
upper surface examined being 7000 per square centimeter. In the furrow
between two ridges is a band of three to seven rows of motor cells. vascular
bundles are collateral, with the xylem towards the upper surface of the leaf
and the phloem bellow. In surface preparation, trichomes or hairs of various
lengths were found scattered along the rows at more or less at regular
intervals except in T. durum.
Phytochemical analyses of wheatgrass revealed that wheatgrass is a rich
source of chlorophyll, various minerals like iron, magnesium, calcium,
phosphorus, antioxidants like beta carotene and insoluble dietary fibers. Thus,
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our analysis supports the scientific reports on nutritional analysis of
wheatgrass (Kohler 1953, Hamilton et al., 1988, Laboratory Analyses 1989).
Three different techniques were adapted to prepare wheatgrass powder
including spray drying, freeze drying and shade drying. In freeze drying
technique, fresh wheatgrass was frozen to sub-zero temperature and
subsequently subjected to low-temperature heating (10 oC -15 oC) in vacuum
to evaporate crystallized water content. Dried wheatgrass was then milled to
obtain powder. In spray-drying technique, fresh wheatgrass was pressed in a
hydraulic press to obtain juice. The juice was then sprayed in aerosol form
through a nebulizing nozzle in a conical vessel from top. A hot air counter
current (55 oC) was passed from bottom of the vessel. The nebulized juice
settled on the bottom of the vessel in the form of powder. In shade-drying
technique, fresh wheatgrass was dried at room temperature in a well-
ventilated dark room. The dried wheatgrass after 3-4 days of drying period
was powdered in a mill.
TLC of the various extract of fresh wheatgrass and its formulations was
carried out in hexane: acetone (60:40) solvent system. In all, 13 spots were
observed at different Rf values viz. (1) 0.07(Light green), (2) 0.21(Yellow), (3)
0.27(Grey), (4) 0.35(Yellow), (5) 0.40(Yellow), (6) 0.47(Light green), (7)
0.54(Yellow), (8) 0.57(Green), (9) 0.61(Blue green), (10) 0.64(Light grey), (11)
0.69(Light grey), (12) 0.74(Grey), (13) 0.92(Orange). By comparing standard
Rf values and colors reported in literature, out of 13 spots representing 13
different components of wheatgrass, seven components at spot number 4, 7,
8, 9, 11, 12 and 13 were identified as Xanthophyll c, Xanthophyll a,
Chlorophyll b, Chlorophyll a, Pheophytin b, Pheophytin a and b carotene
respectively. In comparative TLC study, chlorophyll a was found to be present
in significant quantity in fresh wheatgrass and was absent in rest of the
formulations. Intense grey-colored spots of pheophytin seem to have
compensated the absence of chlorophyll in these formulations, as pheophytin
is the degradation product of chlorophyll. Except chlorophyll a, 12
components were found present in shade dried powder. Spot no. 4, 5, 6, 9
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and 10 were absent in freeze-dried and spray-dried powders. b-carotene was
present in all formulations. Thus, shade drying, the natural method of drying,
was found to preserve all components of wheatgrass and hence, appear to be
the most suitable. The TLC study of wheatgrass extract has not been reported
earlier to our knowledge.
In qualitative HPTLC chromatograms of methanolic extracts of Standard beta
carotene, fresh wheatgrass, shade-dried wheatgrass powder, freeze-dried
wheatgrass powder, spray dried wheatgrass powders were subjected to
HPTLC study. The chromatograms were scanned in combined as well as
individual modes at 254 nm and 354 nm wavelengths. Findings of qualitative
HPTLC confirmed the patterns obtained in TLC study. Individual spots
(components) in chromatogram were scanned at 254 nm wavelength to obtain
their spectra for the purpose of identification of these components of
wheatgrass in further investigations.
Qualitative HPTLC was carried out on extracts wheatgrass formulations at
maximum concentration, for presence of various constituents. Methanolic
extracts of equivalent amounts of these formulations were subjected to
quantitative HPTLC along with those of different species of wheatgrass.
Chromatograms of the formulations or species were recorded. Area under
curve (AUC) of different components were measured in chromatogram of
each formulation or species and analyzed for comparison with that of fresh
wheatgrass. Since all the constituents of wheatgrass could not be identified,
the AUCs of only chlorophyll, pheophytin and beta carotene were used for the
purpose of comparison.
The HPTLC analysis of wheatgrass grown from three major wheat species
revealed that Triticum aestivum had lowest contents (76.8%) as compared to
the contents of Triticum durum (86.92%) and Triticum dicoccum (100 %).
Thus, it seems that wheatgrass grown from tetraploid species of wheat,
especially Triticum dicoccum  (local variety called as DDK) and T. durum, is
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more suitable for medicinal use as compared to the hexaploid species i.e. T.
aestivum or the common wheat.
To determine the effect of fertilizer on quality of wheatgrass, same species of
wheat i.e. T. durum was grown separately in plain soil, in compost fertilizer
and in organic fertilizer. When subjected to HPTLC analysis, contents of
wheatgrass grown in organic fertilizer (91.36%) and that of wheatgrass grown
in compost fertilizer (92.05%) were nearly similar while the contents of
wheatgrass grown in plain soil (100%) were highest among the three. Thus,
presence of a fertilizer does not seem to hamper or interfere much with the
sensitive phytochemical processes being carried out in the young growing
grass in early stages of growth.
It is well known that the stability of components present in wheatgrass, like
chlorophyll, beta-carotene, vitamin A, vitamin E, vitamin C etc, are likely to be
adversely affected upon exposure to changes in air, light, humidity and
temperature. This fact is confirmed by the results of our analysis. When
subjected to HPTLC analysis, wheatgrass tablets of spray-dried powder was
found to have lowest contents (21.66%) as compared to the contents of
tablets of freeze-dried powder (46.68%) and shade-dried powder (87.75%)
considering the contents of methanolic extract of fresh wheatgrass as 100%.
In spray drying technique the use of 550 C temperature might have adversely
affected the stability of thermolabile constituents like chlorophyll, beta-
carotene, vitamin A, vitamin E. In freeze drying process although wheatgrass
is subjected to low-temperature heating (10o C –15o C), the heating is carried
out in high vacuum to evaporate crystallized water content. It is possible that
low temperature (15o C), when applied at high vacuum, has a similar drastic
effect on constituents of wheatgrass as to that of high temperature e.g. 600 C
applied at room temperature. In shade drying technique, wheatgrass is neither
exposed to high temperature nor to sunlight or moisture. Thus, the potency of
wheatgrass is maintained at a substantially higher level. Hence, we infer that
the most suitable method of preparing dry wheatgrass powder, among above
three techniques is shade drying technique.
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Traditionally, wheatgrass juice is prepared by grinding fresh wheatgrass in
mixer/grinder adding little water that is subsequently filtered through a cloth.
When subjected to HPTLC analysis the fresh wheatgrass juice, prepared by
traditional method, was found to have 96.7% contents considering the
contents of methanolic extract of fresh wheatgrass as 100%. Thus, in the face
of it, traditional method seems to be the best method for wheatgrass therapy
compared to any formulations of wheatgrass that were made in our study.
But, when the traditionally prepared green colored juice was passed through a
filter paper the filtrate obtained was only a light yellow colored liquid while the
residue on the filter paper was full of green color. This indicates that the
traditional juice does not extract chlorophyll and other ingredients from the
intact cells in to water but in fact; the juice is a suspension of tissue debris in
water. In our experiment the residue was treated with methanol for estimation
of the contents of juice. Thus the traditional juice ingested by a patient
delivers important constituents of wheatgrass packed inside intact cells made
up of cellulose, which in turn may not be digested by human intestinal tract.
Under these circumstances, how much of wheatgrass contents contained in
the traditional juice, is a matter of speculation. The same logic of
bioavailability also applies to freeze dried and shade dried tablets since both
contain intact grass.
Determination of dose of wheatgrass tablets is an important issue to be
addressed. According to Ann Wigmore, considered to be an authority in
wheatgrass therapy and who is believed to have treated thousands of patients
with wheatgrass juice, the daily dose of wheatgrass for a patient suffering
from a chronic ailment e.g. thalassemia should be: traditional juice prepared
from 100 gm. grass. In the light of foregoing discussion on partial
bioavailability (probably 50%) afforded by the traditional juice, 50 gm. of
methanolic extract of wheatgrass would be equivalent to traditional juice
prepared from 100 gm. wheatgrass. In our investigation, the extractive value
of wheatgrass was found to be 6%. Thus, 3 gm. of methanolic extract
obtained from 50 gm. wheatgrass i.e. 2 tablets of 500 mg. methanolic extract,
given three times a day might be the therapeutically useful dose.
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Investigation in to antibacterial profile of wheatgrass revealed two important
features. Aqueous extract of wheatgrass exibited mild to moderate
antibacterial activity against four common opportuinistic pathogenic bacteria
viz. Staphylococcus aureus, Klebsiella pneumoneae, salmonella typhi and
Bacillus cereus. Staphylococci are Gram-positive spherical bacteria that occur
in microscopic clusters resembling grapes.  Staphylococci are found in
cultures of the nose and skin of humans. Staphylococcus aureas causes skin
lesions such as boils, styes and furuncles. Thus, our observation supports the
claim made by Wigmore about wheatgrass juice being useful in treatment of
skin infections (Wigmore 1985). Klebsiellae are nonmotile, rod-shaped, gram-
negative bacteria with a prominent polysaccharide capsule. Klebsiellae may
be regarded as normal flora in many parts of the colon and intestinal tract. K
pneumoniae is the most medically important species of the group. Availability
of iron increases host susceptibility to K pneumoniae infection. It would be
worth recalling that thalassemic patients are chronic sufferers of iron overload.
The presence of invasive devices, contamination of respiratory support
equipment, use of urinary catheters, and use of antibiotics are factors that
increase the likelihood of nosocomial infection with Klebsiella species. Hence,
thalassemic patients undergoing regular blood transfusions are succeptible to
nosocomial infections. Further, withholding iron from potential pathogens is
one strategy used in host defense (Weinberg, 1978). Transferrin's extremely
high affinity for iron, coupled with the fact that two-thirds of the iron-binding
sites of the protein normally are unoccupied, essentially eliminates free iron
from plasma and extracellular tissues. Both transferrin and the structurally
related protein, lactoferrin, are bacteriostatic in vitro for many bacteria  (Reiter
et al., 1975). The very high transferrin saturations attained in patients with iron
overload compromise the bacteriostatic properties of the protein. Iron
sequestration is not a frontline defense against microbes. Therefore, iron
overload does not produce the susceptibility to infection seen with defects in
more central systems (e.g., chronic granulomatous disease.) Nonetheless, a
number of infections, often with unusual organisms, including Salmonella
typhimurium have been reported in patients with iron overload (Abbott et al.,
1986)  (Bullen et al., 1991). Thus, the antibacterial activity of wheatgrass
could be beneficial for thalassemic patients, in addition to its clinical effects on
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blood picture. The antibacterial activity was exibited only by undiluted extract
of wheatgrass. Also, the antibacterial activity was lost within 2 hours of
preparing the extract. This leads us to conclude that topical application of only
fresh and undiluted wheatgrass extract could be beficial in treatment of skin
infections.
The results of our investigation into effect of wheatgrass on seed germination
reveal that wheatgrass exibits strong antiproliferative activity which could be a
clue to its potential anticancer activity. It has been claimed that the
wheatgrass contains abscisic acid and laetrile, both of which may have anti-
cancer activity (Wigmore 1985). Chlorophyll-rich plant extracts, as well as
water solutions of a chlorophyll derivative (chlorophyllin), dramatically inhibit
the carcinogenic effects of common dietary and environmental chemicals
(Kimm et al, 1982, Ong et al, 1986). However, some evidence suggests that
the observed medical effects of chlorophyll in plants are actually the result of
the total effect of the interaction between different components of the whole
plant, in addition to the sole effects of chlorophyll (Lea 1999, Waladkhani
1998). Other phytochemicals that may work in therapeutic combination with
chlorophylls include carotenoids, flavonoids, indole, isothiocyanate,
poyphenolic compounds, protease inhibitors, sulfides, and terpens
(Waladkhani 1998). Chlorophylls and chlorophyll-related products, both
natural and man-made, have been shown to support normal cellular function,
as demonstrated experimentally through in vitro, in vivo, and animal studies
(Higashi 1998). Studies demonstrate that chlorophyll and chlorophyll-related
products support normal cellular health through anti-mutagenic activity.
Studies have found that chlorophyll binds carcinogens and reduces their
uptake (Harttig 1998, Nakamura 1996). Thus, there is ample evidence to
indicate that wheatgrass may useful in prevention and treatment of cancer.
Results of our investigation support these evidences.
Iron deficiency anemia affects approximately one third of the world's
population. On a worldwide basis, diet is the major cause of iron deficiency. In
countries where little meat is in the diet, iron deficiency anemia is 6-8 times
more prevalent than in America and Europe. This occurs despite consumption
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of a diet that contains an equivalent amount of total dietary iron because
heme iron is absorbed well from the diet than non-heme iron. Anemia due to
deficiency of folic acid and vitamin B12 are not uncommon. Wheatgrass
contains iron, folic acid and vitamin B12. To assess effect of wheatgrass on
anemia an open clinical trial of wheatgrass on anemia was carried out at
Ayurved Hospital functioning under Civil Hospital, Rajkot. Necessary
permission for conducting the clinical trial was obtained from the concerned
ethical committee. 20 anemic patients, visiting the hospital were enrolled for
the trial, after taking informed consent. 20 patients suffering from anemia
whose age ranged from 15 to 50 years were included in the trial. The patients
were given wheatgrass tablets with dosage regimen of 2 tablets (wheatgrass
powder 250 mg.) 3 times in a day for 1 month. Blood samples were collected
at the start and at the end of period of clinical trial (i.e. 1-month period). To
assess effect of wheatgrass on haemopoietic activity, hemoglobin gm%, RBC
count, WBC count were recorded while, to assess effect of wheatgrass on
defense mechanism neutrophil count, lymphocyte count and total lymphocyte
count were recorded. After 1-month treatment with wheatgrass, Hemoglobin
(Hb gm%) was significantly increased. RBC count was significantly
decreased. WBC count, neutrophil count, lymphocyte count and total
lymphocyte count were not affected to any significant level.
An increase in hemoglobin content coupled with increase in RBC count
indicates stimulation of erythropoiesis i.e. increase in overall hemoglobin
content of blood due to increased production of RBC. In our investigation, we
found a decrease in RBC count, which indicates that wheatgrass might have
suppressed the haemopoietic process. The rise in hemoglobin content
indicates stimulation of hemoglobin synthesis in individual RBC, probably by
replenishment of deficient nutritional factors like iron as the major cause of
anemia. WBC count, neutrophil count, lymphocyte count and total lymphocyte
count were not affected significantly. This showed that wheatgrass had no
effect on body’ s defense mechanism. The results of wheatgrass on anemic
patients also suggest that it may also have beneficial effect in patients with
thalassemia.
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A randomized clinical trial of wheatgrass on b-thalassemia was carried out at
K. T. Children Hospital working under Civil Hospital, Rajkot. Necessary
permission for conducting the clinical trial was obtained from the concerned
ethical committee. Twenty patients with thalassemia, visiting K. T. Children
Hospital regularly for blood transfusion and registered at the hospital were
enrolled for the trial, after taking informed consent. The patients above 12
years age were given wheatgrass tablets with dosage regimen of 2 tablets
(wheatgrass powder 250 mg.) 3 times in a day for 9 months. Blood samples
were collected at the start, after 6 months and at the end of period of clinical
trial. The parameters recorded were Hemoglobin, Total RBC count, PCV,
MCV, MCH, MCHC, Total WBC count, Neutrophils, Eosinophils, Basophils,
Lymphocytes, Serum iron, Serum ferritin, Serum magnesium and
Thiobarbituric acid reacting substances (TBARS).
After 9 months treatment with wheatgrass, hemoglobin in patients of normal-
range subgroup, was found to be significantly decreased (before treatment:
12.87 ± 0.10, after treatment: 10.77 ± 0.36). RBC count in normal range
subgroup was also significantly decreased (before treatment: 4.55 ± 0.13,
after treatment: 3.74 ± 0.20). This may be an indication of haemopoietic
suppression effect of wheatgrass.
After 9 months treatment with wheatgrass, hemoglobin content and RBC
count in abnormal range were not affected significantly by wheatgrass
treatment. Treatment with wheatgrass juice in thalassemia patients for a
period of 6 months showed that the ‘ response’ to wheatgrass juice was slow
for couple of months (Marwaha et al., 2004). In our study also, the transfusion
requirements remained unchanged even after a period of 9 months of
ingesting wheatgrass tablets. However, there was a significant improvement
in some hematological parameters related to thalassemia. After 9 months
treatment with wheatgrass, reticulocyte count in abnormal-range subgroup
was significantly decreased. The reticulocyte is an immature erythrocyte.
Normally, the reticulocyte count ranges from 1 to 2% and reflects daily
replacement of 1% of red cell population of red cells (Adomson and Longo
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2001). The rate of reticulocyte release from the marrow into the peripheral
circulation is governed primarily by the rate at which O2 is being supplied to
the tissues. A decrease in PO2 (hypoxia) is recognized by the kidney, which is
stimulated to release erythropoietin (Adomson and Longo 2001). The chronic
hypoxic condition in thalassemia, due to persistent low hemoglobin content of
blood stimulates secretion of erythropoietin, which in turn increases ineffective
erythropoiesis and reticulocyte count. Decrease in reticulocyte count after
wheatgrass treatment is an indication of increase in tissue oxygenation and
decrease in ineffective erythropoiesis.
Thalassemia is characterized by hypochromic microcytic anemic condition.
After wheatgrass treatment mean corpuscular volume (MCV) was significantly
increased. Mean corpuscular volume (MCV) expresses the mean volume of
each red cell. Similarly mean corpuscular hemoglobin concentration (MCHC)
was also significantly increased. Positive changes in both these parameters
reflect correction of both hypochromia and microcytosis, thus exhibiting
reversal of abnormal condition in thalassemia. MCHC provides the mean
concentration of hemoglobin in each red cell. It is most valuable in evaluating
therapy for anemia because it takes in to consideration hemoglobin and
hematocrit (PCV) and not the RBC count. The MCHC reflects defects in
hemoglobin synthesis (Adomson and Longo 2001). Increase in MCHC
indicates rise in hemoglobin concentration in individual RBC. In the face of
increased MCV this rise in MCHC signifies a substantial increase of
hemoglobin in RBC. In our investigation the increase in MCHC i.e. increase in
hemoglobin content of individual RBC was offset by haemopoietic
suppression effect of wheatgrass i.e. decrease in number of RBC. Thus, the
reduction in overall transfusion requirement was not observed after 9 months
treatment with wheatgrass.
Increase in MCHC could be an indication of increased synthesis of
hemoglobin in RBC. Since, total adult hemoglobin comprises of hemoglobinA1
- µ2b2 (97%), hemoglobin A2 - µ2d2 (2.5%) and hemoglobin - µ2g2 (0.5%), it
follows that rise in MCHC was contributed by any of these three type of
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hemoglobin or in other words due to increased expression of b, g or d gene. It
is known that RNA splicing mutations are fairly common and represent a large
portion of all mutations resulting in beta thalassemia (Benz 2001). Probability
of increasing expression of a mutated gene is very low. It is also known that a
critical control region of the delta globin gene (promoter) is known to be
defective. It inhibits messenger RNA (mRNA) processing, resulting in only a
small amount of Hb A2 (alpha2/delta2) production, which accounts for less
than 3% of total Hb in adult RBC. Further, it has been found that stimulation or
induction of fetal hemoglobin in thalassemia can improve the patient’ s clinical
condition (Jones and Taylor 1980). Thus, increase in MCHC after wheatgrass
treatment may be an indication of induction of HbF in thalassemic patients.
Further, consequence of diminished beta-chain production is the formation of
excess alpha chains that form tetramers and inclusion bodies because they
are less soluble than normal Hgb. These inclusion bodies are lethal to
developing erythroid precursors and are responsible for most of the severe
clinical effects of thalassemia. The inclusion bodies cause the destruction of
approximately 95% of red blood cell precursors prior to release into the
circulation (i.e. intramedullary hemolysis), either as a consequence of arrest in
the G1 phase of the cell cycle or by apoptosis during later phases of
maturation (Weatherall 1997, Festa 1985). The only reasonable chance a red
blood cell has for a somewhat normal morphology and lifespan occurs if
significant amounts of non–beta-chain Hgb (e.g. gamma, delta) are available
to bind the excess alpha chains. Thus, increased synthesis of gamma chain
due to wheatgrass treatment can increase the life span of RBC, reduce
severity of clinical picture and inhibit ineffective erythropoiesis in thalassemia.
In our investigation, 90% patients taking wheatgrass treatment reported
feeling of well-being increase in vitality and appetite, which is in concurrence
with the forgoing discussion.
After 9 months treatment with wheatgrass, eosinophil count was significantly
decreased.  Eosinophilia is seen in allergic disorders. Thalassemic patients on
regular blood transfusion therapy are subject to various allergens hence,
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eosinophilia is commonly found in thalassemic patients. Thus, reversal of
eosinophilia may be an indicator of much acclaimed detoxifying or antiallergic
property of wheatgrass.
It is well known that management of ß-thalassemia major  (Cooley's Anemia)
requires patients to have life-long regimen of regular blood transfusions
coupled with iron chelation therapy (Modell 1994, Cao et al., 1997). Blood
transfusion produces on long term, serious and unavoidable side effects
because iron gets deposited in the heart, liver, pancreas and other glands in
the body. This may lead to heart failure, cirrhosis of liver, diabetes mellitus
and malfunctioning of other glands. Iron overload may be treated or prevented
with a chelating agent capable of complexing with iron and promoting its
excretion. At present, only two iron-chelating agents are available for clinical
use in thalassemia viz. desferrioxamine (Desferal - given subcutaneously) and
deferiprone (Kelfer - given orally) (Olivieri et al., 1994, Zurlo et al., 1989).
Painful administration, muscle aches, arthralgia and high cost are major
disadvantages of desferrioxamine while neutropenia, agranulocytosis and
arthropathy, are noted side effects of deferiprone (Al-Refaie et al., 1992, Al-
Refaie et al., 1995, Cohen et al., 2000, Agarwal et al., 1992). Thus, the search
continues for an oral, safe, effective, easily available and economical iron
chelating agent.
As wheatgrass contains substantial quantity of iron, which is contraindicated
for thalassemic patients, the major apprehension expressed by patients and
doctors, at the outset of this study, was the possibility of increase in iron load
with wheatgrass treatment. The measurement of plasma or serum ferritin is
the most commonly used indirect estimate of body iron stores (Brittenham et
al., 2001). In our investigation serum ferritin level, against all predictions, was
significantly decreased at the end of 9 moths treatment with wheatgrass. In
absence of substantial rise in hemoglobin content, the only possible
explanation for decreased iron load is increased excretion of iron. Thus, the
most notable outcome of our investigation, apart from ascertaining the ability
of wheatgrass to increase hemoglobin content, is the detection of its probable
ability to decrease iron load in thalassemia. Wheatgrass may well be the long
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sought-after safe, oral and economical iron-chelating agent for thalassemic
patients.
The deficiency of magnesium in serum or erythrocytes has also been reported
in human ?-thalassemia and that dietary magnesium supplementation
improves some of the characteristic cellular function abnormalities of b-
thalassemia (De Franceschi et al., 1998). Clinical data suggests that the iron-
induced liver damage in thalassemia may play a major role in the depletion of
lipid-soluble antioxidants (Livrea et al., 1996). The synthesis and
accumulation of excess normal globin chain (i.e. ?-chain in ?-thalassemia and
?-chain in ?-thalassemia), within the red cell, lead to the formation of unstable
aggregates, which upon oxidation, due to oxidative stress generated by iron
overload, may precipitate and cause cell membrane damage. These
deformed cells undergo premature destruction either in the bone marrow
(extravascular hemolysis) or the peripheral circulation (intravascular
hemolysis) (Weatherall 1997, Festa 1985). Hence, logical mechanism of
action of wheatgrass in thalassemia, at the onset of the clinical trial, was
either replenishment of magnesium and/or antioxidants that can break this
vicious cycle. In our study, treatment with wheatgrass had no influence on
serum magnesium and thiobarbituric acid reactive substances (TBARS). Both
the parameters were included to investigate probable mechanism of action of
wheatgrass. Thus, our data indicate that although wheatgrass treatment
exhibits beneficial therapeutic effects in thalassemia, the mechanism of action
is neither magnesium supplementation nor replenishment of antioxidants.
In the past few years, several new approaches to the treatment of
thalassemia have included the use of drugs such as hydroxyurea, 5-AzaC and
butyrate compounds to elevate fetal hemoglobin (HbF) (DeSimone et al.,
1982). Mechanism of induction of HbF by butyrate is that it Inhibits histone
deacetylases and thereby increasing histone acetylation, which opens up the
chromatin structure and makes DNA more accessible to transcription factors.
This results in increased transcription of the g-globin gene by making its DNA
more accessible to transcription factors. Early studies demonstrated that
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treatment of tissue culture cells with the cytidine analog 5-azacytidine (5-
azaC) led to cellular differentiation and DNA hypomethylation (Jones and
Taylor 1980). Incorporation of 5-azaC into baboon DNA resulted in a 40- to
70-fold increase in g-globin gene expression in the adult (DeSimone et al.,
1982), and to hypomethylation of the g -globin promoter (Lavelle et al., 1986).
Thus, DNA hypomethylation and histone deacetylation seem to be the chief
mechanism of action of the agents that induce HbF synthesis. This suggests
that inhibitors of DNA methyl transferase and histone deacetylase may
activate transcription of HbF (Bird 2001).
Is there any constituent in wheatgrass that has properties of gene regulation
and ability to cause DNA hypomethylation and histone deacetylation? Wheat
seeds contain substantial amount of abscisic acid (Banowetz, et al., 1994).
That, wheatgrass contains abscisic acid has also been claimed by Ann
Wigmore (Wigmore 1985). Abscisic acid is a known plant growth regulator
(Banowetz, et al., 1994), which inhibits the process of seed priming in adverse
climatic condition thus, allowing germination only under favorable
circumstances. Gene regulating activity of abscisic acid has been further
investigated by Schultz et al (1996) who report that nuclear extract of wheat
enhances binding of the recombinant transcription factor EmBP-1 to Em1a by
80-fold. (Em1a is an ABA response element in the promoter of the Em gene
from wheat.) ‘ Fractionation of nuclear extracts led us to identify histone H1
and HMGb as two factors that can enhance the ability of EmBP-1 to bind to
Em1a. Furthermore, our study points to these chromosomal proteins (i.e.
histones) as potential targets of an ABA- mediated modification (e.g.
acetylation) that could affect the regulation of Em gene expression’ . It is thus
possible that wheatgrass contains abscisic acid, which has proven ability to
regulate transcription of a gene through acetylation of chromosomal proteins
or transcription factors. Ability of wheatgrass to Induce transcription of HbF in
thalassemic patients may be through acetylation of chromosomal proteins
(histones) by abscisic acid, present in wheatgrass. Abscisic acid may have
the potential to emerge as the much sought-after HbF inducer for benefit of
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thalassemic patients. However, further studies are required to substantiate the
results.
In our investigation Hb% and RBC count within normal range were
significantly decreased indicating possible haemopoietic suppression (i.e.
suppression of proliferation of erythroid progenitors) which, when viewed with
antiproliferative activity in the seed germination experiment, points once again
to the involvement of abscisic acid in effects or actions of wheatgrass.
Comparison of effects of wheatgrass treatment in different groups of patients
reveals that patients above 12 years age had more beneficial effects of
wheatgrass treatment as compared to the patients below 12 years age. This
was probably due to lower dose of wheatgrass (two tablets twice in a day)
administered to patients’ bellow 12 years age as compared to higher dose
(two tablets three time in a day) to patients above 12 years age. Significant
difference in the clinical effectiveness between these two dosage regimen
indicate that the minimum dose of wheatgrass should be two tablets (250 mg
tablets) three times in a day, for all thalassemic patients.
The large numbers of abnormal red cells processed by the spleen, together
with its hematopoietic response to the anemia if untreated, results in massive
splenomegaly, leading to manifestations of hypersplenism. Hypersplenism
results in to trapping of a variety of blood cell types causing cytopenia (Henry
and longo 2001). Reversal of ineffective erythropoiesis and consequent
reversal of spleenomegaly with subsequent release of trapped lymphocytes
may be the cause of significantly increased total lymphocyte count in patients
of above 12 years age grouping our investigation. Reversal of splenomegaly
after wheatgrass treatment is further endorsed by the fact that lymphocyte%
was significantly increased in patients with spleen, while it remained
unaffected in spleenectomized group.
Results of clinical study indicate wheatgrass formulation to be one of the
effective treatments for thalassemia. Although direct molecular studies are
required to confirm, it is hypothesized that wheatgrass produces direct
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beneficial effect in thalassemia patients by stimulating hemoglobin synthesis
in RBC. Wheatgrass was found to decrease significantly the iron load and
suppress the ineffective erythropoiesis.
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7. SUMMARY AND CONCLUSIONS
1. The pharmacognostic characteristics of three varieties of wheat (T.
dicoccum, T. durum and T. aestivum) used in the study were in
confirmation with that reported in the literature.
2. The phytochemical analysis of wheatgrass by TLC revealed 13 spots at
254 and 354 nm. Out of these 13 some of the constituents identified
were chlorophyll a and b, pheophytin a and b, xanthophyll a and c and
beta-carotene.
3. For quantitative evaluation of different formulations, chlorophyll,
pheophytin and beta-carotene contents were taken in to consideration.
4. Among three major varieties of wheat T. dicoccum variety may have
highest concentration (100%) of constituents followed by T. durum
(86.92%) and T. aestivum (76.8%).
5. Wheatgrass grown in plain soil may have highest concentration (100%)
of constituents followed by wheatgrass grown in compost fertilizer
(92.05%) and organic fertilizer (91.36%).
6. Wheatgrass powder obtained by shade drying technique seems to
have highest concentration (87.75%) of constituents compared to that
obtained by freeze-drying (46.68%) and spray drying (21.66%)
techniques.
7. The fresh wheatgrass juice prepared traditionally seems to offer
highest contents (96.7%) of wheatgrass, compared to its formulations
i.e. shade drying (87.75%), freeze drying (46.68%) and spray drying
(21.66%).
8. Aqueous extract of wheatgrass may have mild to moderate
antibacterial activity against four common opportuinistic pathogenic
bacteria viz. Staphylococcus aureus, Bacillus cereus, Salmonella
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typhimurium and Kleibsella pneumoneae. The antibacterial activity may
be lost on standing or on dilution of the fresh juice.
9. Wheatgrass juice exhibits antiproliferative activity. This may be a clue
for further investigation into possible anticancer activity of wheatgrass.
10.Treatment with wheatgrass on patients with anemia may have
beneficial effects in the form of increase in hemoglobin content and
decrease in erythropoietic activity.
11.Treatment with wheatgrass on patients with ß-thalassemia (major)
produced a significant decrease in reticulocyte count, especially in
patients having higher reticulocyte count suggesting that treatment is
effective in producing a decrease in ineffective erythropoiesis.
12.There was a significant decrease in MCHC in patients with abnormally
low MCHC levels. This was also observed in MCH and MCV. All these
results suggest a beneficial effect in patients with thalassemia possibly
by stimulating hemoglobin synthesis in RBC.
13. The beneficial effect of wheatgrass was not associated with increase in
iron overload. In fact the iron overload seems to have decreased by the
treatment with wheatgrass as revealed by significant decrease in
serum ferritin levels from 6846 ± 1222 to 3877 ± 676 ng/dl.
14. There was on change in the serum iron content, serum magnesium or
TBARS. Thus, the mechanism of beneficial effect of wheatgrass
appears to be independent of oxidative stress or nutritional
supplementation. Some unidentifiable constituent appears to stimulate
the hemoglobin synthesis and further studies are required to be carried
out in this direction.
15. Treatment of thalassemic patients with wheatgrass did not produce
any effect on platelet count or total lymphocyte count. However, a
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significant decrease in eosinophil count was observed.
16. A significant increase in lymphocyte count was observed only in
patients wherein splenectomy was not done. It is possible that
wheatgrass produces a reversal of splenomegaly.
In nutshell, our studies support, scientifically, some of the therapeutic
claims for wheatgrass. The potential benefit of wheatgrass in thalassemia
appears to be convincing and opens new vista of investigation.
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